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Abstract 
i 
 
Abstract 
Acylcarnitines are intermediates of fatty acid oxidation and accumulate as a result 
of a metabolic defect. Accumulation of palmitoylcarnitine (palcar), a long-chain 
acylcarnitine, has been observed in diabetes mellitus type II, obesity and kidney cancer. 
Certain dietary intervention studies have been shown to reduce serum and urinary levels 
of acylcarnitines. 
It was shown that palcar accumulates in prostate cancer tissue, possibly indicative 
of the metabolic changes associated with cancer development, but that palcar at high 
concentrations may have activities that could be associated with cancer development. 
Through the use of cancerous (PC3, DU145) and non-cancerous (PNT1A, BPH) cell 
models, it was shown that high levels of palcar could induce gene expression of the 
inflammatory cytokine IL-6, and induce its secretion in PC3 cells. This was associated 
with the rapid influx of Ca2+. Through the use of various metabolic inhibitors, it was 
shown that Ca2+ influx includes the activation of G-protein coupled receptors, L-type 
Ca2+ channels and PI3K pathway. However, it was shown through the use of global gene 
arrays that lower levels of palcar with uncorrected P value induced many changes in gene 
expression in PNT1A cells. A comparison with the global changes induced by DHT, an 
androgen linked to prostate cancer progression, revealed a significant overlap in activity 
between palcar and DHT, suggesting that palcar may have a potential role in promoting 
cancer progression. In PC3 cells through the use of real time RT-PCR palcar was shown 
to induce glycolysis.  
In conclusion, it is suggested that palcar may represent a potential biomarker of the 
metabolic dysfunction associated with prostate cancer. At physiological levels palcar had 
no effects on the prostate cancer cells, however, at high levels palcar drive tumour 
development through inducing key inflammatory cytokine and inducing changes in gene 
expression associated with glycolysis. 
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1.1. Introduction  
Cancer is one of leading causes of deaths worldwide. In the UK, prostate cancer is 
second only to lung cancer as the leading cause of cancer related deaths in men [1]. 
According to the 2010 national statistics on the incidence of cancer in England, 25.6% of 
the newly diagnosed cancer cases in men over 50 years were found to be prostate cancer 
[2]. This number is expected to rise as the number of elderly population is rising with 
prostate cancer largely affecting men over 50 years [3]. 
The risk factors for developing prostate cancer have been associated with age, high 
fat diet and chronic disorders, such as obesity and diabetes mellitus type 2 (DM type 2) 
[4]. A common feature between all chronic disorders including cancer is metabolic 
dysfunction, where the metabolic defect has been linked to impaired mitochondrial 
function.  
Prostate cancer is considered a metabolic disease, where the metabolism is re-
programmed due to secretion of citrate into the cytosol to be used as a precursor for the 
lipogenesis that is essential for providing the building blocks required for the biology of 
cancer cells. Since citrate is an intermediate in the TCA cycle, prostate cancer cells rely 
on glutamate metabolism to replenish the TCA cycle. In these cells glycolysis is also 
stimulated to provide the carbon skeleton for the synthesis of pentose sugar, nucleic acids 
and the nicotinamide adenine dinucleotide (NADH)-phosphate through the pentose 
phosphate pathway (PPP). In these cells, pyruvate is converted into lactate. The 
stimulated lipogenesis aids in attenuating the effect of lactate production on cellular pH 
during the stimulated glycolysis and maintains redox balance [5]. This makes the fatty 
acid oxidation, through β-oxidation, an important source for energy. It is important to 
note that lipogenesis is process important during cancer progression, while fatty acid 
oxidation is important during cell transformation [5], but it is unlikely that both processes 
would occur simultaneously in prostate cancer.  
As a consequence of the stimulation of these metabolic processes, the levels of the 
reactive oxygen species (ROS) increase, which can negatively affect the enzymatic 
activities involved in tricarboxylic acid (TCA) cycle. A defect in the latter can affect the 
integration with β-oxidation leading to a metabolic defect resulting from the mismatch 
between their rates. This is important when fatty acids overload β-oxidation as a result of 
persistent lipolysis, which would decrease the ability of the mitochondria to generate the 
intermediates of TCA cycle. As a result of stimulated lipolysis to cover the energy needs 
and the less efficient TCA cycle a spill over of intermediates of fatty acid oxidation, such 
as acylcarnitines, would be expected. 
Chapter 1 
3 
 
Accumulation of acylcarnitines has been observed in chronic diseases, such as 
obesity, DM type 2 [6, 7] and kidney cancer [8]. 
Metabolic defects could also include a dysfunctions in any of the components of 
the carnitine shuttle system, such as the carnitine palmitoyltransferase (CPT) II enzyme 
[8], as well as a defect in β-oxidation itself, any of which could lead to a mismatch with 
the TCA cycle. However, these are notions that are yet to be investigated in prostate 
cancer.  
Fatty acid oxidation is considered one of the main energy sources for prostate 
normal and cancerous cells [9]. In this chapter a review of the general metabolism of 
lipids is described and the role of the acylcarnitines as markers for the metabolic 
dysfunction, in addition to the cellular effect of the accumulation of acylcarnitines is 
discussed. Since recently it has been found that a diet rich in high glucosinolates (GSLs) 
broccoli is able to reduce the accumulation of acylcarnitines, the effect of this diet in 
reducing the accumulation of acylcarnitines is described. Also in this chapter, the biology 
of the human prostate and the development of prostate cancer in addition to the cell lines 
used to study the biology of the prostate are discussed. Finally in this chapter, the 
metabolic changes in healthy and cancerous prostate are described. 
1.2. General metabolism of lipids 
1.2.1. Fatty acid oxidation 
Fatty acids, either from dietary or endogenous sources, are generally considered an 
important source for energy production [10]. The endogenous sources include either de 
novo fatty acid synthesis through lipogenesis or fatty acid released during lipolysis. 
Lipolysis occurs under certain physiological conditions of low levels of glucose, such as 
fasting or starvation [11-13]. The dietary sources of fatty acids include the hydrolysis of 
the circulating triacylglycerol (TG) contained within lipoproteins by the action of the 
circulatory lipoprotein lipase. This occurs during the postprandial state. The main 
lipoprotein that contributes to this process is the low density lipoprotein (LDL), which is 
involved in transferring fatty acids from liver to cells [14].  
In order to be utilised as an energy source, fatty acids need to cross the plasma 
membrane and then enter the mitochondria, which is the main machinery for energy 
production. Fatty acids can cross the cell plasma membrane by the aid of fatty acid 
binding protein, such as albumin, in a process called active transport. Small quantities of 
free fatty acids exist in equilibrium with albumin-bound fatty acids and can cross the 
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membrane via passive or facilitative diffusion [13, 15]. In prostate cells, it has been found 
that the process of fatty acid uptake is via active transport mediated by membrane 
receptor [9]. 
Once inside the cells, fatty acids are converted into a thioester to enable their 
crossing of the mitochondrial membrane and this is because the mitochondrial membrane 
is impermeable to fatty acids [15]. 
Structurally, the mitochondria have outer and inner membranes. The permeability 
of each membrane is different resulting in different metabolite concentrations, proteins, 
and redox state [16]. The outer membrane is permeable to a limited number of 
compounds, while the inner membrane is completely impermeable [16]. 
The conversion of fatty acids into a form that allows them to pass through the 
membrane is called fatty acid activation [17]. This activation step is a thioesterification 
reaction and involves the binding of fatty acids with co-enzyme A (CoA), to form fatty 
acylCoA (or simply called acylCoA) esters [15]. This reaction occurs at the cytosolic 
face of the outer mitochondrial membrane and is catalysed by acylCoA synthetase (figure 
1.1) [15]. 
 
 
 
Figure 1.1: Fatty acid activation. Fatty acids in the cytosol are activated by binding to the 
–SH group of CoA catalysed by acylCoA synthetase. (Source: Devlin and Devlin, 1999 
[13]). 
 
CoA acts as an acyl group carrier, and is therefore considered to be a crucial co-
factor in all living organisms. However, due to the impermeable nature of the inner 
mitochondrial membrane, CoA along with it esters cannot pass the inner mitochondrial 
membrane [16]. Therefore, a sequential trans-esterification reaction then follows, where 
the acyl group is transferred to carnitine to form the acylcarnitines by an enzyme called 
CPT I located on the external surface of the outer membrane [17, 18], which belongs to 
the carnitine acyltransferase family (figure 1.2). 
The resultant acylcarnitine can then pass the inner mitochondrial membrane into 
the matrix via carnitine-acylcarnitine translocase (CAT), which is present in the inner 
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mitochondrial membrane [17, 18], where it catalyses the exchange of acylcarnitines with 
the free intramitochondrial carnitines. This enzyme transports carnitine and acylcarnitines 
with acyl chains of various lengths from 2 to 18 carbon atoms [18].  
The driving force for this transport is the concentration gradient of the substrates 
across the membrane [19]. As the average carnitine concentration inside the organelle 
ranges from 2 to 5 mM and the affinity of carnitine for this enzyme on the matrix side is 
about 10 mM, the intramitochondrial carnitine concentration limits the overall rate of the 
acylcarnitine/carnitine exchange and, hence, represents a regulatory step of fatty acid β-
oxidation. [20-22] 
The consequence of this series of reactions is a net transport of fatty acyl units into 
the mitochondrial matrix [17, 18]. Having arrived in the mitochondrial matrix, 
acylcarnitine is trans-esterified a second time, where the transported acyl group is 
transferred from carnitine to a matrix CoA to generate acylCoA and carnitine. This 
reaction is catalysed by the CPT II enzyme present in the internal surface of the inner 
mitochondrial membrane [18]. The resultant carnitine is then transferred back into the 
cytosol by CAT, while the acylCoA is oxidized by β-oxidation (figure 1.2) [13]. This 
process of transferring fatty acyl groups from the cytosol into the mitochondrial matrix 
using the above enzymatic system is called the carnitine shuttle [18]. 
Studies have shown that deficiency or alteration to any of the molecular 
components of the carnitine shuttle system can lead to a defect in fatty acid oxidation 
resulting in the excretion of specific acylcarnitine esters [23, 24].  
The activity of CPT I, CPT II and CAT is important for the regulation of the 
concentration of carnitines, acylCoA esters, and free CoA in each mitochondrial 
compartment, therefore affecting the carnitine acylation state in the cytosol [16]. It has 
been found that carnitine acylation state in the plasma can reflect the cytosolic 
acylcarnitine pool and serves as a diagnostic marker for altered equilibrium between 
acylCoA and acylcarnitines [16]. This suggests that the accumulation of acylcarnitines 
could be a good indicator for metabolic changes associated with defects in mitochondrial 
function. 
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Figure 1.2: Oxidation of fatty acids. Fatty acids resulting from high fat diets and 
stimulated lipolysis are activated by fatty acylCoA synthase to form fatty acylCoA. The 
latter binds to carnitine by CPT I to form acylcarnitine, an intermediate that is transferred 
by CAT into the mitochondrial matrix to be converted back into acylCoA by CPT II. This 
enzymatic system of transferring acylcarnitines is called the carnitine shuttle (red box). 
OXPHOS; oxidative phosphorylation. 
 
1.2.2. β-oxidation 
In the mitochondrial matrix, acylCoA is oxidized by β-oxidation, in which the 
acylCoA is shortened by the removal of two carbon atoms at the β-carbon position of the 
fatty acylCoA molecule, hence the term β-oxidation [25]. This leads to the production of 
acetylCoA (C = 2) as a final product [26]. The process of β-oxidation can also occur in 
the peroxisome. Peroxisomal β-oxidation is involved in the initial oxidation of very long 
chain fatty acids and the shortened chains are then transferred to the mitochondria for 
further hydrolysis [27].  
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The process of β-oxidation is a cycle of four consecutive reactions: 
dehydrogenation (or oxidation), hydration, dehydrogenation (or oxidation) and thiolytic 
cleavage [26] (figure 1.3).  
 
Figure 1.3: Reactions of β-oxidation. The process of β-oxidation is composed of four 
steps (highlighted in pink); oxidation, hydration, oxidation and cleavage. The enzymes 
are highlighted in blue. (Source: Devlin and Devlin 1999 [13]).  
 
In the first reaction, the single bond is oxidized to a double bond and results in the 
formation of flavin adenine dinucleotide (FADH2). This reaction is catalysed by acylCoA 
dehydrogenases, which are specific to the chain length of the fatty acid [26]. 
The second reaction is catalysed by enoylCoA hydrase. It catalyses the 
stereospecific hydration of the trans-double bond produced in the first reaction to form 3-
L-HydroxyacylCoA. In the third reaction (the second oxidation step), the hydroxyl group 
at the β-position on carbon number three is oxidized into a ketone and generates NADH. 
This reaction is catalysed by 3-L-hydroxyacylCoA dehydrogenase. In the fourth reaction, 
β-ketoacylCoA produced in the previous step is cleaved into fatty acylCoA that is 
shortened by two carbons. This reaction is catalysed by thiolase and in the presence of 
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CoA. The fatty acylCoA that is shortened by two carbon atoms re-enters β-oxidation for 
further cleavage to form acetylCoA (figure 1.3) [25].  
Regulation of β-oxidation depends on many factors; the substrate supply, the rate 
of oxidation of acetylCoA, the rate of CoA recycling, and the redox state [17]. Each cycle 
of β-oxidation produces one mole each of FADH2, NADH, and acetylCoA [13]. 
1.2.3. TCA cycle 
AcetylCoA produced by β-oxidation and glycolysis is oxidized via the TCA cycle. 
The TCA cycle is a consecutive series of enzyme-catalysed reactions that take place in 
the mitochondrial matrix. It starts with binding acetylCoA to oxaloacetate and end up 
with producing free hydrogen ions, CO2, adenosine triphosphate (ATP), NADH and 
FADH2. Therefore, a functioning TCA cycle is essential for the generation of reducing 
molecules that are not only important for energy production, but also for other anabolic 
processes, such as the PPP [13].  
The transamination reactions within the cycle, which involve the reversible 
interconversion of glutamate into α-ketoglutarate and oxaloacetate into aspartate, ensure 
the availability of the TCA cycle intermediates, and thus a functioning cycle. The 
transamination reactions are catalysed by aspartate amino transferase (or also called 
aspartate transaminase) (figure 1.4) [28]. 
The activity of the TCA cycle is controlled by several factors. These include 
NADH/NAD+ ratio, adenosine diphosphate (ADP)/ATP ratio, CoA availability, the rate 
limiting enzymes (citrate synthase, isocitrate and α-ketoglutarate dehydrogenase) and 
calcium (Ca2+) concentration [28]. An increase in Ca2+ concentrations increases the 
activity of TCA cycle by activating Ca2+ sensitive dehydrogenases, such as pyruvate 
dehydrogenase (PDH) [29]. 
It has been found that certain deficiencies of the enzymes involved in the TCA 
cycle may lead to certain types of disorders, such as fumaric aciduria, which is an inborn 
metabolic disorder that is characterised by high levels of fumaric acid in the urine caused 
by a deficient activity of fumarase [30].  
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Figure 1.4: Reactions of TCA cycle. AcetylCoA is oxidised in a series of enzyme-
catalysed reactions in the mitochondrial matrix. The enzymes are highlighted in blue. In 
the cycle CO2, NADH and FADH2 are produced. Transamination reaction within the 
cycle catalysed by aspartate transaminase keeps the cycle intermediates available for a 
functioning TCA cycle (based on Brie`re et al 2006 [28]). 
 
1.2.4. Electron transport chain  
The NADH and FADH2 generated during the oxidation of acetylCoA in the TCA 
cycle and those generated from β-oxidation and glycolysis can enter the electron 
transport chain (ETC) for the production of ATP in a process called oxidative 
phosphorylation [13]. This process takes place within the inner mitochondrial membrane, 
where the electrons are transferred from the NADH and FADH2 into electron carrier 
proteins called cytochromes, which contain iron and copper cofactors. The electrons from 
NADH and FADH2 are transferred down the ETC from one cytochrome into another, 
usually to or from an iron or copper ion, to reach the terminal cytochrome C oxidase 
complex, which catalyses the transfer of electrons to atmospheric oxygen and combines 
them to hydrogen ions to form water [13, 14, 28]. After transferring the electrons from 
NADH and FADH2, the energy generated is used to transfer the hydrogen ions across the 
inner mitochondrial membrane to the intermembrane space, thus generating a 
concentration gradient of hydrogen ions across the membrane. These hydrogen ions can 
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re-enter the mitochondrial matrix through ATP synthase, which is a protein channel for 
hydrogen ions that uses the energy derived from ion movement to catalyse the formation 
of ATP from ADP and inorganic phosphate ion. This process is called oxidative 
phosphorylation and it provides almost 90% of the total energy in the cells [13]. This 
process is also important for re-oxidation of the reduced molecules to generate NAD+ and 
FAD. The availability of these molecules is important to accept more hydrogen ions from 
intermediates in the TCA cycle, glycolysis, and fatty acid oxidation [14]. 
The well balanced series of reactions outlined above can be perturbed during 
moments of metabolic stress affecting the co-ordination between β-oxidation, TCA cycle 
and the ETC , which lead to the accumulation of intermediates, such as acylcarnitines 
that could impair cellular functionality [7]. 
1.3. Acylcarnitines and chronic diseases  
Metabolic dysfunction is a common feature between all chronic diseases including 
cancer. It has been shown that this metabolic dysregulation is associated with an increase 
in the plasma levels of acylcarnitines [6, 7, 23, 31, 32].  
An in vivo study characterizing the acylcarnitine profile in human plasma from 
lean, obese and subjects with DM type 2 diabetic subjects revealed that in both obese and 
diabetic groups the levels of long, medium and short chain acylcarnitines were increased 
[7]. These findings were also observed in Adams et al study, where they found an 
accumulation of medium and short chains acylcarnitines in obese diabetic subjects 
compared to the obese non-diabetic subjects [6].  
In metabolic syndrome and obesity, insulin resistance leads to persistent lipolysis 
and high levels of plasma non esterified fatty acids, leading to an increase in fatty acid 
oxidation. Tissues will use fatty acids as priority when their concentrations are raised in 
the plasma. However, in diabetic subjects, it has been reported that the metabolic defect 
is linked to impaired insulin signalling as well as a poor coordination between the TCA 
cycle and β-oxidation. This can be explained by the overload of mitochondria with fatty 
acids, which overload β-oxidation and decrease the ability of mitochondria to generate 
the intermediates of the TCA cycle, leading to less efficient TCA cycle and the 
accumulation of acetylCoA. To overcome this accumulation acetylCoA is converted into 
ketone bodies, which in turn inhibit enzymes involved in TCA cycle. Accumulation of 
acetylCoA also stimulates pyruvate dehydrogenase kinase, which inhibit PDH and 
stimulate pyruvate carboxylase, leading to an increase in the levels of oxaloacetate, 
which is a substrate for glucose synthesis. The increase in glucose levels induces the 
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secretion of insulin from the β-cells. A persist in insulin secretion can lead to insulin 
resistance [6, 13]. 
In Mihalik et al study, the increased concentrations of insulin in both obese and 
diabetic groups was associated with a lower concentration of short and long chain 
acylcarnitines, which indicates the importance of insulin in regulating the oxidation of 
fatty acids [7]. This was supported by measuring the respiratory quotient (RQ), which is a 
measure of the ratio of CO2 eliminated to the amount of O2 consumed during metabolism. 
It ranges from 1 (indicating a pure carbohydrate oxidation) to around 0.7 (indicating a 
pure fat oxidation) [14]. Higher insulin concentrations were associated with higher RQ, 
which suggest a switch from fatty acid oxidation to carbohydrate oxidation. This was not 
the case in the diabetic subjects, whose insulin levels were higher, where the levels of 
acylcarnitines were not changed in the same pattern as the obese or the lean subjects, 
indicating their inability to switch into more efficient fat oxidation. In addition, diabetic 
subjects showed a secondary accumulation of shorter chain acylcarnitines, which are 
produced from the second round of β-oxidation, suggesting that there is a poor co-
ordination between β-oxidation and the TCA cycle [7]. Further evidence for the poor co-
ordination in diabetic subjects is the increase in the levels of C3 carnitines as well as C4 
dicarboxyl carnitine. The latter is a sum of both methylmalonylcarnitine and 
succinylcarnitine, which suggest that succinylCoA is poorly utilized by the TCA cycle 
[7]. The findings of these studies suggest that acylcarnitines could represent a possible 
biomarker for predicting the development of diabetes.  
In a study involving subjects recently diagnosed with diabetes, the acylcarnitine 
decanoylcarnitine was positively correlated with LDL concentrations, which was 
significantly increased along with triglycerides, interleukin (IL)-6 and tumour necrosis 
factor-α (TNF-α) compared to the non-diabetic subjects [33].  
It has been observed that there is a link between lipid and amino acid metabolic 
pathways. An increase in some amino acid metabolites has been associated with an 
increase in some acylcarnitines. Metabolomic profiling of obese versus lean human 
subjects reveals that in obese subjects, higher levels of short (C3) and medium (C5) chain 
acylcarnitines were detected, in addition to higher levels of branched chain amino acids 
[34].  The link between the accumulation of acylcarnitines and amino acids is that the 
metabolites of amino acids resulting from amino acid metabolism can be used to form 
acylcarnitines. C5 acylcarnitines are composed of α-methylbutyryl and 
isovalerylcarnitine that result from α-methylbutyrylCoA and isovalerylCoA respectively. 
Both α-methylbutyrylCoA and isovalerylCoA are intermediates of the mitochondrial 
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catabolism of isoleucine and leucine respectively, which are present in equilibrium with 
their cognate acylcarnitine esters. C3 acylcarnitine results from the catabolism of 
propionylCoA, which is a by-product of both isoleucine and valine catabolism [7, 34].  
The link between the accumulation of acylcarnitines and amino acids also suggest 
an impaired TCA cycle. In chronic diseases the high levels of oxidative stress resulting 
from the accumulation of ROS can negatively affect the enzymes involved in the TCA 
cycle and thus affect its efficiency. Because the TCA cycle is a central process for many 
catabolic and anabolic processes including amino acid catabolism, reduction in the 
efficiency of the TCA cycle may lead to the accumulation of amino acids and their 
metabolites as well as affect its integration with other processes, such as β-oxidation 
leading to the accumulation of acylcarnitines.  
Elevated levels of certain amino acid metabolites have been found to be correlated 
with insulin resistance, in that they can interfere with insulin mediated glucose uptake 
pathways leading to a reduction in glucose uptake and glycogen synthesis [35]. Because 
amino acids and lipid metabolism are linked through the TCA cycle, this suggests that 
acylcarnitine may also be indirectly linked to insulin resistance [34]. Another study by 
Ganti et al showed that acylcarnitines also accumulate in urine and tissue from kidney 
cancer [8]. Since metabolic dysfunction is a common feature between obesity, DM type 2 
and cancer, accumulation of acylcarnitine has the potential to be used as a biomarker to 
detect the metabolic dysfunction associated with the chronic disease. 
1.4. Cellular effect of acylcarnitines 
Acylcarnitines including palmitoylcarnitine (palcar), the most abundant of the long 
chain acylcarnitines, are formed by transferring an acyl group of fatty acylCoA to 
carnitine (figure 1.5). 
 
 
Figure 1.5: Acylcarnitine formation from acylCoA and carnitine. CPT I catalyse the 
binding of acylCoA to carnitine to form acylcarnitine. Acylcarnitine has an amphiphilic 
nature; the hydrocarbon chain that is specific for each acylcarnitine (R group) represents 
the hydrophobic part of the molecule, and both the carboxylic and amine group represent 
the hydrophilic part. 
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The resultant chemical structure contains both hydrophobic and hydrophilic 
groups. The hydrophobic group is the large hydrocarbon fraction of the compound 
(represented with R group in figure 1.5), with the hydrophilic group being the fraction 
containing the carboxylic and amine groups. This structure gives the acylcarnitines an 
important feature of being amphiphilic. 
The amphiphilic nature of acylcarnitines allows them to induce many cellular 
changes that are related to cell membrane functionality. In the cell membrane 
microenvironment, amphiphiles have been reported to bind to target proteins in the cell 
membrane as well as to the phospholipid bilayer, and this led to a corresponding change 
in membrane fluidity and the corresponding state of the membrane and the protein lipid 
bilayer interface [15, 36-40]. This may cause conformational changes in the proteins 
involved in the interface. These proteins could be either ion channels, thus controlling 
transport of ions and membrane permeability, or receptors that are involved in many 
signalling pathways [13], therefore altering their activity and the ionic movement across 
the membrane, thus modifying cell membrane permeability [36, 39]. The ability of 
acylcarnitines to induce changes in membrane bound proteins have been realized for 
palcar by studying sodium (Na+)/potassium (K+)–ATPase and Ca2+–ATPase activities in 
the sarcoplasmic reticulum (SR) [41-43]. 
Altering membrane permeability could be associated with changes in the 
homeostasis of ions that could act as secondary messengers, such as Ca2+. In endothelial 
cells, palcar has been shown to induce the influx of Ca2+ [44]. The influx of Ca2+ has 
been also observed in response to dihydrotestosterone (DHT), which is a hormone 
essential for prostate growth and development, and associated with prostate cancer 
progression [45].  
Changing the homeostasis of secondary ions, such as Ca2+ could be associated with 
the alteration of many signal transduction pathways, some of which are linked to 
inflammatory responses [45]. Acylcarnitines generally, have been shown to be associated 
with some pro-inflammatory responses. They were able to induce an increase in the 
levels of TNF- α and pro-inflammatory cytokines including IL-3, IL-16 and IL-23 [46, 
47], in addition to an increase in nuclear factor kappa-light-chain-enhancer of activated B 
cells (NFκB); a downstream target of toll-like receptors (TLRs) that are known to 
regulate the synthesis of the IL-6 [6, 48]. The increase in IL-6 levels has been associated 
with the progression of prostate cancer [49-51]. 
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1.5. The role of the diet in reducing acylcarnitines 
One of the most important risk factors that influence human health is the diet. A 
diet high in fat and low in fruit and vegetables can affect the quality of life leading to the 
development of many chronic diseases, such as cardiovascular diseases (CVD), DM type 
2 and cancer.  
Recently, the use of natural product in cancer prevention has increased 
considerably [52]. There is an increasing volume of evidence demonstrating that a diet 
rich in fruit and vegetables including crucifers are beneficial to health. This kind of diet 
provides a variety of potentially health-promoting phytochemicals, such as vitamins, 
carotenoids, polyphenols and GSLs [53].  
GSLs are distinctive phytochemicals that accumulate in cruciferous vegetables, 
which make them unique compared to other green vegetables [54]. The GSL containing 
vegetables belong to the family Brassicaceae and genus Brassica. The name of 
cruciferous vegetables is derived from the cross-shaped flower of the plant [52]. 
A diet rich in cruciferous vegetables has been linked to the reduced risk of many 
chronic diseases, such as CVD [55] and many types of cancers including lung [56], breast 
[57], colon [58, 59] bladder [60], and prostate [61]. The evidence of this link has come 
from a number of worldwide epidemiological studies including those carried out in the 
US [57, 58, 61, 62], Canada [62, 63], Netherland, [64], Shanghai [56, 59] and Western 
Australia [65].  
Part of the cumulative evidence suggesting the protective role of cruciferous 
vegetables also comes from human intervention studies. Recently, a diet rich in high 
GSLs broccoli has been found to decrease the accumulation of acylcarnitines by 
rebalancing the metabolic processes of amino acid metabolism, TCA cycle and β-
oxidation [66]. The beneficial health effect of such a diet is attributed to the GSL break 
down product sulforaphane (SF). SF is thought to exert its effect in rebalancing the 
integration between TCA cycle, fatty acid oxidation and amino acid catabolism through 
the induction of transcription factor nuclear factor E2-related factor 2 (Nrf2) [66]. Nrf2 is 
a transcription factor that regulates the expression of antioxidant genes involved in phase 
II detoxifying systems. When Nrf2 is released from the Kelch-like ECH-associated 
protein 1 (KEAP1), it binds to antioxidant response element sites in the genes and 
induces the expression of enzymes involved in the process of carcinogen detoxification 
[67]. SF was also found to induce the expression of glutathione-S-transferase enzyme 
involved in phase II enzyme [68]. Induction of phase II detoxifying systems reduces the 
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oxidative stress that cause the mitochondrial dysfunction and may enhance the redox-
sensitive enzymes involved in TCA cycle, such as aconitase and α-ketoglutarate 
dehydrogenase [66], which results in a more efficient TCA cycle that is able to properly 
integrate with β-oxidation, thus reducing the accumulation of acylcarnitines.  
The effect of a diet rich in fruit and vegetables on lowering the levels of 
acylcarnitines has been also observed after consuming a diet rich in citrus and soy [69]. 
Furthermore, low levels of acylcarnitines has been associated with the dietary intakes of 
garlic and coffee [70]; both of which induce Nrf2-mediated transcription [71, 72]. 
Recently, a WHO/FAO report recommended a minimum of 400g of fruit and 
vegetables per day for the prevention of chronic diseases, such as heart disease, cancer, 
diabetes and obesity, and also for the prevention of a number of micronutrient 
deficiencies [73]. However, a recommendation for the consumption of cruciferous 
vegetables has not been established. Epidemiological studies show that consumption of 
24.1 – 72.9g/day of cruciferous vegetables is associated with a reduced risk in cancer [62, 
63]. As mentioned previously, consuming a diet rich in broccoli (400g/week) has a 
positive effect on correcting the disrupted metabolic pathway through lowering the 
oxidative stress in people with moderate risk of developing CVD, therefore 400g serving 
per week (57g per day) could be suggested for this special group of vegetables. 
Since prostate cancer is the second leading cause of male deaths in the UK, the 
next sections describe the prostate, how prostate cancer develops, and the role of DHT in 
cancer development, as well as the importance of using in vitro cell models for studying 
prostate biology. Furthermore, how metabolism is between the healthy and cancerous 
prostate is also discussed.  
1.6. The biology of human prostate 
The prostate is one of the organs belonging to the male reproductive system. It is a 
single “donut”-shaped gland that has the size of a walnut and is located in front of the 
rectum and underneath the bladder. It surrounds the upper part of the urethra, into which 
it secretes the semen, an acidic fluid that carries the sperm cells, through hundreds of 
small openings in the side of the urethra; the tube that carries the urine from the bladder 
(figure 1.6) [14].  
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Figure 1.6: Anatomic view of the prostate gland. Prostate gland is located underneath the 
bladder and surrounds the urethra (source: Prostate Cancer Foundation of Australia; 
http://www.prostate.org.au). 
 
The prostate gland consists of epithelial glands surrounded by fibromuscular 
tissue; in other words, a glandular and a stromal part. The stromal part of the prostate 
includes fibroblasts, myofibroblasts, and smooth muscle cells, whereas the glandular part 
is composed, anatomically, of three types of epithelial cells illustrated in figure 1.7:  
1- The basement membrane 
2- The prostatic proliferative basal cells, which form a layer along the basement 
membrane of each prostatic duct and contain the stem cells. This layer also 
contain some scattered neuroendocrine cells, and  
3- The luminal epithelium secretory cells, which form a layer above the basal cells 
and express prostate specific antigen (PSA), prostate acid phosphatase (PAP) and 
androgen receptor (AR).  
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Figure 1.7: Cell layers in prostate gland. Normal columnar secretory epithelium is 
surrounded by basal cells that set on the basement membrane, which is supported by 
stromal cells. These tissue separate the prostate lumen from the capillary bed (source: 
Kirby and Patel 2011 [3]). 
 
Cells that develop from the basal layer start to express ARs and become responsive 
to androgen, causing them to differentiate into columnar secretory luminal cells that are 
capable of producing PSA [74]. 
Testosterone is a male sex hormone that is secreted from the Leydig cells of testes 
and is important for the induction of the differentiation of male reproductive organs and 
the maintenance of their function [14]. The prostate gland develops after puberty as a 
result of the flow of testosterone [75]. Once in cytoplasm, 5α-reductase converts 
testosterone into 5α-DHT, or simply called DHT [3, 14], which then binds to ARs to 
induce their effects. In the absence of testosterone, prostate gland cells normally undergo 
apoptosis.  
In the early stages of the development of prostate cancer, there is a dependence 
upon DHT. At this stage the cancer is described as androgen-dependent. As the cancer 
progresses, the presence of this hormone is not required for its growth, but the cells still 
respond, at this stage cells are described as androgen-sensitive. With time, these cancer 
cells then become androgen-insensitive due to increase or decrease in the number of the 
receptors [3, 14]. 
In some forms of prostate cancer that are sensitive to DHT, blocking the enzymes 
required for the transformation of testosterone to DHT represents a good approach for 
cancer therapy [14]. 
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As a result of the positioning of the prostate, its size is of great importance. Any 
enlargement of this gland could result in the constriction of the urethra causing a 
cessation of the flow of urine. This has been observed in cases of benign prostatic 
hyperplasia (BPH), where an enlargement of the prostate, caused by the development of 
macroscopic nodules with hyperplasia of stromal and epithelial cells, lead to the 
obstruction of the bladder. BPH nodules develop due to chronic inflammation. The 
repetitive wound-healing of the tissue damaged by the activity of the autoimmune system 
that is stimulated by the proliferation of the stromal and epithelial cells in the prostate 
causes the formation of the nodules [76].  
The main function of the prostate is to produce a liquid that contains both the 
semen and PSA. This liquid contributes to around 25–30% of the semen volume and 
PSA, and mainly produced from the luminal prostate epithelial cells to help liquefying 
the semen [74]. 
PSA is a glycoprotein with serine protease activity and regulated by androgen. It 
represents the major protein in the semen and is responsible for liquefying the semen 
allowing sperm cells to swim freely [3, 77]. It is secreted by the prostate epithelium as an 
inactive protein called pro-PSA and becomes activated by proteolytic hydrolysis in the 
lumen into free active PSA. The active PSA then can enter the circulation as an unbound 
form (free PSA). In the circulation, some of the free PSA can directly bind to protease 
inhibitors, such as α1-antichymotrypsin and α2-macroglobulin and circulate as a bound 
form. In prostate cancer, the secreted pro-PSA escape to the circulation as a result of the 
loss of basal cells, basement membrane, and normal lumen architecture resulting in an 
increase in the levels of bound PSA and pro-PSA in the serum [77, 78]. The ratio of 
serum free PSA to total PSA (free, pro- and bound PSA) is used to distinguish between 
the BPH and prostate cancer [77]. 
PSA is used as a diagnostic test for prostate cancer. Men without prostate cancer 
usually have low levels of PSA [75], these can range from 0 – 4.0ng/ml [3]. However, 
men diagnosed with BPH,  prostatitis, urinary tract infection and cancer may be expected 
to achieve levels of between 4.0–10.0ng/ml [3]. Cancer is indicated if their free PSA < 
25% of total PSA, as well as PSA levels between 4.0 – 10.0ng/ml [77]. The risk of cancer 
increases when patients have PSA levels > 10.0ng/mL [3, 77].  
In order to confirm the occurrence of prostate cancer, other screening tests are used 
along with the determination of PSA concentrations. Some of these tests include digital 
rectal examination and transurethral resection of the prostate (TURP). Measuring the 
PSA density, that is the ratio of PSA to gland volume, also aids in distinguishing between 
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prostate cancer and BPH. This is because PSA is produced by both normal prostate and 
BPH, therefore, serum levels can be compared with the volume of the prostate gland, so 
that the PSA released into the serum per gram of cancer tissue is greater than per gram of 
BPH tissue [77]. 
To help evaluate the prognosis of men with prostate cancer, some pathological 
prognostic factors are used; the Gleason grade is one of them. This is a system named 
after Donald Gleason, who first described it in the 60s, where the grade of the prostate 
cancer is evaluated microscopically. The tissue thought to be cancerous is compared to 
that of normal tissue to detect any glandular differentiation. This helps to determine the 
aggressive nature of the cancer. Tumours that are very similar to normal tissue are 
considered well-differentiated and were given a score of 1 (low grade), whereas tumours 
that are clearly different are considered least differentiated and were given a score of 5 
(high grade). Because tumours are heterogeneous and may have multiple levels of 
differentiation, a combined Gleason grade or score is used, which refer to use of two 
grades; primary (most dominant) and secondary (second most dominant). Thus Gleason 
score may range from 2 (1+1) to 10 (5+5) [75].   
The prostate gland itself can also be divided into four major anatomical zones 
(figure 1.8) [74, 77]:  
1. The transition zone, which is composed of two small lobules that surrounds the 
prostatic urethra. It is responsible for the prostate enlargement problems and 
represents the area where BPH mainly originates. 
2. The central zone, which surrounds the transition zone and extends to the angle of 
the urethra and base of the bladder (surrounding the ejaculatory duct system). 
3. The peripheral zone, which extends from the apex to the base of the gland and 
represents the most common site for the developing prostate carcinomas. 
4. Anterior fibromuscular zone or stroma doesn’t contain any glandular parts, but 
consists of a variety of cells including fibroblasts, nerves, infiltrating 
lymphocytes, macrophages, endothelial cells, and smooth muscle cells. It covers 
the area from the bladder neck to the external urethral sphincter.  
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Figure 1.8:  The anatomic zones of the prostate. To the right is the frontal view (coronal 
section) of the prostate and on the left is the 3D view of the whole prostate. The Prostate 
gland is located underneath the bladder and surrounds part of the urethra. It is divided 
into four main zones; central, transition, peripheral and an anterior fibromuscular zone. 
(based on: Notara and Ahmed, 2012 [74] and Manila Genitourinary Clinic, Philippines 
http://www.prostate.com.ph/anatomy.htm [79]).  
 
1.7. The use of in vitro models for studying prostate biology 
The similarities between the immortalised cell lines and the primary tumours from 
where they came, make the use of cell lines a good tool to attempt to understand the 
biological, molecular, and biochemical nature of cancer. Moreover, the flexibility of 
using cell-culturing may also aid in understanding the effect of many drug, chemical or 
food constituents on cancer and thus helps to formulate different hypotheses that could be 
further investigated in more appropriate in vivo systems [80]. There are many in vitro cell 
models of immortalized non-cancerous and cancerous human prostate epithelial cell lines 
that are used to investigate the tumour pathology of the prostate as well as assessing the 
beneficial health effects of many food constituents. 
In order for the in vitro cultured cells to reflect the actual in vivo system, the cell 
line used must be pure; this is important during the initial isolation of the cell line and 
during sub-culturing because cross contamination with another cell line may cause a 
change in the genotype and phenotype of the cultured cells and thus affecting their 
stability, which is another important factors that affect the characteristics of the cultured 
cells and eventually leading to a compromised interpretation of the results [80]. 
Therefore, different methods have been used to distinguish different cell lines. Some of 
the prostate-derived cell lines were characterised using immunocytochemistry, which 
employ the use of antibodies to detect the presence of specific peptides or protein 
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antigens in the cell using different technique such as microscope. Some of the markers 
that are used are cytokeratins, which reflect the differentiation of the epithelial cells, E-
cadherin and catenins, which reflect cell adhesion/anti-adhesion ability, PSA, PAP and 
AR, which are markers for prostatic differentiation [80].  
Prostate cancer can spread into lymph nodes and bones [81] and because most 
human prostate cancer cell lines have been taken from metastatic deposits, the cell line 
models reflecting these two types have different characteristics. LNCaP cells are cells 
derived from a metastatic lesion of human prostatic cancer and derived from the lymph 
node metastasis. They were described in 1980 [82] and are positive for prostatic 
differentiation markers; PSA, PAP and AR [80], thus they are hormone sensitive. 
Whereas, DU145 and PC3 cells are human prostate cancer cells that are derived from 
brain and bone metastasis, respectively. They were described in 1977 [83] and in 1978 
[84], respectively, and are positive for cell adhesion markers, but not for markers of 
prostatic differentiation; PSA, AR and PAP [80], therefore they are not hormone 
sensitive and do not express PSA.  
PNT1A cells are immortalised benign prostatic epithelial cells and were described 
in 1991 [85]. They are positive for some epithelium differentiation and cell adhesion 
markers. These cells do not express AR and PSA.  BPH-1 cells are another type of the 
immortalised benign prostatic epithelial cells and they were described in 1995 [86]. They 
are positive for cell adhesion and some epithelium differentiation markers, but they also 
do not express AR and PSA [80]. 
The work in this thesis, which involve investigating the effect of palcar 
accumulation was performed using in vitro cell models of prostate non-cancerous; 
PNT1A and BPH-1 cells, and cancerous; DU145 and PC3 cells.  
1.8. Metabolic characteristics of the healthy prostate 
Generally, the main energy source for all cells is the oxidation of glucose [13]. 
Glucose is transported into the cells by facilitative diffusion [13], which means down 
concentration gradient involving membrane proteins. Once inside the cells, glucose is 
phosphorylated by hexokinase to glucose–6–phosphate and used for various cellular 
processes depending on the cell needs. It can be used for energy production through 
glycolysis, stored as glycogen, enter PPP to produce pentose for nucleic acid synthesis, or 
used for the synthesis of structural glycoprotein. For energy production, glucose–6–
phosphate is further phosphorylated and converted into pyruvate. The fate of pyruvate 
determines the fate of glycolysis; whether it is aerobic or anaerobic. In aerobic glycolysis, 
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pyruvate enters the mitochondria to be converted into acetylCoA and then metabolised by 
the TCA cycle, whereas in the anaerobic glycolysis, pyruvate is converted into lactate by 
lactate dehydrogenase (LDH) [13].  
In aerobic glycolysis, hexokinase (HK) enzyme converts glucose into glucose-6-
phosphate. Glucose-6-phophate is converted into fructose-6-phosphate, which is then 
phosphorylated by 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB) into 
2,6-fructose bisphosphate [13]. PFKFB is an isoform of phosphofructokinase (PFK)-2 
and it is encoded by four genes; PFKFB1, PFKFB2, PFKFB3 and PFKFB4. It has been 
found that PFKFB4 is expressed in the prostate non-cancer and cancer cells [87].  
Fructose-2,6-bisphosphate regulates the activity of PFK1, which is responsible for 
the conversion of fructose-6-phoshate into fructose-1,6-bisphosphate (figure 1.9).  
 
Figure 1.9: The steps of converting glucose into pyruvate during glycolysis. Glucose is 
converted into puruvate by series of enzyme-catalysed reactions. PGI, phosphoglucose 
isomerase; FBP aldolase, fructose-bisphosphate aldolase; TIM, triosephosphate 
isomerase; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; PGK, 
phosphoglycerate kinase; PGM, phosphoglycerate mutase; ENO, enolase; PK, pyruvate 
kinase. (Based on Devlin and Devlin [13]). 
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Diverting glucose and pyruvate away from TCA cycle for other metabolic 
processes is a key characteristic of prostate cells and the driving force for the oxidation of 
fatty acids as an alternative energy source [10]. In both prostate non-cancer and cancer 
cell lines, it was found that the uptake of fatty acids is more dominant than the uptake of 
glucose and involves an active transport mechanism involving membrane receptor [9]. 
Fatty acids are oxidized by β-oxidation to produce acetylCoA, which is then 
converted into citrate in the TCA cycle. In prostate cells, the accumulation of zinc 
decreases the activity of aconitase, an enzyme that converts citrate into iso-citrate via cis-
aconitate. This decreases the oxidation of citrate, leading to its accumulation and 
secretion into the cytosol [88] (figure 1.10). 
 
Figure 1.10: Metabolism of fatty acids in prostate normal cells. Fatty acids are converted 
into acylCoA and binds with carnitine to produce acylcarnitine. Acylcarnitines are 
transferred into the mitochondrial matrix and converted back to acylCoA to be oxidized 
by β-oxidation and TCA cycle. Zinc accumulation in these cells inhibit the activity of 
aconitase, leading to the accumulation of citrate and its excretion into the cytosol to be 
used for fatty acid and cholesterol synthesis. Glutamine is utilised to replace 
intermediates of TCA cycle. ACLY; ATP citrate lyase, ACAT; AcetylCoA 
acetyltransferase, HMGCS; 3-hydroxy-3-methylglutaryl (HMG)-CoA synthase, 
HMGCR; HMG-CoA reductase, ACC1; AcetylCoA carboxylase 1, FASN; fatty acid 
synthase. 
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Blocking the aconitase step is considered another characteristic feature of prostate 
cells. In order to replace intermediates of TCA cycle and keep it functioning, the uptake 
of glutamate is stimulated to be converted by deamination reaction into α-ketoglutarate, 
which transaminate with aspartate to produce oxaloacetate [5].  
1.9. Metabolic characteristics of the cancerous prostate 
In prostate cancer cells, the metabolic alterations include the induction of aerobic 
glycolysis and this is not for energy production, but rather for providing the carbon 
skeleton required for the PPP. This is due to the neoplastic growth and the poor blood 
supply for the newly formed cells, the levels of O2 and nutrients decrease leading to 
hypoxic conditions and stimulation of cellular metabolism. This may increase the levels 
of ROS. High levels of ROS have been found to induce changes in the sulfhydryl group 
of pyruvate kinase [89], an enzyme that converts phosphoenol pyruvate into pyruvate 
[13]. This conversion leads to the oxidation of pyruvate kinase, which results in diverting 
the glucose from glycolysis toward the PPP [89]. PPP is essential in providing NADH 
phosphate, which is important for maintaining glutathione in the reduced form and thus 
protecting the cells from the oxidative stress resulting from ROS accumulation [89]. 
Under hypoxic conditions, high levels of ROS activate hypoxia–inducible factor–1 
(HIF–1) [90]. Induction of HIF-1 has a role in diverting glucose away from glycolysis 
and pyruvate away from the TCA cycle. HIF–1 has been found to be expressed in 
prostate cancer cells [91]. HIF-1 has been found to induce the gene expression of 
PFKFB4 [92]. In PC3 cells the gene expression of HIF-1 and HK2 has been found to be 
induced under hypoxic conditions [93]. HK2 drives glycolysis to produce glucose-6-
phosphate, but an increase in PFKFB4 decreases fructose-2,6-bisphosphate and since 
fructose-2,6-bisphosphate is a regulator of PFK1, this may cause a decrease the activity 
of PFK1, therefore, the resultant fructose-6-phosphate is diverted into the PPP, 
suggesting that glucose is diverted away from glycolysis in these cells [87]. 
Moreover, in cancerous cells, it was found that HIF–1 induces the expression of 
pyruvate dehydrogenase kinase 1 that is responsible for the phosphorylation of PDH, thus 
deactivating PDH [90]. Also, it was found that HIF–1 induces LDH, which converts 
pyruvate into lactate in anaerobic glycolysis [90]. Deactivation of PDH and activation of 
LDH decreases the entry of pyruvate into the TCA cycle and instead diverts pyruvate 
towards lactate production. Indeed, it has been found that lactate production is higher in 
prostate cancer than non-cancer cells and high levels of lactate are secreted in the media 
[94]. 
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These observations suggest that the rate of aerobic glycolysis in the prostate cancer 
cells is decreased. Citrate production in these cells also account for the decreased rate of 
glycolysis by inhibiting PFK [95]. Therefore, in order to meet the energy need, fatty acid 
oxidation through β-oxidation is stimulated. In these cells, peroxisomal β-oxidation, 
which is specialised in oxidizing long and branched chain fatty acids has been found to 
be increased [27, 95]. 
Another metabolic characteristic of the prostate cancer cells is the oxidation of 
citrate due to the low zinc content, which is reflected in the increased activity of 
aconitase, therefore, increased oxidation of citrate in TCA cycle [5]. However, citrate in 
these cells is exported into the cytosol due the overexpression of citrate transporters; 
therefore, they are being used as a precursor for lipogenesis. In order to keep an efficient 
TCA cycle, glutamate is utilised and subsequently converted into α-ketoglutarate to 
replace the TCA intermediate [5]. 
In the cytosol, citrate is converted back into acetylCoA by ACLY and it was 
suggested that citrate acted as the main source for acetylCoA required for either 
cholesterol or fatty acids synthesis [10]. For cholesterol synthesis, the reformed 
acetylCoA is converted into acetoacetylCoA by ACAT and then into mevalonate, which 
is the precursor for cholesterol synthesis by HMGCS and HMGCR. Cholesterol is 
important for the production of hormones, such as testosterone, which is essential for 
prostate growth.  
AcetylCoA can also be converted into malonylCoA by ACC1. AcetylCoA  along 
with other molecules of malonylCoA can be bind to form fatty acids in multi-enzymatic 
processes [5] (figure 1.11). It is unlikely that the formation of malonylCoA is associated 
with the inhibition of CPTI enzyme since malonylCoA is not accumulated in case of 
prostate cancer, but rather consumed in the process of fatty acid synthesis, which are 
essential for the newly proliferated cells. In fact this assumption does not goes against 
fatty acid-glucose cycle as it has been shown that in prostate cancer cells silencing 
PFKFB4 increases levels of Fru-2,6-BP, which is a regulator of PFK1, therefore 
diverting glucose 6-phosphate towards the glycolytic pathway, thus depleting the pentose 
phosphate pathway [87]. 
One of most abundant fatty acids is that synthesized in the cells is palmitic acid, 
which is a C16 fatty acid that represents approximately 80% of the total fatty acids 
synthesized in the cell [96].  
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Figure 1.11: Metabolism of fatty acids in prostate cancer cells. In these cells, the main 
energy source is the oxidation of fatty acids. The mitochondrial defect results in a loss of 
co-ordination between β-oxidation and TCA cycle, leading to the accumulation of 
acylcarnitines. The latter are also produced due to the low efficiency of TCA cycle as a 
result of high levels of ROS. The produced acetylCoA enters the TCA cycle and is 
converted into citrate and further oxidized to eventually produce NADH and FADH2, 
which are oxidized for energy production through the ETC. Citrate however, can also be 
excreted into the cytosol and used as a precursor for fatty acids and cholesterol synthesis. 
Red arrows indicate the stimulated processes. 
 
It has been shown that the up-regulation of lipogenesis is linked to the 
development of prostate cancer [97, 98]. Generally, lipids are considered important for 
the biology of cancer. They provide the building blocks for membrane synthesis, they 
represent a form of energy storage, a source for synthesizing signalling molecules and 
they are involved in post-translational modification of proteins crucial for cell-signalling, 
and hormonal synthesis [5]. All these factors are important for the growth, proliferation 
and invasion of cancer cells. 
These observations suggest that in prostate cancer cells, the up-regulation of the de 
novo lipogenesis as well as the increased amino acid metabolism could be associated with 
an increase in TCA activity to produce NADH and FADH2 required for these two 
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processes. Since TCA cycle is a central process for many metabolic reactions, the 
stimulation of metabolic processes, such as β-oxidation and lipogenesis along with the 
stimulated fatty acid uptake, may lead to a less efficient TCA cycle. A less efficient TCA 
cycle could affect its co-ordination with β-oxidation, which may result in incomplete 
fatty acid oxidation leading to the accumulation of intermediates of fatty acid oxidation, 
such as acylcarnitines. 
1.10. Thesis aims  
Prostate cancer is a disease where metabolic processes, such as lipogenesis and 
glycolysis have been re-programmed in order to provide sufficient energy to support the 
growth of the proliferating cells. Induction of several metabolic processes is accompanied 
with an increase in the levels of ROS. One of the consequences of ROS accumulation is 
their effect on the enzymes efficiencies involved in metabolic processes, such as the TCA 
cycle, which could affect the balance between metabolic processes. A less efficient TCA 
cycle results in a poor co-ordination with β-oxidation leading to the accumulation of 
intermediates of fatty acid oxidation, the acylcarnitines. Among these acylcarnitines is 
palcar. The presence of palcar was associated with pro-inflammatory responses and Ca2+ 
influx in endothelial cells. However, the levels of palcar and the consequences of the 
presence of palcar have not been investigated in prostate cancer. Therefore, the purpose 
of this thesis is to investigate the levels of palcar in prostate cancer tissue and explore the 
biological consequences of palcar accumulation in prostate epithelial non-cancerous and 
cancerous cells. I accomplish this research goal by addressing and investigating the 
following aims: 
- To test the hypothesis that palcar accumulates in the prostate cancer tissue as 
compared to the non-cancerous tissue, thus providing a biomarker for the 
metabolic dysfunction in prostate cancer (Chapter 2). 
 
- To test the hypothesis that the accumulation of palcar is associated with 
induction of IL-6 and Ca2+ influx in prostate epithelial cancer cells (Chapter 3). 
 
- To test the hypothesis that the mechanism by which palcar induces Ca2+ influx 
involves the activation of PTX-sensitive GPCR and L-type Ca2+ channels 
(Chapter 4). 
 
- To investigate the hypothesis that low concentrations of palcar are associated 
with changes in gene expression in prostate epithelial cells (Chapter 5).
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2.1. Introduction  
In this Chapter, the accumulation of palcar, as an example of long chain 
acylcarnitines, in prostate cancer tissue was investigated and compared to the levels of 
palcar in the benign non-cancerous tissue. As it has been reported that metabolism is 
disrupted in prostate cancer, this Chapter seeks to provide an answer to the question of 
whether palcar accumulation would represent a biomarker for metabolic dysfunction 
associated with prostate cancer. 
Metabolism is a set of chemical transformations that includes both catabolic and 
anabolic reactions. The critical balance of both types of reactions is essential for the 
generation of new organic molecules and the release of energy required for cellular 
growth and development. However, accelerating the rate of one metabolic reaction at the 
expense of others may result in the loss of this balance leading to metabolic dysfunction. 
Chronic disorders, such as CVD [99], DM type 2 [6] and obesity [7], display this type of 
imbalance especially between  β-oxidation and TCA cycle. Prostate cancer is another 
form of chronic disease that has seemingly unique metabolic features [5, 94]; one of them 
being the increase in fatty acid uptake. In prostate cancer cells despite the overexpression 
of glucose transporters [100], the uptake of fatty acids was more pronounced [9]. Fatty 
acids are transferred into the mitochondrial matrix for β-oxidation through the carnitine 
shuttle system. Very long chain and branched chain fatty acids have been found to be 
oxidized via peroxisomal β-oxidation to produce shortened chains that can be then 
transferred to mitochondria for further oxidation and energy production [27].  In prostate 
cancer, the rate of peroxisomal β-oxidation was up-regulated compared to normal 
prostate tissue [27]. 
A defect in the β-oxidation or alteration in any of the molecular components of the 
carnitine shuttle system involved in the transport of fatty acids into the mitochondria, for 
example CPT II and CAT, may result in a defect of fatty acid oxidation and the 
accumulation of intermediates, such as acylcarnitines [23, 24].  
2.1.1. Acylcarnitines 
Acylcarnitines have for some time been used as a biomarker to indicate an “inborn 
error of metabolism”, which is an inherited missing or inadequate enzyme that leads to an 
abnormality of metabolism [101, 102]. Higher levels of acylcarnitines were detected in 
the ischemic heart of animal models [103-105] as well as in the animal models of 
acquired mitochondrial dysfunction [106]. Also, it was noticed that high fat diets, obesity 
and DM type 2 were also associated with high plasma levels of acylcarnitines as a result 
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of impaired metabolic pathways caused by the loss of the integration between TCA cycle 
and β-oxidation [6]. The loss of the integration between these processes maybe caused by 
the less activity of TCA cycle without necessary affecting the rate of β-oxidation leading 
to the accumulation of acetylCoA. AcetylCoA is then converted into acetylcarnitine, 
which is a short chain acylcarnitines, and this is in order to reduce the toxic effect of the 
accumulated acetylCoA.  Moreover, the loss of integration between TCA cycle and β-
oxidation could also involve a less activity of β-oxidation due to a decrease in the activity 
of enzymes involved in β-oxidation leading to the accumulation of acylcarnitines, 
however this notion need further investigation. 
The accumulation of acylcarnitines was also linked to some metabolic disorders of 
protein metabolism, where the inherited deficiencies of important enzymes involved in 
energy production, such as acylCoA dehydrogenase, can cause an increase in the levels 
of acylcarnitines. AcylCoA dehydrogenase is an enzyme that catalyses the first step in 
the β-oxidation [31].  
2.1.2. Palmitoylcarnitine 
Palmitoylcarnitine (palcar) is a C16:00 acylcarnitine (figure 2.1) that is synthesized 
from the fatty acid palmitic acid, which represents approximately 80% of the total fatty 
acids synthesized in the cell [96], therefore, it is one of the commonly studied 
acylcarnitines in human and animal models and used as an example of long chain 
acylcarnitine. 
 
Figure 2.1: Structure of palcar. Palcar consist of a chain of 16 carbon atoms derived from 
the fatty acid palmitic acid, acyl group and carnitine molecule. 
 
The high plasma levels of palcar associated with obesity and DM type 2 [6, 7] 
suggest that the accumulation of palcar may represent a biomarker for metabolic 
dysregulation. In DM type 2, long chain acylcarnitines have been associated with 
oxidative stress, arterial stiffness as well as being linked to the risk of developing DM 
type 2 itself [33]. Lately, palcar accumulation has been reported in kidney cancer tissue 
and urine samples [8].  
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The levels of palcar quantified in different matrices from both human and animal 
models are summarised in table 2.1. The difference between the observed levels of palcar 
in these studies is due to the different techniques used to quantify palcar. In Vieira Neto 
et al study, the subjects were babies who depends on milk as their main food and milk is 
known to have high levels of fatty acids, which indicate that the mitochondria is overload 
with fatty acids, therefore having high rate of fatty acid metabolism [102]. 
Table 2.1: Levels of palcar as reported in the literature. 
Concentration of palcar Sample 
(species) 
Reference 
Healthy levels Unhealthy levels 
0.25µM 1.02 µmol/L  (VLCAD)1  
1.55µmol/L (GA-II)2 
Plasma 
(Human) 
Peng et al. 
Chromatography B, 2013. 
932: 12– 18 [31]. 
1.70 µM - Cord blood samples 
(Human) 
Vieira Neto et al. Braz J 
Med Biol Res, 2012, 45(6): 
546-556 [102]. 
2.16 µM - Heel-prick blood 
samples 
(Human) 
Vieira Neto et al. Braz J 
Med Biol Res, 2012, 45(6): 
546-556 [102]. 
0.04 ± 0.02 µM 
(non-diabetic lean) 
0.07 ± 0.02 µM (obese)  
0.06 ± 0.03 µM (diabetic)  
Plasma 
(Human) 
Mihalik et al. Obesity, 
2010. 18(9): 1695-700 [7]. 
0.352 ± 0.148 µM 0.404 ± 0.220 µmole/L 
(chronic fatigue syndrome)  
Plasma 
(Human) 
Reuter & Evans. J Intern 
Med, 2011. 270(1): 76-84 
[23]. 
0.87 µM - Whole blood 
(Human) 
Minkler et al. Clin Chem, 
2008. 54(9): 1451-62 [32]. 
0.92 µM - Blood spot 
(Human) 
Minkler et al. Clin Chem, 
2008. 54(9): 1451-62 [32]. 
≈ 12 µM - Skeletal muscle 
(Human) 
Minkler et al. Clin Chem, 
2008. 54(9): 1451-62 [32] 
≈ 17µM ≈ 19µM (high fat diet)  Adipose tissue 
(Rat) 
Sampey et al. PloS ONE, 
2012. 7(6): e38812 [46]. 
≈ 6 µM ≈ 12 µM (high fat diet)  Muscles 
(Rat) 
Sampey et al. PloS ONE, 
2012. 7(6): e38812 [46] 
- 60 µM 
(ischemic heart) 
Heart 
(rabbit) 
Moore et al. J Clin Invest. 
1982. 69(2): 377-83  [103] 
1
 VLCAD: very long chain acyl-CoA dehydrogenase; 2GA-II: glutaric acidemia type II.  
 
2.2. Aims 
– To quantify the levels of palcar in both non-cancerous and cancerous prostate 
tissue. 
– To investigate the possibility that palcar may represent a potential biomarker for 
the metabolic dysregulation associated with prostate cancer. 
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2.3. Materials and methods 
2.3.1. Tissue collection and sample preparation 
Prostate tissue samples were obtained from Norwich and Norfolk University 
Hospital (NNUH) Partners in Cancer Research Human Tissue Bank. A total of 20 tissue 
samples were used for method optimization and measurement of palcar. The protocol was 
approved by the Faculty of Medicine and Health Science Research Ethics Committee 
(reference: 2012/2013 – 10HT and 2012/2013 – 37), University of East Anglia.  
Clinical information (procedure, diagnosis and Gleason grade) was obtained for all 
tissue. Benign samples were obtained from either prostate glands with no cancer present 
obtained from a cystoprostatectomy, or from prostate glands with cancer. In the latter 
case the Gleason grade is reported. 
The tissue samples were received frozen and immediately pulverized to a fine 
powder under liquid nitrogen using tissue BioPulverizer (Cat. # YO-36903-00, Cole-
Parmer, UK). The resultant frozen powder was stored immediately at -80°C for later 
analysis.   
Levels of palcar were measured based on a previously published method [107] 
with slight modifications, optimised by Dr. Shikha Saha at the Institute of Food 
Research. These modifications are outlined below. Approximately 20 mg of the frozen 
tissue samples were placed in 2 ml screw cap centrifuge tubes. Fifty microliters of freshly 
prepared 1M potassium phosphate monobasic (KH2PO4) solution and 10µl of 100ng/ml 
of each of the deuterated internal standards solutions, D3-octanoylcarnitine (C8:0) and 
D3-palmitoylcarnitine (C16:0), were added to the sample. Then, 500µl of freshly 
prepared extraction solution of 3:1 acetonitrile:methanol (v/v) was added. The resulting 
mixture was vortexed for 30 seconds and further homogenised with a mechanical grinder 
for 30 seconds, then another 500µl of the freshly prepared extraction solution was added 
to each sample and homogenised for an additional 30 seconds and vortexed again. The 
mixture was centrifuged at 13000 round per minute (rpm) for 5 minutes at 4°C and the 
supernatants were transferred into insert vials to be analysed using a liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) system. 
The use of a mixture of labelled internal standards (figure 2.2) eliminates the issues 
associated with common ion fragmentation, which could result in an overestimation of 
palcar concentrations. Common ion fragmentation means the production of the same 
fragment ion of 85 mass to charge ratio (m/z) by all acylcarnitines (figure 2.3). This 
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means that palcar present in the tissue samples and the internal standard will produce the 
same fragment ion of 85 m/z and will be eluted at the same retention time, so the resulted 
peaks of palcar may sometimes represent an overestimation. To prevent the 
overestimation of palcar coming from internal standard, the deuterated octanoylcarnitine 
was used for accurate quantification because octanoylcarnitine has a different retention 
time. 
 
Figure 2.2: Chemical structures of D3-octanoylcarnitine and D3-palmitoylcarnitine. R1 
and R2 are: 
R2 R1 Name Transition (m/z) 
D3 OCO(CH2)6CH3 D3-octanoylcarnitine 291.2 →229.0 + 85.1 
D3 OCO(CH2)14CH3 D3-palmitoylcarnitine 403.4 → 85 
H3 OCO(CH2)14CH3 Palcar 400.0  → 85 
(Source: based on Sun et al [107]). 
 
 
Figure 2.3: Fragmentation of acylcarnitines. All acylcarnitines can be fragmented by 
breaking the bond indicated with red dashed line to produce a characteristic product 
(fragment) ion of 85 m/z. 
 
2.3.2. Preparation of internal standards and standard curve  
Stock solutions of internal standards of D3-palmitoylcarnitine (Cat. # DLM-1263-
0.01, Cambridge Isotope Laboratories, USA) and D3-octanoylcarnitine (Cat. # DLM-755-
0, Cambridge Isotope Laboratories, USA) were prepared by dissolving the corresponding 
compounds into DMSO to obtain a final concentration of 1mg/ml. These solutions were 
further diluted to 10µg/ml and 100ng/ml using freshly prepared extraction solution of 
acetonitrile and methanol (3:1). Internal standard work solution of 100ng/ml was used for 
standard and sample preparation. The standard curve was prepared using serial dilutions 
of a synthetic palcar stock solution (27mM) and following the same steps for sample 
preparation. Both the peak areas and the concentrations of the standards were used to 
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obtain an equation with a response factor. This equation was used to quantify the 
concentrations of palcar in the prostate tissue samples. 
2.3.3. LC-MS/MS determination and quantification of palcar 
The high performance liquid chromatography (HPLC) system used was Agilent 
1200 series LC combined with Agilent 6490 triple Quad LC/MS with electrospary 
interference (ESI) built in, in addition to a quaternary pump, degasser, auto-sampler, 
thermo-stated column compartment and a wide range of wavelength ultraviolet (UV) 
detector. The separation was performed using reverse phase HPLC silica column 
(Acquity UPLC, 2.1 x 50mm, 1.7 µm, BEHC8 column, Waters Ireland).  
The column temperature was maintained at 37°C and 15°C for the autosampler. A 
small aliquot (10µl) was automatically injected into the LC-MS/MS and eluted with 10% 
of mobile phase A (0.1% ammonium acetate in de-ionized water) and 90% of mobile 
phase B (0.1% ammonium acetate in methanol), at a rate of 0.5ml/minute. Mobile phase 
A was prepared by dissolving 0.2g of mass spectrometer (MS) grade ammonium acetate 
(Cat. # 01244153, Biosolve BV, Netherland) and 0.535g of 0.05% heptafluorobutyric 
acid (Cat. # 52411-5ML-F, Sigma-Aldrich, UK) in de-ionised water. Mobile phase B was 
prepared in the same way as mobile phase A, but dissolved in HPLC-grade methanol 
(Cat. # 1691935328, Merk, Germany). A positive ion mode ESI was used as ionization 
source. The nebulizer gas used was nitrogen with a flow of 12 L/min, pressure 60 psi and 
temperature of 200°C. 
The system lines were purged for 5 minutes at 0.5ml/minute using the prepared 
mobile phase A & B prepared as described above. The operating parameters used are 
shown in Table 2.2. 
Table 2.2: LC-MS/MS parameters for operation 
LC – system 
Injection volume  10µl 
Mobile phase 90% methanol 10% water 
Flow rate 0.5ml/min 
Syringe/system wash Acetonitrile: Methanol: water 
(25:50:25)  
MS–MS system 
Scan mode multiple reaction monitoring (MRM) 
Q2 precursor ion 400 m/z 
Product ion 85 m/z 
Polarity Positive 
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In the MRM mode of analysis, that utilizes a triple quadrupole MS, the mass (m/z) 
of desired parent ion, which was 400 m/z, was selected in the first quadrupole. The 
second quadrupole generates fragment ion(s) through collisional induced dissociation, 
while in the third quadrupole, the product (fragment) ion, which was 85 m/z, was 
monitored. Therefore, the three mass analysers (triple quadrupole) of the MS, cycle 
through a series of transitions (the specific pair of 400/ 85 m/z selected) and record the 
signal of each transition as a function of elution time to give a peak that represent the 
presence of palcar.   
The peak area of palcar was then integrated for each tissue sample and palcar 
concentration was calculated using the response factor obtained from the equation created 
by performing the standard curve (section 2.3.2). For example, if the peak area of palcar 
obtained from a tissue was 251929.24, and the standard curve gives the following 
equation: y = 2470070.31x – 2909.50, then the concentration of palcar would be 
(251929.24+ 2909.5)/2470070.31, which is equal to 0.103µM. 
2.3.3.1. Data processing  
All standard and tissue samples were analysed in triplicate. Mass Hunter B.06 
software was used to integrate the chromatographic peaks and calculate the area under 
the curves. Calibration curves were generated using Excel 2010 and a linear regression of 
the peak areas of the serial dilutions of palcar stock solution was obtained. The response 
factor was used to indirectly calculate the concentration of palcar in the prostate tissue 
samples. 
2.3.3.2. Statistical analysis 
Tissue levels of palcar were quantified from 20 prostatic tissue samples; 10 non-
cancerous (benign) and 10 cancerous tissue. The levels represent mean ± SEM. To 
compare the mean levels of palcar in cancerous tissue to non-cancerous (benign) tissue 
statistical analysis was performed with unpaired t-test using GraphPad Prism version 5.00 
for Windows (GraphPad Software, San Diego California USA, www.graphpad.com). 
2.4. Results  
A fragment ion of 85 m/z was detected in the two internal standards that were used 
to detect the presence of palcar in the prostate tissue (figure 2.4). Total ion chromatogram 
(TIC) showed the peaks of both D3-octanoylcarnitine and D3-palmitoylcarnitine internal 
standards, where the retention times for the D3-octanoylcarnitine and D3-
palmitoylcarnitine were 1.678 and 2.063 minutes, respectively. Since the tissue samples 
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were mixed with the D3-palmitoylcarnitine during sample preparation, the peak of the 
C16:00 represent palcar detected from both the internal standard (403.0/85 m/z) and the 
tissue sample (400.0/85 m/z).  
 
Figure 2.4: TIC of D3-octanoylcarnitine and D3-palmitoylcarnitine from a representative 
prostate tissue sample. The retention time for D3-octanoylcarnitine (C8:0) is 1.678 
minutes detected using selected scan of 291.0/85 m/z, and 2.063 minutes for D3-
palmitoylcarnitine (C16:0) with scan of 403.0/85 m/z. 
 
The MRM chromatogram was extracted from the TIC. D3-Palmitoylcarnitine was 
identified by the mass screening of 403.0/85 m/z (figure 2.5), while palcar detected in 
prostate both non-cancerous and cancerous tissue was identified by the mass screening of 
m/z 400.0/85 (figure 2.6), which has a retention time similar to the palcar internal 
standard.  
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Figure 2.5: LC–MS/MS chromatogram of D3-palmitoylcarnitine from a representative 
prostate tissue sample. Palcar (C16:0) from internal standard was detected using selected 
MRM scan of 403.0/85 m/z. 
 
 
Figure 2.6: LC–MS/MS chromatogram of palcar from a representative prostate tissue 
sample. Palcar was detected using selected MRM scan of 400.0/85 m/z. 
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Analysis of palcar levels in prostate tissue using LC-MS/MS showed significantly 
higher levels of palcar in the prostate cancerous tissue compared to the non-cancerous 
benign tissue (P=0.0135, figure 2.7A). There were individual differences in the quantified 
levels of palcar in both non-cancerous benign and cancerous prostate tissue, these values 
ranged from almost zero to approximately 0.0747±0.0234µM for the benign tissue with 
an average of 0.0329±0.0234µM, and from approximately 0.02167±0.0319µM to 
0.1030±0.0319µM for the cancerous tissue with an average of 0.0671±0.0319µM (figure 
2.7B). The characteristics of each tissue used are depicted in Table 2.3.  
 
Figure 2.7: Concentrations of palcar (µM) in prostate benign and cancerous tissue. 
Tissue samples were obtained from NNUH Partners in Cancer Research Human Tissue 
Bank. A) The mean concentrations of palcar (µM) ± SEM from 10 benign and 10 
cancerous tissue samples. B) Palcar concentrations (µM) ± SEM from each individual 
tissue. The x-axis represents the individual tissue code. Statistical analysis in A was 
performed with unpaired t-test. *P = 0.0135.  
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Table 2.3: Characteristics of prostate benign and cancerous tissue. 
Tissue code Procedure* Diagnosis Gleason grade 
08TB0254 Cystoprostatectomy Normal - 
04TB153 TURP Hyperplasia - 
04TB053 TURP Benign - 
03TB005 Cystoprostatectomy Benign - 
05TB0218 Radical prostatectomy Benign 7 
07TB0033 Radical prostatectomy Benign 7 
06TB0153 Radical prostatectomy Benign 7 
02TB066 TURP Benign 7 
02TB009 Radical prostatectomy Benign 7 
04TB28 Radical prostatectomy Benign 10 
02TB008 Radical prostatectomy Adenocarcinoma 7 
04TB019 Radical prostatectomy Adenocarcinoma 7 
06TB0159 Radical prostatectomy Adenocarcinoma 7 
07TB0031 Radical prostatectomy Adenocarcinoma 7 
04TB134 Radical prostatectomy Adenocarcinoma 7 
02TB008 Radical prostatectomy Adenocarcinoma 7 
05TB0175 Radical prostatectomy Adenocarcinoma 7 
03TB122 TURP Adenocarcinoma Not provided 
04TB003 TURP Adenocarcinoma 9 
08TB0223 Radical prostatectomy Adenocarcinoma 4+3+5 
* Cystoprostatectomy: the removal of the urinary bladder and prostate gland. TURP: the 
removal of a section of the prostate gland. Radical prostatectomy: the removal of the 
prostate and the surrounding tissue. 
 
2.5. Discussion 
In this study, the levels of palcar in both non-cancerous and cancerous prostate 
tissue were quantified to investigate the possibility that palcar may represent a potential 
biomarker for the metabolic dysregulation associated with prostate cancer. The levels of 
palcar in prostate cancer tissues were higher than the levels in the non-cancerous tissue. 
In this study, levels of palcar were measured using an LC-MS/MS method. This 
method is a significant improvement to a previously published method [107] as it does 
not include a derivatisation step. Many studies have analysed carnitine and acylcarnitines 
from different matrices using LC-MS/MS techniques, however, they all have used the 
derivatisation technique before sample injection. The purpose of derivatisation is to 
change the chemical structure of the tested compound to include ionic or charged groups 
in order to increase the intensity of the signal detected on the positive mode, or to change 
the hydrophobicity of the test compound, thus improving the detection [108]. Therefore, 
derivatisation technique is applied for unstable compounds that are not easily detected. 
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Palcar is a stable compound [109]. Its stability was verified and tested by LC-MS/MS in 
our lab in the Institute of Food Research, where it was found that palcar was stable at 
15°C for at least 24 hours. The inclusion of a derivatisation step may have some 
drawbacks including the partial hydrolysis of the test compound and/or incomplete 
reaction [31], which may result in an underestimation of its presence. Due to the small 
size of the obtained prostate tissue samples, it was difficult to use the tissue samples to 
perform both the derivatisation and non-derivatisation steps to compare palcar tissue 
levels between derivatised and non-derivatised tissue samples, which could provide more 
confidence in the data.  
Accumulation of acylcarnitines has previously been measured in animal tissue of 
kidney [8], liver, skeletal muscle and heart [110]. Following the review of the relevant 
literature, the levels of acylcarnitines, specifically palcar, have not been published in 
human prostate tissue, therefore, in this thesis it is the first time that the levels of palcar 
were measured in human prostate tissue. In this study increased levels of palcar were 
observed in prostate cancerous tissue compared to non-cancerous benign tissue. The 
levels of palcar in the cancerous tissue ranged from 0.02 µM to 0.1µM with an average of 
0.07µM compared to 0.034µM average of the non-cancerous benign tissue (figure 2.7A). 
These results were obtained from 20 prostate cancer and non-cancer tissue samples. This 
limited number of tissue samples is in accordance with the ethical approval for 
performing this study, which limits the number of the tissue samples to 20 samples. For 
further analysis with additional samples additional ethical approval would be required. 
However, due to the time limitation for the completion of this work, this study was not 
further investigated. Nevertheless, the results from the 20 tissue samples indicate the 
utility of prostate tissue palcar levels as a diagnostic tool for distinguishing prostate 
cancer from non-cancer tissues. It is important to note that having more tissue samples 
would give a robust assessment of the potential use of palcar as a diagnostic tool for 
prostate cancer.  
There are possible hypotheses that may explain the increased levels of palcar in 
cancer tissue. One explanation is that a higher degree of tissue lipid metabolism is 
occurring in the cancerous tissue. This might indicate mitochondrial overload of the long 
chain fatty acid (palmitic acid), which could be an indication of stimulated lipolysis. 
Stimulated lipolysis is a characteristic feature of cancer cells [111, 112]. In vitro models 
of prostate cells revealed that the uptake of palmitic acid by both malignant and benign 
cells was significantly higher than that of glucose [9], which suggests that fatty acid 
oxidation is a dominant energy source for the prostate cells.  
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Overload with fatty acids either as a result of lipolysis or high fat diet may lead to 
the production of high levels of acetylCoA by β-oxidation. It has been found that 
acetylCoA is a precursor for acetylcarnitine and ketone bodies [113] and it has been 
suggested that formation of ketone bodies may inhibit or reduce the efficiency of TCA 
cycle as the mitochondria is unable to synthesize the intermediate of TCA cycle [6]. A 
less efficient TCA cycle would result in a mismatch between the rates of β-oxidation and 
TCA cycle, leading to a metabolic defect that results in an incomplete fatty acid oxidation 
and the accumulation of other acylcarnitines, such as palcar [6]. In prostate cancerous 
tissue, it has been found that peroxisomal β-oxidation was up-regulated [27]. Alpha-
methylacylCoA racemase and its downstream enzymes pristanoylCoA oxidase and D-
bifunctional protein, involved in peroxisomal β-oxidation, were overexpressed in prostate 
cancer tissue [27]. Peroxisomal β-oxidation is important for the initial oxidation of 
branched and very long chain acylcarnitine. The resultant chain-shortened products can 
then be transported to the mitochondrion for complete degradation. However, a defect in 
mitochondrial β-oxidation may result in the accumulation of fatty acid intermediates, 
such as acylcarnitines, which is another explanation for the accumulation of palcar in the 
prostate cancerous tissue observed in this study.  
In this study the accumulation of palcar in prostate cancer tissue was hypothesized 
to be a result of a metabolic defect. A metabolic defect not only imply a mismatch 
between the rate of β-oxidation and TCA cycle, but also a defect in mitochondrial 
transport system of fatty acids through the mitochondrial membrane, which provide 
another explanation for the observed increased levels of palcar in prostate cancer tissue. 
There are two enzymes responsible for this process, CPT I and CPT II. It seems unlikely 
that a CPT I defect would result in palcar accumulation, as this enzyme is involved in 
transferring the acyl group from fatty acylCoA to carnitine to form palcar. In support of 
this, accumulation of acylcarnitines found in other metabolic disorders, such as obesity 
and DM type 2 was not related to a defect in CPT I enzyme since all fatty acids were 
found to be converted into acylcarnitines and then into long chain hydroxyl acylcarnitines 
[7]. Hydroxyl acylcarnitines are intermediates of β-oxidation occurring as a result of the 
activity of very-long-chain acylCoA dehydrogenase (VLCAD) and long chain 3-
hydroxyacyl-CoA dehydrogenase [7]. However, accumulation of palcar in prostate 
cancer tissue could be a result of an inadequate activity of CPT II enzyme, which is 
involved in transferring the acyl group from acylcarnitines to the mitochondrial CoA. 
This assumption was suggested in diabetic subjects who have high plasma levels of 
palcar compared to non-diabetic subjects [7]. Nevertheless, since the activity of this 
enzyme was not determined in prostate tissues, further research is needed to investigate 
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this notion. The explanations for the accumulation of palcar in prostate cancer tissue 
samples are hypotheses and need further investigations to determine the nature of this 
accumulation. 
The levels of palcar detected in the prostate non-cancer and cancer tissue were in 
the range of the plasma levels from non-diabetic lean subjects and diabetic and obese 
subjects, respectively [6, 7]. It is important to note that accumulation of palcar may start 
in tissue prior to its leakage to the plasma and since the tissue content of carnitine is 
higher than in plasma [114], the expected tissue levels of palcar should be higher than 
that in the plasma. In this study, the plasma levels of palcar from the same prostate tissue 
donors were not measured, and therefore were not possible to compare the levels of 
palcar in tissue samples with that in plasma. However, in this study, when comparing the 
levels of palcar in prostate cancer tissue with that reported in the plasma from diabetic 
and obese subjects, the levels of palcar in prostate cancer tissue samples were not higher 
than that reported in the plasma samples and this might be related to different tissue type 
where the metabolic defect occur. In diabetic and obese subjects the metabolic defect 
occur in the liver and the carnitine content in these tissue were reported to be higher than 
the plasma levels  [114]. 
Accumulation of acylcarnitines has been positively correlated with mitochondrial 
dysfunction associated with a high fat diet [46]. Rats fed with a high fat diet induced an 
increase in the serum levels of palmitic acid to approximately 80µM as well as an 
increase in medium and long chain acylcarnitines in muscle and adipose tissue. Also this 
was accompanied with an increase in the levels of triglycerides, which is a marker for 
metabolic syndrome [46]. Moreover, there is a growing body of evidence suggesting that 
accumulation of acylcarnitines may represent a potential biomarker for metabolic 
dysfunction associated with insulin resistance and obesity [12, 33]. High plasma levels of 
long chain acylcarnitines were detected in obese and diabetic subjects during fasting. 
This was suggested to be as a result of a limitation in fatty acid β-oxidation, which could 
results in a mismatch with the rate of TCA cycle. This leads to an incomplete fatty acid 
oxidation and the accumulation of acylcarnitines. During fasting, fatty acid oxidation is 
activated, which increases the levels of acylcarnitines. These levels were decreased by a 
short-term insulin clamp in obese subjects indicating a switch from fat to carbohydrate 
metabolism. This was in contrast to diabetic subjects, who have an increase in short and 
medium chain acylcarnitines indicating a defect in fatty acid oxidation that was 
associated with insulin resistance [7]. In diabetes type 2, the increase in fatty acid 
oxidation leads to an increase in blood glucose levels because of the glucose fatty acid 
cycle and because glucose is not being used as an energy source, fatty acids are being 
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consumed, however, because of the metabolic defect resulting from the mismatch 
between β-oxidation and TCA cycle, intermediates of fatty acid oxidation including the 
short and medium chain acylcarnitines are accumulated. 
Accumulation of acylcarnitines were detected in kidney and liver cancer and it has 
been shown that this accumulation was associated with cancer grade; the higher the 
cancer grade, the higher the levels of acylcarnitines [8]. In prostate cells, cancer is 
reflected by the Gleason grade; the more aggressive the cancer, the higher the Gleason 
grade. In the work presented in this chapter, most of the tissue obtained from the human 
tissue bank had a Gleason grade of 7 (table 2.3). The results showed that there were 
variations in the levels of palcar between these tissue (figure 2.7B), which could be due 
to inter-individual variability. This variability can be explained by the fact that Gleason 
score of 7 is a sum of two figures that represent the most dominant and second most 
dominant tumour according to the degree of cells differentiation (as discussed in Chapter 
1). A Gleason score of 7 may mean 4+3 or 3+4, which are both different. This means 
different tissue level of metabolism between the two samples. The tissue samples 
obtained for this study were only provided with the combined Gleason score without 
specifying each figure of the score. In addition, these donors may have other 
complications, such as diabetes that could affect their metabolism and therefore affecting 
the levels of palcar.  
Having some of the cancer samples with normal levels of palcar and some of the 
normal samples with high levels suggests the need for further investigation using a higher 
number of tissue samples with more variable Gleason grade in order to validate the use of 
palcar as a candidate for diagnostic purposes in addition to explore whether the increase 
in palcar levels is correlated with the increase in Gleason grade. 
 
2.6. Conclusion  
In this study palcar was found to accumulate in prostate cancerous tissue in levels 
that were higher than benign non-cancerous tissue. The presence of high levels of palcar 
in the cancerous prostate tissue may indicate that palcar could represent a potential 
biomarker for the metabolic disturbance associated with prostate cancer. However 
analysis of higher number of tissue samples is needed in order to confirm the validity of 
using palcar as a diagnostic tool. The reason behind the accumulation of palcar was not 
investigated and therefore further studies are needed to determine the nature of the 
metabolic disturbance. 
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Accumulation of palcar in cancerous prostate tissue may influence the biological 
activities of the cancer cells prior to their leakage into the surrounding environment. 
These activities may include changing membrane permeability, thus changing the 
homeostasis of small intracellular mediators, which have a role in other signalling 
pathways that can be linked to the induction of pro-inflammatory responses and altering 
gene regulating proteins. Therefore, whether the presence of palcar is only a biomarker 
for the metabolic disturbances in prostate cancer or induces other physiological roles in 
the cells is to be addressed in the next chapter, where the effect of palcar on IL-6 
secretion and Ca2+ influx as possible biological consequences are studied in vitro using 
prostate cell lines. 
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Effect of palmitoylcarnitine on 
cellular IL-6 secretion and 
calcium influx 
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3.1. Introduction 
Previously in Chapter 2, the accumulation of palcar was observed in prostate 
cancer tissue at levels that were higher than in non-cancer tissue. This accumulation may 
have biological consequences. In this Chapter, the secretion of the pro-inflammatory 
cytokine IL-6 and changes in membrane permeability, measured as the induction of Ca2+ 
influx, were investigated. Palcar-induced Ca2+ influx was compared to that induced by 
DHT, the hormone that is associated with prostate cancer progression. These properties 
were studied in vitro using prostate non-cancerous PNT1A and BPH-1, and cancerous 
DU145 and PC3 cells.  
3.1.1. Acylcarnitines and pro-inflammatory responses 
Acylcarnitines have been associated with pro-inflammatory responses including 
the secretion of TNF-α and pro-inflammatory cytokines, such as IL-3, IL-16 and IL-23 
[46, 47]. This was in addition to their effect on inducing an increase in the levels of 
NFκB, which is one of the downstream targets of TLRs that are known to regulate the 
synthesis of the IL-6 [6, 48]. 
3.1.2. IL-6 and prostate cancer 
Pro-inflammatory cytokines, such as IL-6, have been associated with the 
development and progression of prostate cancer [49-51]. The mode of action of IL-6 
involves its binding with its membrane-bound receptor, IL-6 receptor α (IL-6Rα), that 
has been found in prostate cancer tissue [115], LNCaP, DU145 and PC3 cancerous cell 
lines [116]. The mode of action of IL-6 involves the binding of IL-6 with IL-6Rα to form 
a complex, then this complex binds to glycoprotein 130 to initiate cellular responses [49]. 
These responses include the induction of different growth phenotypes depending on the 
type of cultured cells and the activated signalling pathways. These phenotypes could be 
growth-inhibitory or growth-stimulatory phenotypes. In PC3 and DU145 cells, IL-6 
induced growth and proliferation via the activation of  phosphatidylinositol-3-kinase 
(PI3K) pathway [117, 118], while in LNCaP cells; it induced growth arrest via the 
activation of signal transducer and activator of transcription 3 (STAT3) and Mitogen–
activated protein kinase (MAPK) pathways [117].  
3.1.3. Acylcarnitines and Ca2+ influx 
Due to their chemical nature, acylcarnitines have been shown to alter membrane 
permeability by changing the activity of membrane associated ion channels [41-43].  
Alterations in a cell membrane permeability could lead to changes in the homeostasis of 
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ions, such as Ca2+. In endothelial cells, palcar has been shown to induce Ca2+ influx [44]. 
This has also been observed in response to DHT in prostate cancer cells [45]. 
3.1.4. DHT and inflammation in prostate cancer 
DHT exerts its effect by binding with the AR to form a complex. This complex 
translocates into the nucleus to bind with the androgen response element.  The DHT-AR 
complex acts as a transcription factor that is able to alter inflammatory responses. In 
human prostatic myofibroblast cells (hBPH), DHT acts as an anti-inflammatory agent, 
where it reduces the secretion of IL-6 and IL-8 in response to oxidized LDL [119]. 
However, in different cell lines, different concentrations of DHT have been found to 
induce a variety of effects; either pro- or anti-inflammatory. In HUVEC cells, 10nM 
DHT decreased the endotoxin–induced adhesion molecule, cyclooxygenase-2, IL-6 and 
TLR4 expression [120]. Whereas higher concentration (400nM) were found to enhance 
the activation of NFκB due to its suppressing effect on NFκB  inhibitory protein, which 
leads to an increase in the activity of vascular cell adhesion molecule-1promoter [121], 
thus acting as a pro-inflammatory agent.  
3.2. Aims 
- To investigate in vitro the biological consequences of palcar accumulation in 
prostate cancerous and non-cancerous cell lines, through investigating: 
• Palcar pro-inflammatory activity via the induction of IL-6 secretion. 
• The effect of palcar on changing membrane permeability assessed by 
measuring the induction of Ca2+ influx. 
- To compare the effects of palcar and DHT on IL-6 secretion and Ca2+ influx. 
3.3. Materials and methods 
3.3.1. Cell-culturing techniques 
3.3.1.1. Cell lines 
Human epithelial cell line from normal post pubertal prostate (PNT1A) (Cat # 
95012614), human prostate adenocarcinoma (PC3) (Cat # 90112714) and human 
Caucasian prostate carcinoma (LNCaP) (Cat # 89110211) cell lines were obtained from 
the European Collection of Cell Culture. The human Caucasian prostate adenocarcinoma 
(DU145) cell line was obtained from the American Type Culture Collection (Cat # HTB-
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81). The benign hyperplastic prostatic epithelial (BPH-1) cell line was obtained from the 
German collection of microorganism and cell cultures (No. ACC 143, DSMZ, Germany).  
3.3.1.2. Cells resuscitation  
All cell-culture work was carried out in laminar flow biological safety cabinet 
using sterilised equipment and aseptic techniques. PC3, DU145, PNT1A and BPH-1 cells 
were suspended in fetal bovine serum (FBS, Cat # 10270, Life Technologies, UK) 
containing 20% dimethyl sulphoxide (DMSO; Cat # 276855, Sigma-Aldrich, UK) and 
kept in cryovials in liquid nitrogen at -80˚C. The cryovial was transferred to cell culture 
room in dry ice. A small piece of tissue paper sprayed with 70% ethanol was used to 
sterilize, partially opened and re-tightened the cryovial. These steps were carried out in 
the safety cabinet. The cryovial was placed in the water bath at 37˚C for approximately 
one minute to defrost the cells. 
PNT1A, BPH-1 and LNCaP cells were routinely resuscitated and cultured in RPMI 
media (Cat # E15-885, PAA cell-culture Company, UK). DU145 and PC3 cells were 
cultured in EMEM (Cat # M2279, Sigma-Aldrich, UK) and HAMS (Cat # BE02-014F, 
Lonza Verviers sprl, UK) media, respectively. All media were supplemented with 10% 
FBS, 1% glutamine and 100 units/ml penicillin and streptomycin (Cat # 10378-016, Life 
Technologies, UK). 
The cell suspension was mixed gently and centrifuged at 1500 rpm for 3 minutes to 
remove the DMSO. The cell pellet was re-suspended in the warmed FBS-supplemented 
media, seeded into T-25 flask and incubated at 37˚C and 5% CO2. The medium was 
changed after 48 hours to remove the non-adherent cells and subsequently every two days 
until the cell growth reached 70-80% confluence and ready for sub-culturing. Figure 3.1 
shows the cell morphology. 
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Figure 3.1: Cell morphology of prostate non-cancerous and cancerous cell lines. A) 
PNT1A, B) BPH-1, C) PC3, D) DU145 and E) LNCaP cells. 
 
3.3.1.3. Cells sub-culturing 
Cells were sub-cultured by removing the media followed by washing with 1x 
Dulbecco's Phosphate Buffered Saline (PBS; Cat # 14200059, Gibco, UK) twice. Then 
cells were trypsinized using 2ml of 0.05% EDTA trypsin (1x)/10cm (Cat # 25300054, 
Life Technologies, UK) at 37°C for 3 minutes. The cells were then collected using FBS-
supplemented media. The cells suspension were seeded into 10cm dishes and incubated 
at 37˚C and 5% CO2. The media was then changed every 48 hours and then after two 
days until the growth reached 70 – 80% confluence.  
3.3.2. Viability assays  
3.3.2.1. Water-soluble Tetrazolium (WST-1) viability assay  
3.3.2.1.1. Background 
The principle of water-soluble tetrazolium (WST-1) assay relies on measuring the 
intensity of the formazan dye formed by converting a tetrazolium salt, contained within 
the WST-1 reagent, by the mitochondrial dehydrogenase enzyme present in the cells. As 
the number of viable cells increases the activity of the mitochondrial dehydrogenase 
increases, therefore the intensity of the dye formed is directly proportional to the amount 
of mitochondrial dehydrogenase [122].  
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3.3.2.1.2. Measurement of cell viability using WST-1 
A range of palcar concentrations (5, 10, 50 or 100µM) was selected to test their 
effect of cells viability. This range was selected based on the levels of plasma 
acylcarnitines reported under metabolic dysfunction [31, 103]. Palcar at 50µM was above 
the concentrations reported in human plasma, but within the range reported in ischemic 
heart of animal model [103], whereas 100µM was above the reported levels in human 
and animal models. However, both 50 and 100µM palcar have been previously 
investigated in cardiac sarcolemmal membrane under ischemic conditions [41, 123], 
which is another form of metabolic dysfunction that include a dysfunction of fatty acid 
metabolism, but were not investigated in human prostate cells. The effect of 50µM was 
compared to that of 100µM.  
PNT1A and PC3 cells were seeded on 96-well culture plate. Once the cells reached 
70% confluence, cells were treated with DMSO or 5, 10, 50 or 100µM palcar for 24hour 
at 37°C and 5%CO2. Then, 10µl of cell proliferation reagent WST-1 (Cat # 
11644807001, Roche, UK) was added to each treatment and incubated for 30 minutes at 
37°C and 5% CO2. The spectrophotometric absorbance, which corresponds to the cell 
metabolic activity or viability, was then measured at a wavelength of 450nm.  
3.3.2.2. Trypan blue based viability assay 
3.3.2.2.1. Background 
Trypan blue is a dye used to measure cell viability based on the integrity of the cell 
membrane. Viable cells have an intact cell membrane and thus will exclude the dye and 
upon visual examination under microscope, cells will appear clear and non-stained as 
their cytoplasm is clear. Nonviable cells, lacking an intact membrane, will appear blue 
under microscopic examination as the dye is able to penetrate into the cytoplasm. 
3.3.2.2.2. Measurement of cell viability using trypan blue 
The PC3 cell suspension was collected and centrifuged at 1500rpm for 3 minutes 
at room temperature. The cell pellet was washed, re-suspended in media supplemented 
with 10% FBS  and left for one hour at 37°C to recover from trypsin, then the suspension 
was seeded into 96 well plate. Palcar (50µM) was then added to the cell suspension and 
incubated for 5 minutes at 37°C. A volume of 50µl of cell suspension was transferred to a 
1.5ml eppendorf tube containing 400µl media, supplemented with 10% FBS, and 50µl 
trypan blue (1:1 v/v). The mixture was mixed and incubated at room temperature for 2 
minutes to allow the dye to penetrate the cells. During the 2 minutes incubation time, the 
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haemocytometer and the cover slip were prepared for cell. Both unstained (viable) and 
blue stained (non-viable) cells were counted. The percentage (%) of cell viability was 
calculated using the following equation. 
 
The % viability = 	 			
				
(		
						
			)
× 100 
 
3.3.3. Measuring IL-6 secretion using enzyme-linked immunosorbant assay 
(ELISA)  
3.3.3.1. Background 
The principle of using the enzyme-linked immune sorbent assay (ELISA) depends 
on the special binding between the proteins (antigens) of interest and the antibodies 
attached to a solid surface/support, where a solution of the antigen molecules to be 
assayed is added, so that the antigen binds to their specific antibody. Then, a second 
antibody is then added, which has an enzyme attached and specific for the antigen. 
Finally a substrate solution specific for the enzyme is added that produces a fluorescent 
compound on interaction with the enzyme. The intensity of the fluorescence is then 
measured, which gives a direct indication of the amount of antigen present in the sample. 
3.3.3.2. Measurement of IL-6 secretion  
PNT1A and PC3 cells were seeded in 24-well culture plate and once cell growth 
reached 70% confluence, they were treated with DMSO, palcar (5, 10, 50 and 100µM), 
lysophosphatidylcholine (LPC; 5, 10, 50 and 100µM) or DHT (1, 10, 100 and 1000nM) 
for 24 hours at 37°C and 5% CO2. The media was then collected in labelled 1.5ml 
eppendorf tubes and stored at -20°C until analysis. IL-6 secretion was measured using the 
commercially available Human IL-6 Quantikine ELISA kit (Cat # D6050, R & D 
Systems, UK) following the manufacturer’s protocol. Diagram 3.1 show the steps 
followed to measure IL-6 in the media. 
Chapter 3 
52 
 
Diagram 3.1: Steps of measuring IL-6 secretion using ELISA kit. 
 
3.3.4. Measuring gene expression  
3.3.4.1. Background  
Measuring gene expression depends on using RNA extracted from the cells by 
disturbing the plasma membranes using highly denaturing buffer. This results in the 
inactivation of the other RNAs (mRNA, rRNA and tRNA) and ensures the purification of 
intact RNA. A homogenization step is applied in order to reduce the viscosity occurring 
as a result of the presence of genomic DNA and other high molecular weight cellular 
components. The mRNA is selectively separated using silica-based membrane present 
within a spin column in presence of ethanol and eluted using RNA free water. 
3.3.4.2. Extraction of total RNA 
PNT1A and PC3 cells were seeded in 6-well culture plate and once growth reached 
70% confluence, the cells were treated with 5, 10, 50 or 100µM palcar and incubated for 
24 hours at 37°C and 5% CO2. Cell culture media were removed and cells were rinsed 
Assay diluent (100µl) was added to the each wells 
Standards or the samples (100µl) was added to each well 
The plate was covered with a plate sealer and incubated for 2 hours at room temperature
The wells were washed 4 times
A conjugate (200µl) was added to each well
The plate was covered with a new plate sealer and incubated for 2 hours at room 
temperature
The wells were washed 4 times
Substrate solution (200µl) was added to each well, then incubated at room temperature for 
20 minutes and protected from light
Stop solution (50µl) was added to each well followed by reading the absorbance at 450 nm 
within 30 minutes
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twice with cold PBS (1x). Then, cells were collected using rubber scrappers and total 
RNA was extracted using RNeasy mini kit (Cat # 74104, Qiagen, UK) following the 
manufacturer’s procedure (diagram 3.2). The extracted RNA was used as a template for 
measuring gene expression.  
Diagram 3.2: RNA extraction using RNeasy mini kit 
 
3.3.4.3. Determination of RNA quantity and quality using Nanodrop  
The quantity and quality of RNA present in the cell sample was measured using 
UV absorbance as determined by RNA Nanodrop 1000 (Life Technologies, UK). The 
two wavelengths used is 260 and 280nm. An absorbance reading at 260nm reflects the 
quantity of RNA; an absorbance of one unit at 260nm corresponds to 40µg/ml RNA, 
while absorbance readings at 280nm are used to measure the amount of protein in the 
sample. The ratio of the readings at 260nm and 280nm provides an estimate of purity of 
RNA with respect to proteins, thus reflecting the quality of the RNA. Pure RNA has a 
ratio of 1.9 – 2.1. The ratio for All RNA samples used in the experiments needed for 
conducting the work in this thesis were within this ratio. 
Cell culture medium was removed and cells were washed twice with PBS (1x). 
Cells (1 x 106 cells/9.4cm2 well)  were disrupted using 600µl β-mercaptoethanol 
containing RLT buffer
Cells lysates were collected and homoginized by centrifugation at ≥10000rpm for 2 minutes
Ethanol (70%, 600µl) was added to the lysates and mixed by pipetting
Samples (700µl) were transferred to RNeasy spin column and centrifuged for 15 seconds at 
≥10000rpm 
Buffer RW1 (700µl) was added to the RNeasy spin column and
centrifuged for 15 seconds at ≥10000rpm
Buffer RPE (500µl) is added to the RNeasy spin column and
centrifuged for 15 seconds at ≥10000rpm to wash the spin column membrane
The RNeasy spin column is placed in a new 2ml collection tube and centrifuged for 15 
seconds at ≥10000rpm
The RNeasy spin column was placed in a new 1.5 ml collection tube and 30µl RNA-free 
water was directly added to the spin column membrane followed by centrifugation for 1 
minute at ≥10000rpm to elute the RNA.
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3.3.4.4. Quantification of gene expression of IL-6 using real-time reverse-
transcription-polymerase chain reaction (RT-PCR)  
IL-6 gene expression was measured by real time RT-PCR performed using  an 
Applied Biosystems OneStep Plus real time RT-PCR system on an optical 96-well plate 
in a total volume of 20 µl/well, consisting of TaqMan 1-step RT-PCR master mix reagent 
kit (Applied Biosystems), 20 ng total RNA, and IL-6 primers and probes: IL-6 forward 
sequence 5’-CTCTTCAGAACGAATTGACAAACAAAT-3, 100µM,  reverse sequence 
5’-ATGTTACTCTTGTTACATGTCTTCTTTCTC-3, 100µM and probe 5’ 
TACATCCTCGACGGCATCTCAGCCC-3’, 100µM. All were designed and purchased 
from Eurofins, UK. Reverse transcription was performed for 30 minutes at 48°C, 
amplification Taq activation for 10 min at 95°C, followed by 40 PCR cycles of 
denaturation at 95°C for 15 seconds and annealing/extension at 60°C for 1 minute.  
Reactions were carried out in triplicate and were normalized against an 
endogenous housekeeping gene, 18S ribosomal RNA. The 18S ribosomal RNA was 
quantified using 18S primers and probes: forward sequence 5’-
GGCTCATTAAATCAGTTATGGTTCCT-3, 100µM, reverse sequence 5’-
GTATTAGCTCTAGAATTACCACAGTTATCCA-3, 100µM, and probe 5’-
TGGTCGCTCGCTCCTCTCCCAC-3, 100µM. All were designed and purchased from 
Sigma-Aldrich, UK.  
The probes used in this study were labelled with a 5’ reporter dye FAM (6-
carboxyfluorescein) and a 3’ quencher dye TAMRA (6-carboxytetramethylrhodamine). 
The amount of mRNA and thus gene expression was quantified based on a 
standard curve method. Standard curves were produced for each set of primers and 
probes using 5, 10, 20, 40, and 80 ng total RNA/reaction. 
3.3.5. Plate reader-based kinetic measurement of intracellular calcium levels 
using the fluorescent dye FURA-2AM 
3.3.5.1. Background 
Kinetic measurement of Ca2+ influx in response to various reagents used in this 
thesis was performed using a fluorescent plate reader; FLUROstar optima (Cat # NP-
RFM-048, BMG labtech, UK), where Ca2+ influx was measured by monitoring 
fluorescence. This technique was chosen due to its availability and low cost. The 
fluorescence was measured by using FURA, which is a ratiometric dye that has two 
excitation wavelengths; 340nm, representing the Ca+2–saturated FURA and 380nm, 
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representing the Ca+2–free FURA [124, 125], thus allows the representation of the 
fluorescence as a ratio to reflect the amount of the Ca2+ in the cells [124].  It is used in the 
form of FURA-2AM, which is the acetoxymethyl ester of the fluorescent Ca2+ probe 
FURA. The presence of ester groups facilitates the movement of the dye through the 
cellular plasma membrane [126, 127]. Once applied to the cells, FURA-2AM can cross 
the cell membrane into the cytosol where the intracellular esterases cleave the ester group 
to release the polar FURA that is sensitive to Ca2+. In this form it cannot re-cross the cell 
membrane and the carboxyl groups of the free FURA can bind with the Ca2+ to form the 
FURA-Ca2+ complex (figure 3.2A).  The binding of Ca2+ to FURA results in a change in 
the wavelength and fluorescence intensity [125], excitation at 340nm increases the 
fluorescence emission detected at 510nm, while excitation at 380nm decreases the 
fluorescence emission detected at 510nm (figure 3.2B). The ratio of fluorescence 
therefore, can be used to indicate the intracellular Ca2+ concentration ([Ca2+]i). 
 
Figure 3.2: FURA-2AM as Ca2+ probe. A) Once FURA-2AM is loaded, cellular esterase 
cleaves the ester bonds to activate the FURA and become membrane impermeable. In 
this form it can binds the free Ca2+ to form FURA–Ca2+ complex. B) Fluorescence 
spectrum of FURA-2AM. Presence of Ca+2 increases fluorescence emission detected at 
510nm (green line) when excited at 340nm (green dashed-line) and decreases 
fluorescence emission at 510nm (blue line) when excited at 380nm (blue dashed-line). 
(Source:http://www.invitrogen.com/site/us/en/home/support/Research-
Tools/Fluorescence-SpectraViewer.html?fileId1=1200ca). 
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Ca2+ measurement was performed by detaching the cells first, then counting the 
cells, followed by loading the FURA to the cell suspension and finally measure Ca2+ 
influx. These steps are explained below.  
3.3.5.2. Cells detaching  
Under aseptic conditions the culture medium of the 70-80% confluent cells in the 
10cm dishes were discarded and the cells were rinsed twice with 10ml of 1x PBS solution 
to remove the remaining culture medium. The cells were then incubated with 2ml 0.05% 
EDTA trypsin solution for 3 minutes at 37°C and 5% CO2 incubator to detach the cells. 
Then, 10ml of culture medium supplemented with 10% FBS were added and the cell 
suspension was mixed gently using Gilson micropipette. The cell suspension was then 
transferred into a 50ml falcon tube and centrifuged at 1500 rpm for 3 minutes to remove 
the trypsin. The supernatant was discarded using vacosafe and the cell pellet was re-
suspended using 10ml culture medium supplemented with 10ml FBS. The cell pellet was 
mixed gently using a pipette. The cells were then counted using the haemocytometer.  
3.3.5.3. Loading FURA-2AM  
Before performing the experiment, FURA-2AM (Cat # F0888, Sigma-Aldrich, 
UK) stock solution of 1mM was prepared in DMSO and away from light. This solution 
was kept under dark conditions and stored at -20°C. On the day of the experiment the 
stock solution was diluted in the media supplemented with 10% FBS to the required 
concentration. 
Cells were detached and collected in 50ml falcon tube and centrifuged at 1500rpm 
for 3 minutes at room temperature. The cells pellet was washed and re-suspended using 
10ml media supplemented with 10% FBS. The cell suspension was then left for 1hour in 
the incubator at 37°C and 5% CO2 to recover from trypsin. An aliquot of this suspension 
was kept in 0.5ml eppendorf tube and was incubated at 37°C and 5% CO2 to be used for 
blank measurement (cells with no FURA). The tube of the cells suspension was wrapped 
with aluminium foil then loaded with 250nM of FURA-2AM. This was performed in the 
dark. The cell suspension was then incubated for 30 minutes at 37°C and 5% CO2. The 
cells suspension was mixed three times during the incubation period. Then, the cell 
suspension was centrifuged at 1500rpm for 3 minutes at room temperature to remove the 
excess FURA and the supernatant was discarded using the vacosafe. The cell pellet was 
washed and re-suspended in media supplemented with 10% FBS. The volume of media 
used was equal to the volume that is needed to obtain the required cell number (1x106 
cells/ml). A volume of 100µl of cell suspension was then seeded in black 96-well culture 
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plate with clear bottom and were placed in the fluorescence plate reader to measure Ca+2 
influx. 
3.3.5.4. Preparing stock and work solutions of histamine, palcar and DHT 
for measuring Ca2+ influx 
A stock solution of 27mM palcar (Cat # P4509, Sigma-Aldrich, UK) was prepared 
in DMSO. This stock solution was kept in a water bath at 37°C for 5 minutes. The stock 
solution of 100mM histamine (Cat # H7125-1G, Sigma-Aldrich, UK), the positive 
control, was prepared in de-ionized water. The DHT (Cat # 31573-100MG, Sigma-
Aldrich, UK) stock solution of 3.44mM was prepared in DMSO. All stock solutions were 
prepared under aseptic conditions and at the end of each experiment; these solutions were 
stored at -20°C. The exception to this was the histamine stock solution, which was 
freshly prepared for every experiment of Ca2+ measurement since it is light and air 
sensitive.  
Working solutions of DMSO (control), histamine (500µM), palcar (500µM) and 
DHT (10µM) were prepared in media supplemented with 10% FBS and placed in the 
reagent box of the plate reader to be used for priming the pumps and injecting the volume 
required to reach the final concentration into the cell suspension. 
The plate reader is equipped with two pumps to be filled with work solutions and 
to be used for sample injection. The culture plate was placed in the fluorescence plate 
reader. In the OPTIMA software, the “fluorescence intensity” and “well mode” were 
selected. The protocol for measuring Ca+2 influx was set by determining the parameters 
in the “basic parameter”, the “Layout”, “Concentration/Volume/Shaking” and 
“Multichromatic” windows as shown in figure 3.3. 
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Figure 3.3: The “Fluorescence Intensity – Well mode” window of the OPTIMA software. In the figure is an example on preparing three samples. 
A) The basic parameters were determined as shown in A. B) The layout (position) of samples were selected. C) The volume of injection and the 
pump containing the treatment solution were determined (for example 4µl from pump 2). D) The multichromatic window, in which the gain and 
the filters for excitation and emission were determined. These windows are illustrated and explained in the manual of the FLUROstar optima 
plate reader. 
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Ca2+ influx in response to DMSO (control), histamine, palcar and DHT was 
measured by injecting the required illustrated in Table 3.1. 
Table 3.1: Injection volumes needed from the work solutions. 
Name Concentration of 
work solution 
Concentration 
required in wells 
Injection volume  
form work solution 
DMSO 
(control) 
  4µl 
Histamine 
 
500 µM 10 µM 2µl  
20 µM 4µl  
Palcar 500 µM 5 µM 1µl  
10 µM 2µl 
20 µM 4µl 
50 µM 10µl  
DHT 10µM 0.1µM 1µl 
1µM 10µl 
 
Once control measurements were completed, the pump was washed with MilliQ 
water, then with 70% ethanol followed by MilliQ water again. The pump was then 
primed with the palcar working solution and Ca+2 measurements were performed as 
mentioned above. The washing step was repeated once palcar readings were completed. 
This process of washing was repeated when DHT was used.  
3.3.6. Measuring Ca2+ influx 
PNT1A, BPH-1, DU145 and PC3 cells were seeded in 10cm dishes and once 
growth had reached 70% confluence, cells were harvested, collected, counted as 
described earlier and used for the measurement of Ca2+ influx. The method of Ca2+ influx 
was developed using histamine as a positive control since it has been shown that it 
increased the [Ca2+]i in PC3 cells [128, 129]. Cell suspensions were then loaded with 
250nM FURA-2AM for 30 minutes at 37°C and excited at two wavelengths: 340nm and 
380nm. Cells were injected with either DMSO, histamine (10 or 20µM), or palcar (5, 10, 
20 or 50µM) after 50 seconds of the start of Ca2+ measurement. Following method 
optimisation, 2.5µM FURA for 45 minutes was chosen to measure Ca2+ influx in 
response to DHT (0.1and 1µM) as described in details above. The emission at 510nm 
was measured every 10 seconds for 5 minutes and the ratio of fluorescence was used to 
indicate the [Ca2+]i. 
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3.3.7. Statistical analysis  
Cell growth in response to each palcar treatment in both PNT1A and PC3 cells was 
represented as the means ± SD of six biological replicates of one experiment. The levels 
of IL-6 secretion were represented as the means ± SD of three biological replicates of one 
experiment. To compare between the means of the different treatments within cell line, 
statistical analysis was performed with a one-way ANOVA followed by Bonferroni's 
multiple comparison post-test. To compare between the means of each treatment between 
two cell lines, statistical analysis was performed with two ways ANOVA followed by 
Bonferroni's multiple comparison post-test. 
The findings of IL-6 gene expression were obtained from one experiment 
conducted in three biological replicates with three technical replicates each. The levels of 
IL-6 gene expression represent means ± SD of the three biological replicates of one 
experiment. In order to compare the fold change of IL-6 gene expression between the 
PNT1A and PC3 cells, statistical analysis were performed with a two way ANOVA 
followed by Bonferroni’s multiple comparison post-test. To compare the fold change of 
IL-6 gene expression between each treatment within cell line, a one way ANOVA 
followed by Bonferroni’s multiple comparison post-test was performed. 
All statistical analyses above were performed using GraphPad Prism version 5.00 
for Windows (GraphPad Software, San Diego California USA, www.graphpad.com). 
The results of the kinetic measurement of Ca2+ influx represent the mean of three 
independent experiments. In order to compare between the effects of different treatments 
on kinetic Ca2+ influx in each cell line, statistical analysis were performed with mixed 
effect model using GenStat software 16th Edition. 
The corrected ratio of fluorescence in each cell line in response to DHT injection 
were analysed with a one way ANOVA followed by Bonferroni’s multiple comparison 
post-test using GraphPad Prism version 5.00 for Windows (GraphPad Software, San 
Diego California USA, www.graphpad.com).  
3.4. Results  
3.4.1. Cell viability in response to palcar in PNT1A and PC3 cells 
The effect of palcar on the viability of both PNT1A and PC3 cells was tested prior 
to starting the investigation of palcar effect on IL-6 secretion and Ca2+ influx. Cell 
viability was examined using the WST-1 viability assay. Both cell lines were treated with 
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DMSO and palcar (5, 10, 50 and 100µM) for 24 hours at 37°C and 5% CO2. Treatment 
with palcar (5–100µM) was not associated with any toxic effect in PNT1A cells 
compared with DMSO-treated cells (control) (P>0.05). However, high concentrations of 
palcar (50 and 100µM) were associated with a significant decrease in the viability of PC3 
cells compared with the control (P≤0.05 and P≤0.01) and PNT1A cells (P≤0.05 and 
P≤0.01) (figure 3.4). However upon visual inspection, cells treated with palcar (50 and 
100µM) were observed to cover the growth area of wells, and that the cells morphology 
and number of floating cells were the same as the cells treated with the DMSO (control).  
 
 
Figure 3.4: Viability assay in PNT1A and PC3 cells. Cells were seeded in 96-well plate 
and treated with DMSO (control), palcar (5, 10, 50 or 100µM) for 24 hours at 37°C and 
5% CO2. WST-1 reagent (10µl) was added and incubated for 30 minutes at 37°C and 5% 
CO2. The absorbance was measured at 450nm. Palcar (50 and 100µM) significantly 
reduced the viability of PC3 cells compared to the control and PNT1A cells.  Results 
represent means ± SD of six biological replicates of one experiment. Statistical analysis 
between PNT1A and PC3 cells were performed using a two way ANOVA followed by 
Bonferroni's multiple comparison post-test, and between each treatment in one cell line 
using a one way ANOVA followed by Tukey’s multiple comparison post-test, *P≤0.05 
and **P≤0.01. 
 
3.4.2. Effect of palcar on IL-6 
To assess the potential pro-inflammatory property of palcar in PNT1A and PC3 
cells, the secretion of IL-6 was measured in response to treatments with 10, 50 and 
100µM palcar for 24 hours. After 24 hours exposure of palcar, only high concentrations 
(50 and 100µM) were able to induce a significant increase in IL-6 secretion in PC3 cells 
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compared to the control (P≤0.01). Palcar treatment was not associated with any pro-
inflammatory responses in the non-cancerous PNT1A cells (figure 3.5). 
 
 
Figure 3.5: IL-6 secretion in PNT1A and PC3 cells in response to palcar. Cells were 
treated with DMSO or palcar (10, 50 and 100 µM) for 24 hours at 37°C and 5% CO2. 
Culture medium was collected and IL-6 was measured using human IL-6 ELISA kit. 
Results represent means ± SD of three biological replicates. Palcar (50 and 100µM) 
induced a significant increase in IL-6 secretion in PC3 cells compared to control and 
PNT1A cells. Results represent means ± SD of three biological replicates of one 
experiment. Statistical analysis between PNT1A and PC3 cells were performed using a 
two way ANOVA followed by Bonferroni’s multiple comparison post-test, and between 
each treatment in one cell line using a one way ANOVA followed by Bonferroni’s 
multiple comparison post-test, **P≤0.01. 
 
The reasons for the high levels of IL-6 secretions at high concentrations were 
either due to palcar induced gene expression of IL-6 or a palcar detergent effect on the 
cell membrane, in which it lyses the membrane causing the leakage of the cellular IL-6 
into the media. Therefore, the gene expression of IL-6 in response to 24 hours treatment 
with palcar was investigated. Figure 3.6 represent palcar-induced IL-6 gene expression 
normalised to 18S. In PNT1A cells, 50 and 100µM palcar induced a significant two-fold 
increase in the IL-6 gene expression compared to the control (P≤0.001 and P≤0.01, 
respectively), but in PC3 cells, 50 and 100µM palcar induced a significant four-fold and 
six-fold increase in gene expression, respectively (P≤0.001; figure 3.6). This suggests 
that palcar was able to induce a pro-inflammatory response in PC3 cells as well as 
causing a modest increase in IL-6 gene levels in PNT1A cells. The results suggested that 
palcar at these concentrations was not associated with detergent effect on the cell-
membrane of both PNT1A and PC3 cells.  
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Figure 3.6: IL-6 gene expression in PNT1A and PC3 cells in response to palcar. Cells 
were treated with DMSO or palcar (10, 50 and 100 µM) for 24 hours at 37°C and 5% 
CO2. Cells were collected and total RNA was extracted using the RNeasy kit. IL-6 Gene 
expression was quantified using real time RT-PCR. The expression of the housekeeping 
18S gene was used for normalisation of the gene expression. Palcar (50 and 100µM) 
induced an increase in the fold change of IL-6 gene expression in both PNT1A and PC3 
cells compared to the control. Results represent means ± SD of three biological replicates 
of one experiment. Statistical analysis between PNT1A and PC3 cells were performed 
using a two way ANOVA followed by Bonferroni’s multiple comparison post-test, and 
between each treatment in one cell line using a one way ANOVA followed by 
Bonferroni’s multiple comparison post-test, ***P<0.001 and ##P<0.01, ###P<0.001 versus 
control. 
 
The effect of palcar on inducing IL-6 secretion in PC3 cells was compared with 
LPC, another lipid related compound derived from phosphatidylcholine and exhibiting an 
amphiphilic properties similar to that of palcar. In this experiment, cells were treated with 
LPC for 24 hours and the secretion of IL-6 was measured in PC3 cells. Figure 3.7 shows 
the levels of both LPC and palcar-induced IL-6 secretion (pg/ml). After 24 hours 
exposure to LPC and palcar, high concentrations of LPC (50 and 100µM) significantly 
reduced the secretion of IL-6 compared to the control (P<0.001). The observed effect of 
LPC was opposite to that of the effect of palcar in PC3 cells.  
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Figure 3.7: IL-6 secretion in response to palcar and LPC in PC3 cells. Cells were treated 
with DMSO, palcar (10, 50 or 100µM) or LPC (10, 50 or 100µM) for 24 hours at 37°C 
and 5% CO2. Culture medium was collected, and IL-6 was measured using human IL-6 
ELISA kit. Palcar (50 and 100µM) induced a significant increase in IL-6 secretion in 
PC3 cells in contrast to LPC (50 and 100µM), which significantly decreased the IL-6 
secretion compared to control. Results represent means ± SD of three biological 
replicates of one experiment. Statistical analysis between palcar and LPC were performed 
using a two way ANOVA followed by Bonferroni's multiple comparison post-test, and 
within each palcar and LPC treatments using a one way ANOVA followed by 
Bonferroni’s multiple comparison post-test, ***P<0.001, and ##P<0.01, ###P<0.001 versus 
control. 
 
Since palcar is a lipid intermediate in fat oxidation, its effect on inducing IL-6 
secretion was compared to that of DHT, which is a lipid-related hormone. Therefore both 
PNT1A and PC3 cells were treated with palcar and DHT for 24 hours and the IL-6 
secretion was measured. The concentration range of DHT investigated in this study 
covered the physiologically relevant levels, 1 – 10nM [130]. Figure 3.8 showed that DHT 
treatment was not associated with IL-6 secretion in both PNT1A and PC3 cells contrary 
to the effect of palcar. 
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Figure 3.8: IL-6 secretion in PNT1A and PC3 cells in response to DHT. Cells were 
treated with DMSO or DHT (1, 10, 100 or 1000µM) for 24 hours at 37°C and 5% CO2. 
Culture medium was collected, and IL-6 was measured using human IL-6 ELISA kit. 
DHT is not associated with any pro-inflammatory responses in either PC3 or PNT1A 
cells. Results represent means ± SD of three biological replicates of one experiment. 
Statistical analysis between PNT1A and PC3 cells were performed using a two way 
ANOVA followed by Bonferroni’s multiple comparison post-test, and between each 
treatment in one cell line using a one way ANOVA followed by Bonferroni’s multiple 
comparison post-test. 
 
3.4.3. Ca2+ influx in prostate cell lines 
3.4.3.1. Trypan blue viability assay 
The effect of palcar on Ca2+ influx was measured for a 5 minute period. Since 
treatment with 50µM palcar for 24hour decreased the viability of PC3 cells to 
approximately 65%, the effect of this concentration of palcar on cell membrane integrity 
was investigated using the trypan blue viability assay. The Trypan blue assay was 
selected because it allows mimicking the experimental procedure of measuring the Ca2+ 
influx for 5 minutes, therefore testing whether palcar has an effect on cell membrane 
integrity during Ca2+ measurement.  
The results indicate that palcar treatment for 5 minutes has no lethal effect on PC3 
cells. The calculated viability percentage for 50µM palcar was very close to that of the 
control, which was approximately 78% and 80%, respectively. The 78% viable cells was 
an average of three replicates, which was consisting of 78%, 77% and 80% viable cells. 
These numbers were close to the counting of the viable cells in the control, which were 
80%, 82% and 84%. 
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However, these values are considered low for a viability test and this could be 
attributed to the procedure of measuring Ca2+ influx, where the cells needed to be in a 
suspension state for one hour in the incubator (37°C and 5% CO2). Figure 3.9 show the 
results of the trypan blue in response to 50µM palcar and DMSO; where the bright cells 
represent the viable cells and the blue stained cells represent the non-viable cells. The 
actual count of the cells present in these figures were higher than what it was shown in 
the figure 3.9, because the microscope used for this count has an extra magnification lens 
on the camera attached to it, which produce a photo taken from a section of the 
haemocytometer square where the count was performed and could not cover the whole 
area of the counting square (which consist of 16 smaller squares). This produces a photo 
that is more magnified compared with the other photos taken by other light microscopes 
using the same magnification lens. 
 
Figure 3.9: Trypan blue viability test in PC3 cells suspension. Cells were treated for 5 
minutes with A) DMSO (x10) or B) 50µM palcar (x10). Bright and blue stained cells 
represent the viable and the non-viable cells, respectively. C) Higher magnification at the 
viable and the non-viable cells (x40). The photos are representative of three replicates.  
 
 
3.4.3.2. Ca2+ influx in non-cancerous cell lines 
3.4.3.2.1. Histamine effect on Ca2+ influx 
In this experiment histamine was used as a positive control and therefore, the effect 
of palcar on Ca2+ influx was compared to the effect of histamine on both PNT1A and 
BPH-1 cells. In PNT1A cells, at the baseline and before injection with histamine the 
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fluorescence values of Ca2+–saturated FURA (red line, figure 3.10) was less than that of 
the Ca2+–free FURA (blue line, figure 3.10) indicating that there was no Ca2+ induced. 
Injection of 20µM histamine increased the fluorescence values of Ca2+–saturated FURA 
with a concurrent decrease in the fluorescence values of Ca2+–free FURA (figure 3.10A). 
This was also observed in BPH-1 cells (figure 3.10B), which suggest that histamine was 
able to induce Ca2+ influx and increase the cellular content of Ca2+. This would suggest 
that Ca2+ bound with the FURA inside the cells leading to an increase in the levels of 
Ca2+–saturated FURA, which in turn decreased the levels of Ca2+–free FURA. The effects 
of histamine was represented by the rapid increase in the calculated fluorescence ratio 
that indicate [Ca2+]i. These results prove the validity of the protocol followed to measure 
palcar-induced Ca2+ influx.   
3.4.3.2.2. Palcar effect on Ca2+ influx 
In PNT1A and BPH-1 cells, injection of palcar after 50 seconds of the start of Ca2+ 
measurement, did not have any effect on Ca2+ influx. In figure 3.11A the fluorescence 
values in response to 50µM palcar injection in PNT1A cells shows that the fluorescence 
values of Ca2+–free FURA are higher than the values of Ca2+–saturated FURA before and 
after injection, suggesting that there was no Ca2+ induced to bind to the free FURA and 
become Ca2+–saturated. This was reflected in the constant values of fluorescence ratios, 
which are similar to the ratios at the baseline. These results indicate that palcar injection 
was not able to induce any Ca2+ influx that could bind to the FURA inside the cells and 
increase the fluorescence levels of the Ca2+–saturated FURA, therefore no increase in the 
fluorescence ratio was observed (figure 3.11A).   
BPH-1 cells behaved in the same manner as the PNT1A cells in response to palcar, 
where palcar was not associated with any change in the ratio of fluorescence indicating 
no Ca2+ influx. Figure 3.11B shows the fluorescence values and ratios in BPH-1 cells 
after injection with 50µM palcar. 
In PNT1A and BPH-1 cells, injection with different concentrations of palcar (5, 
10, 20 and 50µM) was not associated with any change in the fluorescence values, unlike 
the Ca2+ influx in response to histamine, which showed a trend towards inducing a dose–
dependent increase in Ca2+ influx (figure 3.12). 
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Figure 3.10: Representative fluorescence values in PNT1A and BPH-1 cells in response 
to histamine. FURA-loaded cells were excited at both 340nm (red line) & 380nm (blue 
line) and emission was detected at 510nm. Cells were injected with 20µM histamine after 
50 seconds of the start of Ca2+ measurement. The increased ratio of fluorescence (green 
line) immediately following histamine injection in A) PNT1A and B) BPH-1 cells is 
indicative of Ca2+ influx. 
PNT1A cells 
BPH-1 cells 
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Figure 3.11: Representative fluorescence values in PNT1A and BPH-1 cells in response 
to palcar. FURA-loaded cells were excited at both 340nm (red line) & 380nm (blue line) 
and emission was detected at 510nm. Cells were injected with 50µM palcar after 50 
seconds of the start of Ca2+ measurement. The unchanged ratio of fluorescence (green 
line) after DHT injection in A) PNT1A and B) BPH-1 cells is indicative of no Ca2+ 
influx. 
 
PNT1A cells 
BPH-1 cells 
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Figure 3.12: Ca2+ influx in PNT1A and BPH-1 cells in response to palcar and histamine. 
FURA (250nM)-loaded cells were injected with DMSO (control), histamine (10 or 
20µM) or palcar (5, 10, 20 or 50µM) at 50 seconds. The ratio of fluorescence emission 
(510nm), excited at both 340nm & 380nm, indicated the [Ca2+]i. In PNT1A and BPH-1 
cells, ratio of fluorescence after palcar (5, 10, 20 or 50µM) injection was not significantly 
different from the control (P = 0.110, 0.521, respectively), whereas it was significantly 
different after histamine (10 and 20µM) injection (P≤0.001 and P≤0.05, respectively). 
There were no significant differences between 10 and 20µM histamine on Ca2+ influx (P 
= 0.323 and 0.892, respectively). Data are means of three independent experiments. The 
statistical analysis was performed with mixed effect model test using the Genstat 
software. 
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3.4.3.2.3. DHT effect on Ca2+ influx 
The unresponsiveness of both PNT1A and BPH-1 cells to palcar in terms of Ca2+ 
influx was compared to that in response to DHT, a hormone important for prostate 
growth and associated with the prostate cancer progression. This comparison was made 
to investigate whether DHT induced the same effect as palcar.  
In both PNT1A and BPH-1 cells the fluorescence values of the Ca2+–saturated 
FURA were elevated before injection. This is attributed to the procedure of measuring 
Ca2+ influx that require the cells in one well of the culture plate to be injected with the 
treatment followed by measuring Ca2+ influx for a duration of 5 minutes. Then this was 
repeated for the next treatment in the cells in the next well. During this time the levels of 
Ca2+ are subjected to a continuous change as they are dynamic ions that move into and 
out of the cells. Upon entry into the cells, Ca2+ may bind to the FURA leading to an 
increase in the levels of the Ca2+–saturated FURA before injection. Having the levels of 
Ca2+–saturated FURA higher than the levels of Ca2+–free FURA leads to the high 
fluorescence ratio observed at the baseline levels (figure 3.13A). Although the 
fluorescence value of the Ca2+–saturated FURA was high before injection, the calculated 
fluorescence ratios after 1µM DHT injection were the same as the values of the baseline 
levels, suggesting that DHT was not able to induce Ca2+ influx.   
This was also true in BPH-1 cells, where injection of DHT did not lead to an 
increase in the calculated ratio of fluorescence (figure 3.13B).  Therefore, these results 
suggest that 1µM DHT had no effect on PNT1A and BPH-1 cells, a similar effect to 
palcar. 
Figure 3.14 showed the fluorescence ratios of both PNT1A and BPH-1 in response 
to different concentrations of DHT (0.1 and 1µM) in comparison to histamine. In this 
experiment, only one concentration of histamine (20µM) was investigated due to the 
observed increase in the levels of baseline. Because of this increase, the ratio of 
fluorescence was corrected to the baseline levels of each injection and was compared. 
The corrected ratio of fluorescence after DHT injection was not significantly different 
from that of the control (P>0.05) and that the increase in Ca2+ influx induced by 
histamine was significantly different from the control (P<0.001) (figure 3.14C).
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Figure 3.13: Representative fluorescence values in PNT1A and BPH-1 cells in 
response to DHT. FURA-loaded cells were excited at both 340nm (red line) & 
380nm (blue line) and emission was detected at 510nm. Cells were injected with 
1µM DHT after 50 seconds of the start of Ca2+ measurement. The unchanged ratio 
of fluorescence (green line) after DHT injection in A) PNT1A and B) BPH-1 cells 
is indicative of no Ca2+ influx. 
PNT1A cells 
BPH-1 cells 
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Figure 3.14: Ca2+ influx in PNT1A and BPH-1cells in response to DHT. FURA-loaded PNT1A (A) and BPH-1 (B) cells were injected 
with DMSO (control), 20µM histamine or DHT (0.1 or 1µM) at 50 seconds of the start of the Ca2+ measurement. The ratio of fluorescence 
emission (510nm), excited at both 340nm & 380 nm, indicated the [Ca2+]i. DHT (0.1 or 1µM) did not induce Ca2+ influx in PNT1A and 
BPH-1; Ca2+ influx was not significantly different to the control (C). Data represent means ± SD of three independent experiments. 
Statistical analysis was performed using two ways ANOVA followed by Bonferroni’s post-test in each cell line. 
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3.4.3.3. Ca2+ influx in cancerous cell lines 
3.4.3.3.1. Histamine effect on Ca2+ influx  
As histamine was shown to induce Ca2+ in both PNT1A and BPH-1 cells, 
the effect of histamine on Ca2+ influx in DU145 and PC3 cells were investigated to 
assess the effect of palcar in the prostate cancerous cells. In DU145 and PC3 cells, 
there was no change in the ratio of fluorescence at the baseline (figure 3.15). In 
both cell lines injection of 20µM histamine immediately increased the fluorescence 
values of Ca2+–saturated FURA and decreased the fluorescence values of Ca2+–free 
FURA, therefore, increasing the ratio of fluorescence, which indicate an induction 
of Ca2+ influx. Interestingly, in DU145 cells, the levels of Ca2+ after histamine 
injection did not return to the baseline levels during the time of Ca2+ measurement 
(3.15A), as compared to PC3 cells (figure 3.15B). These results suggest that 
histamine was able to induce Ca2+ influx in these cells similar to PNT1A and BPH-
1 cells and also indicate the validity of the protocol followed to measure Ca2+ 
influx in the cancerous cell lines. 
3.4.3.3.2. Palcar effect on Ca2+ influx 
In DU145 cells, injection with palcar was not associated with any change in 
Ca2+ influx. Figure 3.16A is a representative of fluorescence values in response to 
50µM palcar injection, which indicates that after palcar injection the fluorescence 
values of Ca2+–saturated FURA and Ca2+–free FURA did not change, therefore, the 
fluorescence ratios were not affected. This was not observed in PC3 cells (figure 
3.16B), where injection of 50µM palcar, after 50 seconds of the start of Ca2+ 
measurement, rapidly increased the fluorescence values of Ca2+–saturated FURA 
with concurrent decrease in the fluorescence values of Ca2+–free FURA. This 
indicates that palcar induced influx of Ca2+ leading to an increase in the levels of 
Ca2+ in the cells, thus binding with the FURA and increasing the levels of Ca2+–
saturated FURA (figure 3.16B). This effect of palcar followed the same pattern of 
histamine (figure 3.15B).  
Chapter 3 
75 
 
 
Figure 3.15: Representative fluorescence values in DU145 and PC3 cells in 
response to 20µM histamine. FURA-loaded cells were excited at both 340nm (red 
line) & 380nm (blue line) and emission was detected at 510nm. Cells were 
injected with 20µM histamine after 50 seconds of the start of Ca2+ measurement. 
The increased ratio of fluorescence (green line) immediately following histamine 
injection in A) DU145 and B) PC3 cells is indicative of Ca2+ influx. 
 
DU145 cells 
PC3 cells 
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Figure 3.16: Representative fluorescence values in DU145 and PC3 cells in 
response to 50µM palcar. FURA-loaded cells were excited at both 340nm (red 
line) & 380nm (blue line) and emission was detected at 510nm. Cells were 
injected with 50µM histamine after 50 seconds of the start of Ca2+ measurement. 
Unchanged ratio of fluorescence (green line) following palcar injection in DU145 
cells (A) is indicative of no Ca2+ influx, whereas in PC3 cells (B) the immediate 
increase in the ratio of fluorescence is indicative of Ca2+ influx. 
 
In both DU145 and PC3 cells, the effect of different concentrations of palcar 
on Ca2+ influx was compared to that induced by histamine. In DU145 cells, 
different concentrations of palcar (5, 10, 20 and 50µM) had no effect on inducing 
DU145 cells 
PC3 cells 
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Ca2+ influx; the levels of Ca2+ influx were the same as the levels of the cells 
injected with DMSO (control) which was in contrast to the effect of histamine that 
showed a trend toward inducing a dose–dependent increase in Ca2+ influx (figure 
3.17A). This pattern was also observed in PC3 cells, where histamine showed a 
dose–dependent increase in Ca2+ influx. In these cells, injection with different 
concentrations of palcar also induced a trend of a dose-response increase in Ca2+ 
influx (figure 3.17B). The effect of both histamine and palcar on Ca2+ levels in 
PC3 cells lasted for approximately two minutes before returning back to the 
baseline levels. In contrast, in DU145 cells histamine-induced Ca2+ influx 
sustained to the end of the experiment of measuring Ca2+ influx. 
3.4.3.3.3. DHT effect on Ca2+ influx 
In order to investigate whether the lipid nature of palcar has a role in Ca2+ 
influx, the effect of DHT on Ca2+ influx was studied since both palcar and DHT are 
lipid related compounds. In DU145 cells, 1µM DHT injection had no effect on 
Ca2+ influx, which was similar to the effect of palcar shown previously (figure 
3.16). Although the fluorescence value of the Ca2+–saturated FURA was high at 
the baseline due to the time that this sample had to wait before injection (see 
section 3.4.3.2.3), the calculated fluorescence ratios after 1µM DHT injection were 
the same as the values of the baseline levels before injection, which suggest that 
DHT injection did not induce any Ca2+ influx in these cells (figure 3.18A).  
However, in PC3 cells, the fluorescence values of the Ca2+–saturated FURA were 
also high due to the same reason above, injection of 1µM DHT, after 50 seconds of 
the start of the Ca2+ measurement, induced a further increase in the Ca2+–saturated 
FURA with a decrease in the Ca2+–free FURA leading to an increase in the 
fluorescence ratio (figure 3.18B). These results suggest that DHT was able to 
induce Ca2+influx leading to an increase in the levels of Ca2+ in the cells. 
In both DU145 and PC3 cells, the effect of different concentrations of DHT 
(0.1 and 1µM) on Ca2+ influx was compared to that induced by histamine. In 
DU145 cells, DHT (0.1 and 1µM) has no effect on inducing any Ca2+ influx as 
compared to the effect of histamine (figure 3.19A), whereas in PC3 cells, injection 
with DHT induced a Ca2+ influx in pattern similar to that of histamine. In these 
cells, 0.1 and 1µM DHT induced a trend of a dose-response increase in Ca2+ influx 
(figure 3.19B). Only 1µM DHT induced a significant induction of Ca2+ influx 
compared to both the control (P≤0.01) and 0.1µM DHT (P≤0.05) (figure 3.19C). 
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The effect of DHT on Ca2+ levels last for approximately 3 minutes before returning 
to baseline levels, which was also observed after palcar injection. 
 
Figure 3.17: Ca2+ influx in DU145 and PC3 cells in response to palcar and 
histamine. FURA (250nM)-loaded cells were injected with DMSO (control), 
histamine (10 or 20µM) or palcar (5, 10, 20 or 50µM) at 50 seconds. The ratio of 
fluorescence emission (510nm), excited at both 340nm & 380nm, indicated the 
[Ca2+]i. A) In DU145 cells, palcar-induced Ca2+ influx was not significantly 
different compared to the control (P = 0.110). Histamine-induced Ca2+ influx was 
significant compared to the control (P=0.003), but there was no significant 
difference within the different concentrations of palcar or histamine.  B) In PC3 
cells, palcar and histamine-induced Ca2+ influx were significantly different from 
the control (P = 0.011 & 0.016, respectively), but there was no significant 
difference in Ca2+ influx within the different concentrations of palcar (P = 0.839) 
or histamine (P = 0.642). Data are means of three independent experiments. 
Statistical analysis was performed with mixed effect model test using the Genstat 
software. 
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Figure 3.18: Representative fluorescence values in DU145 and PC3 cells in 
response to 1µM DHT. FURA-loaded cells were excited at both 340nm (red line) 
& 380nm (blue line) and emission was detected at 510nm. Cells were injected with 
1µM DHT after 50 seconds of the start of Ca2+ measurement. Unchanged ratio of 
fluorescence (green line) following DHT injection in DU145 cells (A) is indicative 
of no Ca2+ influx, whereas in PC3 cells (B) the rapid increase in the fluorescence 
ratio is indicative of Ca2+ influx. 
 
DU145 cells 
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Figure 3.19: Ca2+ influx in DU145 and PC3 cells in response to DHT. FURA-loaded DU145 (A) and PC3 (B) cells were injected with 
DMSO, 20µM histamine or DHT (0.1 or 1µM) at 50 seconds. The ratio of fluorescence emission (510nm), excited at both 340nm & 
380nm, indicated the [Ca2+]i. DHT (1µM) did not induce Ca2+ influx in DU145 (A) cells, but it did in PC3 cells (B) compared to the 
DMSO (control). In PC3 cells, the Ca2+ influx induced by 1µM DHT was significant compared to both control and 0.1µ DHT (C). Data 
represent means ± SD of three independent experiments. Statistical analysis was performed using one way ANOVA followed by 
Bonferroni’s post-test in each cell line, P≤0.05, P≤0.01 and P≤0.001. 
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3.5. Discussion  
In this chapter, the role of increased concentrations of palcar was 
investigated in vitro using prostate non-cancerous and cancerous cell lines. High 
concentrations of palcar was associated the induction of IL-6 gene expression in 
the non-cancerous PNT1A and PC3 cells, which was associated with IL-6 
secretion in PC3 cells, but not in PNT1A cells, suggesting the pro-inflammatory 
role of palcar in PC3 cells. High concentrations were also associated with 
induction of Ca2+ influx in PC3 cells, but not in the cancerous DU145 cells and 
non-cancerous PNT1A and BPH-1 cells, which suggest that palcar induces 
changes in membrane permeability in PC3 cells. Induction of Ca2+ influx in PC3 
cells in response to palcar was also observed for DHT. 
3.5.1. Palcar potential pro-inflammatory property 
A viability test against a range of palcar concentration (5, 10, 50 and 
100µM) was investigated. This range of palcar was above those reported in plasma 
and tissues from humans (Table 2.1, Chapter 2). However, it has been shown that 
the plasma levels of other acylcarnitines in subjects who have a defect in 
metabolism is within this range [31]. Palcar at 50µM has been reported in ischemic 
heart of animal model, which is another form of metabolic dysfunction that involve 
a defect in fatty acid metabolism [103]. Therefore, high concentrations of palcar 
could be expected during prolonged accumulation. Furthermore, 50µM was 
previously studied in vitro and has been shown to be associated with functional 
changes in cell membrane properties [41, 123]. The highest concentration (100µM) 
was selected to study its effect on prostate cells and whether it is associated with a 
detergent effect since the effect of palcar in general was not investigated in 
prostate cells. 
The results of the viability test showed that palcar did not affect PNT1A cell 
viability, but in PC3 cells 50 and 100µM palcar reduced the cells’ viability to 
approximately 65% and 50% respectively, (figure 3.4). However, upon the visual 
examination of the cells at these two concentrations, cells morphology and growth 
were the same as the cells treated with DMSO (control) and that an increase in the 
number of the floating cells in comparison to the control was not observed, 
suggesting that at these two concentrations the remaining 35% of “unviable” cells 
were not died, but rather their growth was inhibited. This is because the WST-1 
assay is a measure for the activity of the mitochondrial dehydrogenase enzyme; 
therefore an inhibition of the enzymatic activity of the dehydrogenase does not 
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necessary indicating cell death. Thus, suggesting that palcar at these two 
concentrations do not affect cell growth in PC3 cells.  
The pro-inflammatory effect of palcar was investigated by studying the 
effect of palcar on IL-6, an inflammatory biomarker. Palcar at 50 and 100µM 
induced a significant increase in IL-6 secretion in PC3 cells (figure 3.5). Although 
the viability test in response to 50 and 100µM palcar observed in PC3 cells 
indicate that palcar at these concentrations may not be associated with cell death, 
the low cell viability (65%) accompanied with the increased IL-6 secretion in these 
cells suggest that this was either due to the detergent effect of palcar on the cell 
membrane, leading to the leakage of the cellular IL-6 into the media, or due to the 
induction of the gene expression of IL-6, which in this case might indicate that 
palcar was associated with a stress response in PC3 cells. 
It seems unlikely that palcar within the concentration investigated (≥50µM) 
was associated with detergent effect on the cell membrane since the levels of 
palcar-induced IL-6 in PNT1A cells was close to that of the control. To confirm 
that palcar was not associated with a damaging effect on the cell membrane in PC3 
cells, palcar-induced IL-6 gene expression was measured in PC3 cells and 
compared to that in PNT1A cells. Since in PNT1A cells, palcar did not affect the 
cell membrane integrity, as suggested by the data of IL-6 secretion, data from IL-6 
gene expression in both cell lines would indicate that palcar is not associated with 
a detergent effect in PC3 cells, in that the increase in IL-6 secretion would be as a 
result of the induction of IL-6 gene expression. Indeed, the results showed that 50 
and 100µM palcar induced a two- and six-fold increase in IL-6 gene expression, 
respectively, in PC3 cells (figure 3.6), suggesting that the increase in IL-6 
secretion is due to the induction of IL-6 gene expression and not due to the loss of 
the membrane integrity and the release of IL-6 into the media. Interestingly, in 
PNT1A cells the results also show that palcar at 50 and 100µM was associated 
with an induction of IL-6 gene expression despite the lack of change in IL-6 
secretion in these cells. This supports the hypothesis that high concentrations of 
palcar are associated pro-inflammatory activity via the induction of IL-6 and that 
this induction may indicate a stress response in prostate cells. It is unlikely that 
palcar-induced IL-6 secretion would suggest an apoptotic response since it has 
been shown that IL-6 protect gastric cancer from apoptosis [131] and inhibit 
apoptosis in malignant plasma cells [132] and human ovarian cancer cells [133]. In 
fact, IL-6 is associated with growth promotion in prostate cancer [49, 51]. 
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The explanation for palcar-induced IL-6 in these cells might be related to the 
amphiphilic nature of palcar. This property allows palcar to interact with the 
phospholipid bilayer leading to a change in the physical state of the membrane, 
which affects the associated proteins leading to a change in their properties. This 
may trigger the inflammatory responses and the secretion of the pro-inflammatory 
cytokines. Therefore, the effect of the amphiphilic nature in inducing IL-6 was 
investigated by comparing palcar-induced IL-6 secretion to that of LPC, a 
compound that also exhibits amphiphilic properties. It has been observed that LPC 
induced the secretion of IL-6 in HUVEC cells [134]. The results of this Chapter 
showed that LPC treatment significantly reduced the levels of IL-6 compared to 
the control and 50µM palcar (figure 3.7), contrary to the effect of palcar. Hence, 
suggesting that palcar-induced IL-6 secretion in PC3 cells was not due to the 
amphiphilic property.  
A further comparison was made with DHT, an androgen that promote 
prostate cancer. This comparison was made in order to investigate whether palcar 
has the same effect as that of DHT; especially that DHT is known to induce 
prostate growth. As stated above, IL-6 is known to promote the growth of prostate 
cancer [49, 51] and that the DHT effect on inducing prostate growth might be 
related to IL-6 secretion. Therefore if DHT induces IL-6 secretion, which was 
observed in response to palcar, this would indicate that palcar might induce 
prostate cancer progression indirectly through the induction of IL-6. The results 
indicate that DHT within the investigated physiological and pathophysiological 
levels neither increased nor decreased the levels of IL-6 in both PNT1A and PC3 
cells compared to control, thus having no effect on the inflammatory responses 
(figure 3.8). It is important to note that the constitutive levels of IL-6 in PNT1A 
cells in figure 3.8 were not consistent with that observed in figure 3.5. This can be 
attributed to the high passage number of the cells used to measure the effect of 
DHT on IL-6. 
Acylcarnitines have been previously observed to be associated with pro-
inflammatory responses. In PBMCs isolated from healthy volunteers, short chain 
acylcarnitines induced the secretion of TNF-α [47]. In bone marrow-derived 
macrophages isolated from mice, medium chain acylcarnitines induced the 
secretion of pro-inflammatory cytokines [46]. These acylcarnitines increased the 
levels of the transcription factor NFκB [6], which is known to be a regulator of IL-
6 synthesis [48]. The secretion of IL-6 has been linked to the progression of 
prostate cancer in humans [49, 51]. In prostate cancerous tissue the levels of IL-6 
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were higher than the benign non-cancerous tissue [49]. IL-6 has been found to 
induce the expression of AR [135]. AR signalling is considered essential for the 
development and proliferation of prostate epithelial cells, and since prostate cancer 
develops from the epithelial part of the prostate, AR maybe linked to the 
development of prostate cancer. Therefore, the effect of palcar in inducing IL-6 in 
PC3 cells, which represent the most aggressive metastatic form of prostate cancer, 
may indicate that palcar can be indirectly linked to the progression of prostate 
cancer. 
3.5.2. Ca2+ influx in prostate cell lines  
Structurally, the amphiphilic nature of palcar enables the molecule to 
interact with both the phospholipid bilayer and the proteins within the bilayer. This 
could, as mentioned previously, lead to changes in the membrane properties and 
alter protein functions, which could result in changes in the membrane 
permeability affecting the homeostasis of certain ions. One of these ions is Ca2+. In 
this study, the effect of palcar on membrane permeability was determined by 
measuring the Ca2+ influx in PNT1A, BPH-1, DU145 and PC3 cells, and was 
compared to the effect of the positive control (histamine). Ca2+ influx within these 
cells was studied in 5 minutes duration. Although WST-1 assay showed that palcar 
was not associated with toxic effect, the effect of palcar on cell membrane during 
Ca2+ measurement was investigated using trypan blue. This assay was chosen to 
mimic the experimental procedure of palcar injection. The results showed that 
presence of 50µM palcar for 5 minutes was associated with approximately 78% 
viable cells compared to 80% viable cells injected with DMSO (control) (figure 
3.9). Therefore, suggesting that incubation with 50µM palcar for 5 minutes has no 
major effect on the cell membrane integrity and that the Ca2+ influx is not due to 
the loss of membrane integrity. The low viability (approximately 78%) can be 
attributed to the procedure of measuring Ca2+ influx, which requires the cells to be 
in a suspension for one hour to recover from trypsin and then for another 30 – 45 
minutes for FURA incubation, which might affect the cell viability. 
3.5.2.1. Prostate non-cancerous cells: the effect of histamine versus 
palcar and DHT on Ca2+ influx 
In order to evaluate the effect of palcar and DHT on Ca2+ influx, the Ca2+ 
influx should be compared to a positive control that is known to induce Ca2+ 
influx. In PC3 cells histamine has been reported to increase the [Ca2+]i [128, 129]. 
There are two modes of action for histamine to induce Ca2+ increase: extracellular 
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Ca2+ entry and intracellular Ca2+ release. Extracellular Ca2+ entry involved second 
messenger-operated channels [129], while intracellular Ca2+ release involved the 
activation of H1 receptors in the cell-membrane, which in turn activated the 
phospholipase C (PLC). The latter can hydrolyse the phosphatidylinositol-4,5-
bisphosphate (PIP2) at the cytosolic surface of the cell membrane into inositol-
1,4,5-triphosphate (IP3) and diacylglycerol (DAG). IP3 binds to the IP3 sensitive 
Ca2+ stores to release Ca2+ into the cytosol and therefore increase [Ca2+]i [128, 
129]. Based on these studies histamine was used as a positive control for all 
prostate cells used in this study. 
In FURA loaded PNT1A and BPH-1 cells, histamine injection induced an 
increase in the fluorescence values of Ca2+–saturated FURA together with a 
decrease in the Ca2+–free FURA (figure 3.10) suggesting that histamine increased 
the levels of Ca2+ inside the cells. This was demonstrated by an increase in the 
fluorescence ratio (an index of Ca2+ influx), thus an increase in [Ca2+]i. This 
increase was observed for approximately two minutes, after which it returned back 
to baseline levels. This recovery could be either due to Ca2+ being pumped out of 
the cells or back into the Ca2+ stores, which is important in maintaining the 
homeostatic levels of [Ca2+]i. These results indicate that the protocol followed to 
measure Ca2+ influx in these cells is valid and that histamine is a suitable positive 
control for the effect of palcar on Ca2+ influx. 
Compared to histamine, injection with different concentrations of palcar (5, 
10, 20 or 50µM) was not associated with any increase in the fluorescence ratios in 
the PNT1A and BPH-1 cells. This was clear from the fluorescence data illustrated 
in figure 3.11. Injection with 50µM palcar was associated with neither an increase 
in Ca2+–saturated FURA nor decrease in Ca2+–free FURA compared to the baseline 
levels, which suggests that palcar does not induce Ca2+ influx in either cell line. 
This pattern of unchanged fluorescence ratio was also observed after injection with 
5, 10 and 20µM palcar (figure 3.12). This was also true for DHT (0.1 and 10µM) 
injection (figure 3.13 and 3.14).  
3.5.2.2. Prostate cancerous cells: the effect of histamine versus 
palcar and DHT on Ca2+ influx 
In DU145 and PC3 cells, histamine (10 or 20µM) was able to induce Ca2+ 
influx in a similar pattern to that observed in PNT1A and PBH-1 cells. 
Interestingly, the increase in Ca2+ influx in DU145 cells was maintained for the 
entire duration of measuring Ca2+ influx and did not return to baseline levels as 
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was observed in PC3 cells, where the effect was observed for approximately two 
minutes (figure 3.15). This may suggest that in DU145 cells, the number of Ca2+ 
stores may be higher than that in PNT1A, BPH-1 and PC3 cells.  
Palcar did not induce any Ca2+ influx in DU145 cells. The fluorescence data 
of FURA loaded DU145 cells injected with 50µM palcar showed that fluorescence 
values at both 340 and 480nm were not changed as a result of palcar injection, and 
thus the resultant ratio of fluorescence was not changed (figure 3.16A). This was 
also the case with the injection of 5, 10 and 20µM palcar (figure 3.17A). However, 
in PC3 cells, palcar injection after 50 seconds induced an increase in Ca2+ influx, 
this was indicated from the fluorescence data illustrated in figure 3.15B, where 
injection with 50µM palcar caused an increase in Ca2+–saturated FURA and a 
decrease in Ca2+–free FURA. In these cells, 5, 10, 20 and 50µM palcar showed a 
trend of a dose-dependent increase in Ca2+ influx (figure 3.17B).  
This ability of palcar to induce an increase in [Ca2+]i has been previously 
observed in endothelial cells [136, 137], but this is the first time where it has been 
shown that palcar is able to induce Ca2+ influx in PC3 cells, which represent an 
aggressive form of prostate cancer. This effect of palcar may represent a stress 
response in these cells. 
When comparing the effect of palcar in inducing Ca2+ influx with that of 
DHT in the prostate cancerous cells, the results showed that injection with 1µM 
DHT produced a similar effect to that of palcar. In DU145 cells, 1µM DHT did not 
induce Ca2+ influx; there was neither an increase in Ca2+–saturated FURA nor a 
decrease in Ca2+–free FURA after injection, hence, unchanged fluorescence ratio 
(figure 3.18A). This was not true in PC3 cells, which directly after DHT injection, 
Ca2+–saturated FURA increased with a decrease in Ca2+–free FURA, which 
produce an increase in the ratio of fluorescence (figure 3.18B). In these cells, 
injection with DHT (0.1 and 1µM) induced a trend of a dose-response influx 
(figure 3.19) and only 1µM DHT was associated with a significant Ca2+ influx 
compared to the control (figure 3.19C). 
This effect of DHT on inducing Ca2+ influx has been previously observed in 
another prostate cancerous cell line; the LNCaP cells [45]. In these cells DHT-
induced Ca2+ influx was due to the activation of a PTX-sensitive G-protein coupled 
receptor (GPCR) and L-type Ca2+ channels. The similarities between palcar and 
DHT in their abilities to induce an increase in Ca2+ influx in PC3 cells, may 
suggest that palcar’s mode of action in changing membrane permeability may 
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include activation of a signalling pathway that is induced by DHT and only present 
in PC3 cells. This suggestion may explain the unresponsiveness of DU145, 
PNT1A and BPH-1 cells to both palcar and DHT. Another explanation for the 
unresponsiveness of DU145, PNT1A and BPH-1 cells to both palcar and DHT 
may include the existence of an efficient Ca2+ buffer system in these cells with a 
concentration that is high enough to balance the Ca2+ influx induced by either 
palcar or DHT [138].  
It has been shown that incubation with palcar (>25µM) was associated with 
cell toxicity leading to a reduction in cell survival in renal cancer cells, but have 
less effect on the normal kidney cell [8]. In HUVEC and bovine aortic endothelial 
cells (BAEC), high concentrations of acylcarnitines (>20µM) were found to create 
a detergent-like effect on the cell membrane. This was also observed in heart 
muscle using concentrations higher than 10µM palcar [139]. The detergent effect 
was indicated by FURA leakage from the cells as a result of the damaged cell 
membrane and the drop of the fluorescence signal from both 340 and 380nm. 
However, in all prostate cells that were used in this study, palcar (5 – 50µM) 
injection was not associated with FURA leakage, since a drop of the fluorescence 
values from both 340 or 380nm was not observed (figure 3.11 and 3.16), which 
confirm again that palcar was not associated with any detergent effect. 
Collectively, the results of this study highlight the ability of palcar, at high 
concentrations, to instigate the induction of IL-6 and Ca2+ influx in PC3 cells, 
which were not observed in DU145, PNT1A and BH-1 cells. These biological 
effects of palcar may represent a stress response in PC3 cells and since these 
effects were only observed in this cell line, it suggest that palcar could act as a 
signalling molecule in these cells to induce changes in the membrane proteins, 
which could be either ion channels or receptors that eventually linked to IL-6 
secretion.  
 
3.6. Conclusion  
Palcar at high concentrations exert some biological roles in prostate cancer 
PC3 cells, these include its role as a pro-inflammatory mediator and its ability to 
change membrane permeability demonstrated by the induction of Ca2+ influx. 
These effects were observed at 50µM, which is a concentration that is higher than 
that reported in the human plasma, but occur under ischemic conditions reported 
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from animal model. However, from the results of the viability test this 
concentration was not associated with cellular death. 
The pro-inflammatory effect of palcar was indicated by the induction of 
gene expression of IL-6 (a marker of inflammation), which was accompanied with 
IL-6 secretion in PC3 cells. In the non-cancerous PNT1A cells, palcar induced IL-
6 gene expression, but not IL-6 secretion. This suggests that palcar may be 
associated with stress response in prostate cells. The increase in IL-6 in PC3 cells 
could be related to effect of palcar on inducing Ca2+ influx. In PC3 cells, palcar 
induced a trend of a dose-dependent increase in Ca2+ influx, but not in DU145, 
BPH-1 and PNT1A cells. The effect of palcar on inducing Ca2+ influx observed in 
these cells was the same as the effect of DHT; a lipid-related hormone that is 
synthesized from cholesterol and have a role in prostate cancer progression. 
Ca2+ is a secondary messenger that is involved in stimulating pro-
inflammatory responses, such as the induction of IL-6 secretion. Therefore, the 
results of this study suggest that palcar accumulation may mediate pro-
inflammatory responses in the prostate cancerous PC3 cells and highlight the 
possibility that palcar could act as a signalling molecule in these cells. Further 
investigation into the mechanism by which palcar induces Ca2+ influx could be 
considered important in uncovering signalling pathways that may represent a target 
for future dietary interventions aiming to investigate the role of dietary 
components on reducing the effect of palcar accumulation in prostate cancer. 
Therefore in the next chapter, the mechanism by which palcar induces Ca2+ influx 
in PC3 cells is investigated. 
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4.1. Introduction  
Previously, in Chapter 3 palcar was shown to have a potential pro-
inflammatory effect through the induction of IL-6. This effect was observed in the 
prostate cancerous PC3 cells but not in the non-cancerous PNT1A cells. It was also 
shown that palcar has the ability to induce Ca2+ influx in PC3 cells, but not in 
prostate cancerous DU145 cells and prostate non-cancerous PNT1A and BPH-1 
cell lines. Induction of Ca2+ influx in PC3 cells was also observed by DHT, a 
hormone that is associated with prostate cancer progression. The similarity 
between the effect of palcar and DHT could suggest that palcar induces the Ca2+ 
influx by the same mechanism as DHT. In this Chapter, the mechanisms of Ca2+ 
influx induced by palcar and DHT were therefore investigated.   
Ca2+ is an important intracellular mediator for many reactions, therefore 
regulation of [Ca2+]i is essential and maintained by signalling pathways that control 
the channels and pumps by which Ca2+ is transferred (figure 4.1).  
 
Figure 4.1: Ca2+ channels and pumps controlling the [Ca2+]i. Ca2+ can be 
transferred into and out of the cells by five means, which are (A) voltage–gated 
Ca2+ channels that open in response to membrane polarization, (B) store operated 
Ca2+ channels, which opens in response to Ca2+ store depletion, (C) Na+/Ca2+ 
exchange ion channels; they couples the efflux of Ca2+ to influx of Na+,  (D) 
Ca2+/ATPase pumps, which pumps the Ca+2 ions back to the stores and (E) ligand–
gated Ca2+ channels that open the Ca2+ stores in response to ligand, such as IP3 and 
ryanodine [140-142]. 
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Some of these signalling pathways are associated with the activation of 
receptors that can couple to guanosine diphosphate (GDP)–binding proteins, also 
called G–proteins. G-proteins are heterotrimeric proteins consisting of three 
subunits; α, β and γ. These receptors use the G-proteins to transmit the signal to the 
cell interior, therefore they are called GPCRs [13, 14]. 
4.1.1. G-protein coupled receptors 
GPCRs form the largest family of cell surface receptors. They are important 
for cellular communication in response to external stimuli. The signalling 
molecules that activate these receptors vary in structure and include proteins, small 
peptides, amino acid and fatty acid derivatives. Examples of fatty acid derivatives 
include lysophospholipids and their derivatives, such as lysophosphatidic acid 
(LPA) and sphingosine-1-phosphate, and arachidonic acid-derived eicosanoids, 
such as prostaglandins and leukotrienes [143]. Such ligands can be termed as 
bioactive lipids or lipid mediators. These ligands are not specific for one GPCR, 
but can activate several GPCR family members [142].   
All GPCRs share the same structure, which consists of a single polypeptide 
chain that transverses the phospholipid bilayer back and forth seven times, thus 
they are described as seven trans-membrane helices or domains [13, 142]. 
Upon their activation, GPCRs undergo a conformational change that enables 
them to activate the trimeric G-proteins. The G-proteins are attached to the 
cytosolic face of the plasma membrane, and link the receptor to the appropriate 
intracellular targets known as effector proteins. These effector proteins can be gene 
regulatory proteins, a component of a metabolic pathway or a membrane bound 
protein, including an ion channel or an enzyme. An ion channel or an enzyme can 
be a part of a secondary messenger system, such as adenylyl cyclase or PLC [13, 
14, 142]. In some cases, G-proteins can be physically attached to the receptor prior 
to receptor activation, and in other cases they bind only after receptor activation 
[142]. GPCR can be activated as a result of a chemical reaction such as 
palmitoylation. Palmitoylation is a reversible post-translational lipid modification, 
where a membrane-bound acyltransferase enzyme catalyses the transfer of a C16-
carbon saturated fatty acyl chain to the cytoplasmic cysteine residue of a protein, 
and to a lesser extent to serine and threonine residues, through a thioester bond 
[144]. Palmitoylation can also occur through a non-enzymatic reaction [144, 145]. 
Some G-proteins were found to undergo palmitoylation, which modifies their 
structure and facilitates their transfer to the lipid raft [146]. The lipid raft is a 
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subdomain of the plasma membrane that is enriched with cholesterol and 
sphingolipids as well as GPCR [147]. This transfer increases the interaction 
between the hydrophilic G-proteins to form heterotrimeric molecule as well as 
increasing their interaction with the hydrophobic protein (the receptor), thus 
palmitoylation aids the recruitment of the soluble G-proteins the cytoplasmic face 
of the membrane and the receptor [148]. 
All G-proteins have identical basic structures and function in the same way. 
However, there are different types of G-proteins that are specific for a certain set 
of GPCR and for a particular set of target or effector proteins in the membrane. 
Gα-subunit has four subfamilies, the Gs, Gi/o, Gq & G12. The signalling pathway 
ultimately induced by these G-proteins depends on ligand-binding and the type of 
Gα-subunit activated (figure 4.2). 
 
Figure 4.2: Pathways activated by the G-protein subunits. Gα subunit has four 
subfamilies; Gq, Gs, Gi/o and G12. The Gqα subunit involves in regulating the 
activity of PLC that catalyses the breakdown of PIP2 into DAG and IP3 [149]. 
DAG remains attached to the cell membrane due to hydrophobic interaction and 
drives the recruitment of protein kinase C (PKC) [150]. IP3 binds to the receptor at 
the surface of endoplasmic reticulum and releases Ca2+. The latter is required for 
the activation of PKC [150]. PKC can activate many proteins that stimulate 
proliferation and growth [151]. Gsα and Gi/oα regulate the activity of adenylyl 
cyclase. Gsα stimulates adenylyl cyclase activity to produce cyclic adenosine 
monophosphate (cAMP) from ATP, while Gi/oα inhibits the activity [152]. cAMP 
activates protein kinase A (PKA), which activates L-type Ca2+ channels to allow 
the influx of extracellular Ca2+ [150]. G12α is involved in the regulation of prostate 
cancer growth and proliferation [149]. βγ complex can activate PI3K pathway 
and/or phosphorylate the β-subunit of the L-type Ca2+ channel. 
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In the inactive state, the α-subunit is bound to GDP. When the receptor is 
activated, it functions as a guanine nucleotide exchange factor and stimulates the 
Gα-subunit to exchange its GDP with guanosine triphosphate (GTP). The Gα-
subunit then dissociates from both the receptor and the Gβγ complex [149, 153, 
154]. The Gα-subunit together with the bound GTP (Gα-GTP) activates the 
effector proteins, such as PLC and adenylyl cyclase [149]. The dissociated Gβγ 
dimer can activate other signalling pathways, such as the PI3K pathway, or directly 
phosphorylate L-type Ca2+ channels, which upon their activation allow influx of 
Ca2+ from the extracellular space into the cells [155].  
4.1.2. L-type Ca2+ channels 
L-type Ca2+ channels belong to the voltage-dependent channels that allow 
the entrance of Ca2+ in both excitable and non-excitable cells in response to 
membrane depolarization [156]. Excitable cells are those that are able to produce 
action potentials, such as muscle and nerve cells [14]. L-type Ca2+ channels can 
regulate many intracellular processes, such as cell contraction and hormone 
secretion [157] and they are regulated by phosphorylation in response to secondary 
messengers [156].  
From an electrophysiological and pharmacological perspective these 
channels can be classified into low voltage–activate (LVA) and high voltage–
activate (HVA) channels. LVA channels require very low voltage (approximately 
–70mV) for their activation. They are characterised by transient current with a 
small conductance, therefore they are called T-type channels; “T” referring to 
“tiny”. HVA channels are activated when the membrane voltage is high (≥ –
30mV). There are different types of HVA channels and L-type Ca2+ channels are 
one of them [140]. L-type Ca2+ channels are located in the cell membrane of many 
cells and are important for providing Ca2+ required for excitable cells, such as 
cardiac and smooth muscle cells [140]. These channels are characterised by a large 
current, high activation threshold and slow inactivation, and therefore have long 
lasting effects, thus they were given the name “L”; referring to long [140]. These 
channels can be blocked by dihydropyridines (such as nifedipine), verapamil and 
diltiazem [140, 157].  
L-type Ca2+ channels are protein complexes consisting of up to 5 subunits; 
α, β, γ, λ and δ [157]. The main subunit is α1 and it is the voltage sensor of the 
channel as well as the pore forming subunit, which allows the passage of the ions. 
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It also contains the binding site for agonists and antagonists. The structure of α1 is 
illustrated in figure 4.3. 
 
 
Figure 4.3: Structure of L-type Ca2+ channel. α1-subunit is the main subunit of L-
type Ca2+ channel and consists of four domains (DI – DIV), each domain have six 
transmembrane segments; S1 – S6 [157]. A link between S5 and S6 forms the 
channel pore. Adapted from Lacinova [158] and Splawski et al [159]). 
 
It has been found that the gene of the α1-subunit of the L-type Ca2+ channel 
(Cav1.2) was expressed in prostate tissue [159] and prostate cell lines [160].  
In prostate LNCaP cancer cells an increase in [Ca+2]i has been observed in 
response to DHT [45]. This increase in [Ca+2]i is thought to be due to the activation 
of GPCR [45]. 
The role of GPCR-activated L-type Ca2+ channels in Ca2+ influx was 
reported in androgen-dependant prostate cancerous LNCaP cells [45]. In these 
cells, GPCRs were pertussis toxin (PTX)-sensitive. PTX is an exotoxin produced 
by the bacterium Bordetella pertussis and belongs to the A/B toxin family. From 
their name, A/B toxins consist of two parts; “A” and “B”. “A” consists of one 
subunit called S1, while “B” consists of 4 subunits; S2 – S5. “A” behaves as an 
ADP-ribosyltransferase, whereas “B” responsible for the receptor–binding [161-
163]. The mode of action of PTX involves the inhibition of the activity of Gα 
inhibitory (Giα)-subunit. The inhibition occurs by binding the “B” part of the toxin 
to the cellular receptor followed by the transfer of the S1 subunit to the cytosol. S1 
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catalyses the hydrolysis of the oxidized form of NADH, the NAD, present in the 
cytosol followed by the addition of the released ADP-ribose to the cysteine residue 
at the C-terminal of the Giα-subunit. This leads to a blocking of the Giα subunit 
from exchanging its GDP with GTP, thus rendering the Giα subunit in an inactive 
state and it uncouples from the receptor [161, 163, 164]. This uncoupling 
inactivates the signalling pathways induced by the GPCR [161, 163, 164] (figure 
4.4). 
 
Figure 4.4: Inactivation of Giα subunit by PTX treatment. ADP-ribosyltransferase 
of PTX catalyses the transfer of ADP-ribose from NAD to the Giα-subunit. This 
makes it unable to couple with both the receptor and the Gβγ complex, thus no 
signalling pathways are activated.  
 
As shown previously in Chapter 3, DHT was able to induce Ca2+ influx in 
PC3 cells, thus it was hypothesized in this chapter that the mechanisms of Ca2+ 
influx in PC3 cells in response to palcar includes the activation of PTX-sensitive 
GPCR followed by the activation of L-type Ca2+ channel. In this Chapter, the 
mechanism of Ca2+ influx in response to palcar was compared to that of DHT. 
4.2. Aims 
– To investigate the mechanism by which palcar induces Ca2+ influx in PC3 
cells via the activation of GPCR and L-type Ca2+ channel. 
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– To compare the mechanism of palcar-induced Ca2+ influx with that of DHT. 
4.3. Materials and methods  
4.3.1. Measuring Ca2+ influx through L-type Ca2+ channels  
PC3 cells were seeded in 10cm dishes and when the growth reached 70% 
confluence, cells were harvested, counted (as described in Chapter 3, section 
3.3.5.2) and incubated for 1 hour for trypsin recovery, then loaded with 2.5µM 
FURA-2AM (as described in Chapter 3, section 3.3.5.3) for a further 45 minutes at 
37°C and 5% CO2. 
During the incubation period, nifedipine stock solution (50mM) was freshly 
prepared in DMSO in an opaque vial. After incubating for 45 minutes, the cell 
suspension was centrifuged at 1500 rpm for 3 minutes to remove the excess 
FURA. The cell pellet was washed and re-suspended with HAMS media 
supplemented with 10% FCS. The cell suspension (1x106 cells/ml) was then 
seeded in black 96-well culture plate with clear bottom followed by incubation 
with 1mM nifedipine for 5 minutes at room temperature before injection with the 
test compound. Nifedipine selectively binds to the α1 subunit of the L-type Ca2+ 
channel in the inactive mode (zero mode), in which the channel is close, and thus 
interfering with the gating machinery of the channel and prevent it opening, 
therefore rendering the channel in the inactive state [140].  
Since nifedipine is extremely photosensitive, it was applied to the cells in 
the plate away from light. DMSO, palcar, histamine or DHT were prepared at the 
start of the experiment as described in Chapter 3 (section 3.3.5.5) and applied in 
the cell suspension after 50 seconds to give a final concentration of 50, 20 or 1µM 
palcar, histamine or DHT, respectively. The fluorescence ratio of excitation at both 
340 and 380nm (detected at 510nm) was measured, as described in chapter 3 
(section 3.3.6), for 5 minutes and used to reflect the change in [Ca2+]i. 
4.3.2. Measuring Ca2+ influx through PTX-sensitive GPCR 
PC3 cells were seeded in 10cm dishes and when the growth reached 70% 
confluence, they were incubated with 200ng/ml PTX for 24 hour at 37°C and 5% 
CO2. The stock solution of PTX was prepared by dissolving the content of the vial 
(50µg) in 500µl of buffer solution consisting of 100mM sodium phosphate and 
500mM sodium chloride (pH 7.0). After 24 hours of PTX incubation, the cells 
were harvested and the cell suspension was loaded with 2.5µM FURA-2AM for 45 
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minutes at 37°C and 5% CO2. During the incubation time, DMSO, palcar, 
histamine and DHT were prepared as described in Chapter 3 (section 3.3.5.5). The 
cell suspension was centrifuged and the cell pellet washed, re-suspended with 
HAMS media supplemented with 10% FCS and seeded (1x106 cells/ml) in black 
96-well culture plate with clear bottom. Then, DMSO, palcar, histamine or DHT 
was applied to the cells to a final concentration of 50, 20 or 1µM palcar, histamine 
or DHT, respectively. The fluorescence ratio was measured for period of 5 minutes 
as described in chapter 3 (section 3.3.6). 
4.3.3. Measuring Ca2+ influx through PI3K pathway 
PC3 cells were seeded in 10cm dishes and when the growth reached 70% 
confluence, they were harvested as described in section 4.3.1. During trypsin 
recovery, the cell suspension was incubated with 50µM PI3K inhibitor 
(LY294002) for 1 hour at 37°C and 5% CO2. After incubation, the cell suspension 
was treated with 10% FBS supplemented-HAMS media containing 2.5µM FURA-
2AM and 50µM PI3K inhibitor and incubated for 45 minutes at 37°C and 5%CO2. 
Then, the cell suspension was centrifuged and the cell pellet was washed, re-
suspended with HAMS media supplemented with 10% FBS containing 50µM 
PI3K inhibitor and seeded (1x106 cells/ml) in black 96-well culture plate with clear 
bottom. Cells were then injected, after 50 seconds, with DMSO, palcar, histamine 
or DHT to a final concentration of 50, 20 or 1µM palcar, histamine or DHT, 
respectively. The fluorescence ratio was measured for 5 minutes as described in 
chapter 3 (section 3.3.6). 
4.3.4. Constitutive gene expression of GPCRs 
The gene expression of GPCRs was obtained from a microarray analysis of 
PC3, DU145, PNT1A and RWPE1 cells (experiment performed by Melchini and 
Sivapalan at the Institute of Food Research). Briefly, cells were cultured until 70% 
confluence and total RNA was extracted using the RNeasy mini kit (Qiagen) as 
described in Chapter 3 (section 3.3.4.2). The quantity and quality of RNA was 
determined using RNA 1000 Nanodrop (Agilent Technologies) as described in 
Chapter 3 (section 3.3.4.3). The analysis of the gene expression of these cells was 
performed as previously reported [165]. DMSO-treated cells were considered for 
comparing the baseline gene expression between all cell lines and were filtered for 
the expression of GPCRs. This was performed by extracting the log2 expression of 
all the GPCRs genes present in the Affymatrix human exon 1.0 ST array. There 
were 103 GPCRs genes out of a total of 18708 genes measured.  
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4.3.5. Measuring protein expression 
4.3.5.1. Extraction of total cell proteins using RIPA lysis buffer 
4.3.5.1.1. Background 
Total cell proteins were extracted using radio immuno precipitation assay 
(RIPA) lysis buffer. This buffer lyses the cell membrane by the aid of sodium 
dodecyl sulphate (SDS) and sodium deoxycholate (DOC) contained within the 
buffer. SDS is an anionic denaturing detergent that disrupts membranes by 
breaking protein-protein interactions. The presence of DOC also assists in the 
process of disrupting and dissociating protein interactions. Once the lysis was 
started, the resulting polypeptides are susceptible to degradation; therefore, a 
protease inhibitor is added to inhibit the cellular proteases. 
4.3.5.1.2. Extracting total cell proteins 
Prostate non-cancerous PNT1A and BPH-1, and cancerous DU145 and PC3 
cells were seeded in 6-well culture plates and when the growth reached 70% 
confluence, the plates were placed on ice after removing the media and washed 
twice with cold PBS (1x). Ice-cold lysis RIPA buffer (50µl) containing 4% SDS, 
0.5% DOC and protease inhibitor (Roche tablet) was added to each well and left 
for approximately 2 minutes on ice. The cells were then scraped off the wells 
whilst still on ice using a plastic cell scraper. The cells lysates were pooled and 
gently transferred into pre-cooled micro-centrifuge tubes. The tubes were then 
vortexed for 20 seconds three times. The cells lysates were centrifuged for 
13000rpm for 10 minutes at 4°C and the supernatants, which represent the total 
cell protein, were quantified using bicinchoninic acid (BCA) protein assay kit (Cat 
# BCA1 AND B9643, Sigma-Aldrich, UK). The protein lysates were stored at -
20°C for further analysis.  
4.3.5.2. Extraction of cell membrane proteins using transmembrane 
protein extraction kit 
4.3.5.2.1. Background 
Membrane proteins were extracted using ProteoExtract® Transmembrane 
Protein Extraction kit. The principle of using this kit relies on the use of a 
detergent free chemical reaction. This reaction consist of two steps: first, the cells 
are permeabilized with an extraction buffer that contain protease inhibitor to 
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protect the proteins from degradation once the lyses started, followed by 
centrifugation to remove the soluble protein leaving the insoluble proteins 
contained within the lipid bilayer. Second, membrane proteins are extracted from 
the lipid bilayer using transmembrane solubilising reagent. Using this kit has many 
advantages; it minimizes the potential protein loss that may results from severe 
vortexing, sonication or incubation at high temperatures that is used in other 
procedure for extracting membrane proteins. 
4.3.5.2.2. Extracting membrane proteins 
PNT1A, BPH-1, DU145 and PC3 cells were seeded in 6-well culture plates. 
When growth reached 70% confluence, plates were placed on ice and washed with 
twice with PBS (1x). Then, membrane proteins were isolated using ProteoExtract 
Transmembrane Protein Extraction Kit (Cat # 71772, Millipore LTD, UK) 
following the manufacturer’s protocol (diagram 4.1). The protein concentration of 
both soluble and membrane fractions were determined immediately after extraction 
using the BCA protein assay kit (Sigma-Aldrich). 
Diagram 4.1: Steps of protein separation using ProteoExtract® Transmembrane 
Protein Extraction kit. 
 
Culture medium was removed and cells were washed twice with 1x PBS (4°C)
PBS (1x, 3ml) was added and cells were detach from the plate using cell scraper
Cells were centrifuged at 1000×g for 5 minutes at 4°C
Lysates were resuspend in 1ml Extraction Buffer (I) containing 5µl protease inhibitor
The suspension was incubated for 10 minutes at 4°C with gentle agitation to avoid cell 
clumps formation
The susbension was centrifuged  at 1000×g for 5 minutes at 4°C. The supernatant 
represents the soluble/cytosolic proteins
Pellets were resuspend in 0.2ml Extraction Buffer (II) containing transmembrane 
solubilizating reagent (B) and 5µl of protease inhibitor. 
The suspension was incubated for 45 minutes at room temperature with gentle 
agitation
The suspension was centrifuged at  16000×g for 15 minutes at 4°C. The supernatant 
represent the integral membrane proteins
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4.3.5.3. Quantifying protein concentrations using Bicinchoninic 
Acid (BCA) 
4.3.5.3.1. Background  
The principle of BCA assay depends on first, the formation of a Cu2+–
protein complex under alkaline conditions and second, the reaction of cuprous ion 
(Cu1+) with the BCA reagent. In the first reaction, the peptide bond in a protein 
reduces the cupric ion (Cu2+) in the cupric sulphate reagent into cuprous ion (Cu1+). 
The amount of reduction is proportional to the amount of protein present in the 
sample. In the second reaction, the BCA reagent reacts with the resultant Cu1+ to 
form a stable purple–blue complex. The protein present in a sample can then be 
monitored by measuring the absorbance of the purple–blue complex and amount of 
protein can be calculated using a standard curve. 
4.3.5.3.2. Determination of protein levels using BCA 
The assay was performed by diluting the protein lysates into 1:6 using 
sodium phosphate buffer. Then, in a 96-well plate containing 200µl BCA reagent, 
25µl of the diluted protein extract was added in duplicate. The plate was incubated 
at 37°C for 30 minutes and the absorbance of each sample was measured at 562nm 
using FLUROstar optima plate reader (BMG labtech). The amount of the protein 
was calculated using a standard curve of 0–1000µg/ml bovine serum albumin. 
4.3.5.4. Measuring protein expression of Giα2 subunit 
Total cell protein lysates (40µg) from each PNT1A, BPH-1, DU145 and 
PC3 cells were prepared by mixing with sample loading buffer (Cat # NP0007, 
Invitrogen, UK) and reducing agent (Cat # NP0004, Invitrogen, UK) followed by 
denaturing at 70C° for 10 minutes. Protein lysates were then separated, under 
reducing conditions, onto 10% SDS-poly acrylamide gel electrophoresis (PAGE) 
in running buffer (Cat # NP0001, Invitrogen, UK) containing NuPAGE antioxidant 
(Cat # NP0005, Invitrogen, UK). MagicMark protein ladder (Cat # LC5602, 
Invitrogen, life technologies, UK) was loaded to determine the molecular weight of 
the protein on the gel. Gels were run for 50 minutes at 200V using the XCell 
SureLock system. 
Proteins were then transferred into nitrocellulose membranes (Cat # 162-
0112, BIO RAD, UK) using NuPAGE transfer buffer (Cat # NP00061, Invitrogen, 
UK) containing 10% methanol and 0.1% antioxidant. The transfer was run at 30V 
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for 60 minutes. Then the membrane was washed with 1x Tris buffer saline 
Tween20 (TBST) solution firstly for 5 minutes, secondly for 15 minutes and 
finally for another 5 minutes replacing the TBST each time. The membrane was 
then blocked for 1 hour in 10ml 5% skim milk in 1x TBST at room temperature 
with gentle agitation. Then the membrane was washed with 1x TBST solution as 
above and incubated overnight with gentle agitation at 4°C with primary rabbit 
anti-G protein alpha inhibitor 2 antibody (Cat # ab20392, Abcam LTD, UK), 
1:500. The membrane was washed with 1x TBST as above and incubated with 
gentle agitation for 1 hour at room temperature with secondary anti-rabbit IgG 
horseradish peroxidase (HRP) linked antibody (Cat # 70745, New England Biolabs 
LTD, UK), 1:1000. The membrane was then washed with 1x TBST solution as 
above. Skimmed milk powder (5%) dissolved in 1x TBST was used to dilute the 
antibodies. 
GAPDH was used as a loading control and was detected with primary 
GAPDH mouse monoclonal antibody (Cat # AM4300, Life Technologies LTD 
Invitrogen, UK) (1:1000) and secondary anti-mouse IgG HRP linked antibody (Cat 
# 7076S, Cell signalling, UK). 
4.3.5.5. Measuring protein expression of GPCRs 
Membrane proteins (30µg) from each PNT1A, BPH-1, DU145 and PC3 
cells were prepared, separated on 10% SDS-PAGE gel and then transferred onto 
nitrocellulose membranes as described in section 4.3.5.4. After washing and 
blocking the membranes as described in section 4.3.5.4, GPR110, GPR87 and 
GPRC6A were detected using rabbit anti-GPR110 antibody (Cat # ab75306) 
(1:500), rabbit anti-GPR87 (Cat # ab77517) (1:500) and rabbit anti-GPRC6A (Cat 
# ab96504) (1:500), respectively. These antibodies were purchased from Abcam 
LTD, UK and were diluted as described in section 4.3.5.4. The membrane was 
incubated overnight with the primary antibody with gentle agitation at 4°C. Anti-
rabbit IgG, HRP linked antibody (1:1000) was used as a secondary antibody. 
Integrin β-1 protein was used as a loading control and was detected with 
primary rabbit anti-integrin β-1 antibody (Cat # 4706S, New England Biolabs 
LTD, UK), 1:500, and anti-rabbit IgG, HRP linked antibody was used as a 
secondary antibody. Protein was visualised using chemiluminescent substrate as 
described in next section 4.3.5.6. 
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4.3.5.6. Immunodetection 
The Immunodetection was performed using chemiluminescent substrate 
working solution from SuperSignal West Pico Chemiluminescent Substrate (Cat # 
34080, thermo scientific, USA) prepared by mixing 2ml of reagent A with 2ml of 
reagent B. The membranes were then incubated with the working solution for 5 
minutes in the dark with gentle agitation. The HRP conjugated on the secondary 
antibody catalyses the oxidative degradation of the chemiluminescent substrate to 
produce light emitting luminescence molecule. The fluorescence intensity was then 
measured using Fluor-S MultiImager (Biorad Laboratories) and the protein bands 
were quantified using Quantity One software (Biorad Laboratories). The 
quantification of the protein bands is based on band density (volume) and the 
levels of the quantified protein were given as the percentage (%) of adjusted 
volume. 
For re-probing of the membranes, the previous antibodies were stripped for 
40 minutes at room temperature with gentle agitation using RestoreTM Western 
blot stripping buffer (Cat # 21059, thermo scientific, USA). 
4.3.6. Statistical analysis  
All experiments were repeated three times. Statistical analysis of the kinetic 
measurement of Ca2+ influx was performed with a mixed effect model using 
GenStat software 16th Edition. A mixed effect model was performed when the 
baseline levels of Ca2+ were approximately the same in all samples injected with 
different treatments in one experiment. When the baseline levels were not the same 
between the different treatments injections, the ratio of fluorescence was corrected 
to the baseline levels of each treatment injection and the data plotted represent the 
means ± SD of three independent experiments. In order to compare effect of one 
treatment on the corrected means of different treatment injections, statistical 
analyses were performed with one way ANOVA followed by Tukey's multiple 
comparison test. 
To compare the quantified protein levels of GPR110, GPR87 and GPRC6A 
between the different cell lines, statistical analysis was performed using one way 
ANOVA followed by Tukey’s multiple comparison test.  
All statistical analysis performed with one way ANOVA followed by 
Tukey’s multiple comparison test were accomplished by using GraphPad Prism 
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version 5.00 for Windows (GraphPad Software, San Diego California USA, 
www.graphpad.com). 
4.4. Results  
4.4.1. Ca2+ influx through L-type Ca2+ channels 
4.4.1.1. Palcar 
Palcar (50µM) induced Ca2+ influx in PC3 cells, but to a lesser extent than 
20µM histamine, the positive control (figure 4.5A). Treatment with 1mM 
nifedipine for 5 minutes significantly blocked the influx of Ca2+ in cells injected, at 
50 seconds, with both 50µM palcar and 20µM histamine (P=0.033 and P=0.016, 
respectively, figure 4.5A).  
Because the baseline levels of Ca2+ varied between the different samples 
injected with different treatments in one experiment, the fluorescence ratios were 
corrected to the baseline levels. Correction was performed by subtracting the value 
of fluorescence ratio at maximum Ca2+ influx, which was observed at 80 seconds 
of treatment injection, from that of the baseline level at 50 seconds for each 
sample. Figure 4.5B illustrates the corrected ratios of fluorescence and is used to 
demonstrate the significant inhibitory effect of nifedipine on Ca2+ influx in 
response to both palcar and histamine.  
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Figure 4.5: Palcar-induced Ca2+ influx in PC3 cells through L-type Ca2+ channels. 
Cell suspension was loaded with 2.5µM FURA-2AM for 45 minutes at 37°C and 
5% CO2 prior to treatment with 1mM Nifedipine for 5 minutes. The ratio of 
fluorescence emitted at 510nm and excited at both 340 & 380nm indicate [Ca2+]i. 
A) Both nifedipine treated and untreated cells were injected with DMSO, palcar or 
histamine at 50 seconds. B) Corrected ratio of fluorescence. Data represent means 
± SD of three independent experiments. Statistical analysis was performed with 
mixed effect model test (A) and one way ANOVA followed by Tukey’s post-test 
(B). Pre-treatment with 1mM nifedipine blocked Ca2+ influx in response to both 
palcar and histamine injections compared to nifedipine-untreated cells; P=0.033, 
P= 0.016, respectively (A). *** P≤0.001 (B). 
 
4.4.1.2. DHT 
In a separate experiment, 1mM nifedipine was also shown to block Ca2+ 
influx in response to 1µM DHT (figure 4.6A). The levels of Ca2+ influx in 
nifedipine-treated cells injected with 1µM DHT were significantly (P≤0.001) 
different from the levels of Ca2+ influx in nifedipine-untreated cells (figure 4.6B).  
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Figure 4.6: DHT-induced Ca2+ influx through L-type Ca2+ channels. PC3 cells 
suspension was loaded with 2.5µM FURA-2AM for 45 minutes at 37°C and 5% 
CO2 prior to treatment with 1mM Nifedipine for 5 minutes at 37°C. The ratio of 
fluorescence emitted at 510nm and excited at both 340 & 380nm indicate [Ca2+]i. 
A) Both nifedipine-treated and untreated cells were injected with DMSO, DHT or 
histamine at 50 seconds. B) Corrected ratios of fluorescence. Data represent means 
± SD of three independent experiments. Statistical analysis in B was performed 
with one way ANOVA followed by Tukey’s post-test. Pre-treatment with 1mM 
nifedipine blocked Ca2+ influx in response to both DHT and histamine injection 
compared to nifedipine-untreated cells, *** P≤0.001. 
 
4.4.2. Ca2+ influx through PTX-sensitive GPCRs 
4.4.2.1. Palcar  
PTX treatment was unable to block or reduce Ca2+ influx in response to 
50µM palcar injection at 50 seconds (figure 4.7A, P>0.05; figure 4.7B). In 
contrast, PTX treatment significantly reduced the levels of Ca2+ influx in response 
to 20µM histamine (P≤0.05, figure 4.7B).  
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Figure 4.7: PTX-sensitive GPCR and palcar-induced Ca2+ influx in PC3 cells. 
Cells were treated with 200ng/ml PTX for 24 hour at 37°C and 5% CO2 and then 
loaded with 2.5µM FURA-2AM for 45 minutes at 37°C and 5% CO2. The ratio of 
fluorescence emitted at 510nm and excited at both 340 & 380nm indicate [Ca2+]i. 
PTX-treated and untreated cells were injected with DMSO, palcar or histamine at 
50 seconds. B) Corrected ratios of fluorescence. Data represent means ± SD of 
three independent experiments. Statistical analysis in B was performed with one 
way ANOVA followed by Tukey’s post-test. Palcar induces Ca2+ influx in both 
PTX- treated and untreated cells, ***P≤0.001 and *P≤0.05. 
 
4.4.2.2. Constitutive levels of Giα2 protein expression 
In order to investigate the involvement of Giα subunit in the mechanism of 
Ca2+ influx, protein expression of Giα2 subunit was determined in PNT1A, BPH-1, 
DU145 and PC3 cells. As Ca2+ influx was only observed in PC3 cells, it may 
suggest that the Giα2 subunit is more highly expressed in PC3 cells than the other 
cell lines, especially as it has been shown that Giα2 subunit is the predominant 
subunit present in PC3 cells [164]; therefore the protein expression of Giα2 subunit 
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was measured in PNT1A, BPH-1, DU145 and PC3 cells. However, no differences 
in the levels of expression was observed (figure 4.8). 
 
 
Figure 4.8: Western blot of Giα2 subunit expressed in PC3, DU145, PNT1A and 
BPH-1 cell lines. A band of 40kDa was detected in all cell lines. GAPDH was the 
loading control. M: Marker. The protein expression was performed in duplicates 
(A and B) in each cell line. This blot is a representative of three independent 
protein extracts. 
 
4.4.2.3. DHT 
Ca2+ influx through the PTX-sensitive GPCRs were also investigated in 
response to DHT. PTX treatment reduced the influx of Ca2+ in response to both 
DHT and histamine injection at 50 seconds (figure 4.9A). Figure 4.9B illustrate the 
significant effect of PTX-treatment on Ca2+ influx induced by both DHT (P≤0.01) 
and histamine (P≤0.05) injection compared to the PTX-untreated cells injected 
with DHT or histamine; respectively. 
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Figure 4.9: DHT-induced Ca2+ influx in PC3 cells through PTX-sensitive GPCR. 
Cells were treated with 200ng/ml PTX for 24 hour at 37°C and 5% CO2 and then 
loaded with 2.5µM FURA-2AM for 45 minutes at 37°C and 5% CO2. The ratio of 
fluorescence emitted at 510nm and excited at both 340 & 380nm indicate [Ca2+]i. 
PTX-treated and untreated cells were injected with DMSO, DHT or histamine after 
50 seconds. B) Corrected ratios of fluorescence. Data represent means ± SD of 
three independent experiments. Statistical analysis in B was performed with one 
way ANOVA followed by Tukey’s post-test. ***P≤0.001, **P≤0.01 and *P≤0.05. 
 
4.4.3. Ca2+ influx through PI3K pathway 
Treatment with PI3K inhibitor (LY294002) reduced the Ca2+ influx in 
response to 50µM palcar injection after 50 seconds (figure 4.10A). This reduction 
was significant when compared to the PI3K-uninhibited cells (P≤0.01, figure 
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4.10B). Treatment with PI3K inhibitor (LY294002) also significantly reduced the 
levels of Ca2+ influx in response to histamine (P≤0.05, figure 4.10B).  
 
 
Figure 4.10: Palcar-induced Ca2+ influx in PI3K inhibited PC3 cells. Cell 
suspension was loaded with 2.5µM FURA-2AM for 45 minutes at 37°C and 
5%CO2 prior to incubation with 50µM P13K inhibitor for 1 hour at 37°C and 5% 
CO2 and washed with PI3K inhibitor containing media. A) PI3K-inhibited and 
uninhibited cells were injected with DMSO, palcar or histamine at 50 seconds. B) 
Corrected ratios of fluorescence. Data represent means ± SD of three independent 
experiments. Statistical analysis in B was performed with one way ANOVA 
followed by Tukey's multiple comparison test. Treatment with PI3K inhibitor 
significantly reduced Ca2+ influx induced by both palcar and histamine compared 
to PI3K-uninhibited cells injected with palcar and histamine, respectively, 
***P≤0.001, **P≤0.01, *P ≤0.05. 
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4.4.4. Constitutive gene expression of GPCRs in prostate non-
cancerous and cancerous cell lines 
The gene expression of GPCRs was analysed in the non-cancerous PNT1A 
and RWPE1, and cancerous DU145 and PC3 cells. From these data it was 
observed that certain GPCRs, such as GPR110, was highly expressed in PC3 cells, 
while others, such as GPR87 was highly expressed in PNT1A cells (figure 4.11).  
When comparing the profile of the gene expression of GPCRs between PC3 
and DU145 cells, certain genes were highly expressed in PC3, but not in DU145 
cells (figure 4.12). The same pattern of the gene expression profile was observed 
when PC3 were compared to RWPE1 cells (figure 4.13).  
The profile of the gene expression of GPRCs in DU145 in comparison to 
PNT1A cells (figure 4.14) was similar to that observed in DU145 compared to 
RWPE1 cells (figure 4.15). 
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Figure 4.11: Fold difference of GPCR genes expressed in PC3 as compared to PNT1A cells. Red columns indicate genes highly expressed in 
PC3 as compared to PNT1A cells, whilst blue columns indicate genes highly expressed in PNT1A as compared to PC3 cells. The names of the 
genes are indicated at the top of the columns. 
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Figure 4.12: Fold difference of GPCR genes expressed in PC3 as compared to DU145 cells. Red columns indicate genes highly expressed in 
PC3 as compared to DU145 cells, whilst blue columns indicate genes highly expressed in DU145 as compared to PC3 cells. The names of the 
genes are indicated at the top of the columns. 
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Figure 4.13: Fold difference of GPCR genes expressed in PC3 as compared to RWPE1 cells. Red columns indicate genes highly expressed in 
PC3 compared to RWPE1 cells, whilst blue columns indicate genes highly expressed in RWPE1 as compared to PC3 cells. The names of the 
genes are indicated at the top of the columns. 
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Figure 4.14: Fold difference of GPCR genes expressed in DU145 as compared to PNT1A cells. Red columns indicate genes highly expressed in 
DU145 as compared to PNT1A cells, whilst blue columns indicate genes highly expressed in PNT1A as compared to DU145 cells. The names of 
the genes are indicated at the top of the columns. 
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Figure 4.15: Fold difference of GPCR genes expressed in DU145 as compared to RWPE1 cells. Red columns indicate genes highly expressed in 
DU145 as compared to RWPE1 cells, whilst blue columns indicate genes highly expressed in RWPE1 as compared to DU145 cells. The names 
of the genes are indicated at the top of the columns. 
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4.4.5. Protein expression of GPCRs in prostate non-cancerous and 
cancerous cell lines 
Protein expression of GPCRs; GPR110, GPR87 and GPRC6A was 
quantified using western blotting in PNT1A, BPH-1, DU145 and PC3 cells.  
GPR110 protein (approximately 100kDa) was detected in the membrane 
protein fraction of the PC3 cells and had higher levels of expression as compared 
to PNT1A and BPH-1 cells, but was not detected in the cancerous DU145 cells 
(figure 4.16A). The number of protein bands detected for the loading control 
integrin β-1 varied with the different cell lines investigated. In BPH-1 cells, one 
strong protein band (120kDa) was detected as compared to PC3, DU145 and 
PNT1A cells, in which two bands (100 and 120kDa) were detected. 
The protein expression of GPR87 (approximately 41kDa) and GPRC6A 
(approximately 95kDa) were detected in the membrane fractions of PNT1A, BPH-
1, DU145 and PC3 cells (figure 4.12B and C, respectively). In DU145 cells, 
GPRC6A was less expressed as compared to the other investigated cell lines 
(figure 4.16C). The protein bands of GPR110, GPR87 and GPRC6A detected by 
western blot were quantified and presented as the percentage (%) of adjusted 
volume of each protein in each cell line (figure 4.16D). In PC3 cells, GPR110 was 
significantly (P≤0.001) more expressed when compared to GPR87 and GPRC6A, 
and more highly expressed than in the other investigated cell lines.  
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Figure 4.16: Protein expression 
of GPR110, GPR87 and 
GPRC6A in PNT1A, BPH-1, 
DU145 and PC3 cells. A) 
GPR110 is more highly 
expressed in PC3 cells than 
PNT1A and BPH-1, and not 
detected in DU145 cells. B) 
GPR87 was equally expressed 
in all cell lines tested. C) 
GPRC6A is expressed equally 
in PNT1A, BPH-1, PC3 cells 
and to lesser extend in DU145 
cells. D) Protein quantification 
of GPR110, GPR87 and 
GPRC6A in PNT1A, BPH-1, 
DU145 and PC3 cells. These 
data are representative of three 
independent experiments. 
Statistical analysis was 
performed using one way 
ANOVA in each cell line 
followed by Tukey’s multiple 
comparison test, ***P≤0.001.
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4.5. Discussion  
In this study, the mechanism by which palcar induces Ca2+ influx in PC3 
cells was studied and was compared with that induced by DHT. The mechanism by 
which palcar induced Ca2+ influx was different from that induced by DHT and 
involve the stimulation of L-type Ca2+ channels, but not the activation of PTX-
sensitive GPCRs. Also this influx was partly due to the activation of PI3K 
pathway. In contrast, DHT induced Ca2+ influx through the activation of PTX-
sensitive GPCRs, which stimulate the L-type Ca2+ channels. 
The mechanism by which DHT induces Ca2+ influx has previously been 
investigated in prostate androgen–dependent LNCaP cells [45] and implicated the 
involvement of PTX–sensitive GPCR.  Since both DHT and palcar are lipid-related 
compounds and both PC3 and LNCaP cells are prostate cancerous cell-models, it 
was hypothesized that palcar may act through the same mechanism as DHT and 
therefore palcar activate PTX-sensitive GPCR, which then stimulate L-type Ca2+ 
channel. However, the results support the null hypothesis that palcar and DHT do 
not act through the same mechanism.  
The mechanism of Ca2+ influx in PC3 cells was investigated by using three 
different inhibitors; nifedipine, PTX and PI3K inhibitor (LY294002). Ca2+ influx 
was then investigated in response to palcar, histamine (the positive control) and 
DHT. Table 4.1 summarise the findings of these treatments. 
Table 4.1: Summary of the effect of different inhibitors on Ca2+ influx induced by 
palcar, histamine and DHT in PC3 cells.  
Treatment  Nifedipine PTX PI3K inhibitor (LY294002) 
Palcar Blocked No effect Reduced  
Histamine Blocked Reduced Reduced 
DHT Blocked Reduced Not determined 
 
In contrast to palcar the role of PI3K pathway was not investigated in 
response to DHT. Palcar-induced activation of PI3K pathway was studied to 
investigate the presence of a possible link between the activation of L-type Ca2+ 
channels and the GPCR, which would confirm the involvement of GPCR in the 
mechanism of palcar action and that the Ca2+ influx was not solely due to the 
activation of L-type Ca2+ channels. In contrast, the mechanism induced by DHT 
was clearer in that the involvement of GPCR was confirmed. 
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4.5.1. Activation of L-type Ca2+ channels 
The investigation of the mechanism of Ca2+ influx started first by exploring 
the role of L-type Ca2+ channels since these channels are responsible for the 
majority of Ca2+ influx in most cells. This was performed by inhibiting the 
channels with 1mM nifedipine. Nifedipine is an L-type Ca2+ channel antagonist 
that blocks the entry of Ca2+ through the pore forming subunit; α1-subunit [140]. 
The inability of each palcar, DHT and histamine to induce Ca2+ influx in 
nifedipine-treated cells suggests that the Ca2+ influx was via the activation of L-
type Ca2+ channels (figure 4.5 and 4.6). 
It was noticed that the levels of Ca2+ influx in response to histamine were 
higher than the levels induced by palcar (figure 4.5) suggesting that histamine is 
able to induce Ca2+ influx from the exterior of the cells, in addition to the release of 
Ca2+ from stores. Blocking Ca2+ influx by nifedipine suggests that histamine-
induced Ca2+ influx was mostly due to the activation of L-type Ca2+ channels. The 
activation of these channels may stimulate a signalling pathway that induces the 
release of Ca2+ from stores. 
Histamine was reported as a ligand for H1 [166] and H4 [167] receptors, in 
which their activation causes the stimulation of PLC, which catalyses the 
production of IP3 and DAG from PIP2. IP3 can act as a key for the release of Ca2+ 
from Ca2+ stores [166, 167]. It has been found that the released Ca2+ along with 
DAG can activate PKA, which is involved in phosphorylating the L-type Ca2+ 
channel allowing the influx of Ca2+ into the cells [168].  
The variation of the baseline levels of Ca2+ observed in figure 4.5 can be 
attributed to the time difference when the samples were injected with the different 
treatments, which is one of the drawbacks of using the plate reader for measuring 
Ca2+ influx. Despite the increase in the baseline levels, the ratio of fluorescence 
that indicate the change in [Ca2+]i was not altered after injecting the cell suspension 
with histamine or palcar, which indicates that nifedipine blocked the Ca2+ influx. 
4.5.2. PTX-sensitive GPCRs 
Since L-type Ca2+ channels can be an effector protein for the activation of 
GPCRs, the effect of palcar on GPCR activation was investigated. This was 
achieved using 2.5µM FURA-2AM loaded PC3 cells treated with 200ng/ml PTX 
for 24 hours. The results showed that 50µM palcar induced an increase in Ca2+ 
influx in PTX-treated cells to the same degree as non PTX-treated cells (figure 
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4.7A) suggesting that in PC3 cells palcar-induced Ca2+ influx was not mediated via 
PTX-sensitive GPCR.  
PTX treatment, nevertheless, significantly reduces the levels of Ca2+ influx 
in response to histamine compared to the non PTX-treated cells (figure 4.7B), 
which confirms the validity of the PTX stock solution used in the experiment. 
Since PTX treatment is only specific for the Giα that can bind to the receptor, the 
insensitivity of palcar to the PTX treatment implies that Giα was not involved in 
the mechanism of palcar-induced Ca2+ influx and that the downstream signalling 
pathways of Giα subunit, such as PLC, would also be not involved in palcar–
induced Ca2+ influx. This is supported by a work performed in prostate cancerous 
LNCaP cells, where it has been shown that the activation of PLC was not involved 
in changing the levels of Ca2+ influx and blocking the activity of PLC did not alter 
[Ca2+]i, thus the intracellular Ca2+ stores were not involved in changing the [Ca2+]i 
[45]. Moreover, palcar was found to inhibit the activation of PKC purified from 
mouse brain, which is a downstream protein for the PLC [151]. It has also been 
shown that palcar does not activate PKC in rabbit aortic endothelial cells [136]. 
These observations support that the mechanism by which palcar induces Ca2+ 
influx in PC3 cells do not involve PLC. 
The un-involvement of Giα in the mechanism of action was confirmed by 
investigating the protein expression of Giα in the four cell lines; PC3, DU145, 
PNT1A and BPH-1 cells, in which the Ca2+ influx was only observed in PC3 cells 
(Chapter 3). It was hypothesised that in PC3 cells the Giα is overexpressed 
compared to the other cell lines.  However, the western blot findings in figure 4.8 
indicate that there were no differences in the protein expression of the Giα subunit 
between the cell lines; the lack of involvement of Giα subunit in the palcar 
mediated mechanism of Ca2+ influx is thus supported. 
Since Giα is only one type of the other Gα subunit that can bind to the 
receptor and that palcar mode of action did not involve Giα, the mechanism of 
palcar action in PC3 cells may involve the recruitment of a different Gα subunit, 
other than Giα, to bind with the receptor. 
PTX treatment has a different effect in response to histamine; it significantly 
reduced the Ca2+ influx in PC3 cells (figure 4.7), suggesting that histamine induced 
Ca2+ influx observed via the activation of L-type Ca2+ channels was as a result of 
the activation of PTX-sensitive GPCRs.  
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Histamine-induced Ca2+ influx in PC3 cells agrees with that induced in  
human leukaemia and mast cells, in which histamine induces its effect via PTX-
sensitive way through the activation of Giα subunit [167], which has been linked to 
PLC [166, 167]. In contrast, histamine has been found to induce Ca2+ influx in 
bovine adrenal cells in a PTX-insensitive way through the activation of Gq subunit 
that is linked to PLC [169].  
In this study presented in this thesis, the signalling pathway that link the 
activation of PTX-sensitive GPCRs and L-type Ca2+ channels in PC3 cells was not 
explored, thus need further investigations and may involve the activation of PLC.  
The link between the activation of PLC and the Ca2+ released from stores 
may explain the high levels of Ca2+ influx induced by histamine compared to 
palcar. 
In regards to DHT, PTX treatment significantly reduced the Ca2+ influx in 
PC3 cells (figure 4.9), which was similar to the effect of histamine, but not palcar, 
suggesting that DHT induced Ca2+ influx via the PTX-sensitive GPCRs and which 
support null hypothesis that palcar induces Ca2+ influx in a manner different from 
DHT.  
The ability of DHT to induce Ca2+ influx via the activation of L-type Ca2+ 
channels and PTX-sensitive GPCR agrees with that of LNCaP cells from Sun et al 
study [45], in which DHT was able to induce Ca2+ influx following the same 
mechanism of activating L-type Ca2+ channels and PTX-sensitive GPCRs. 
4.5.3. Activation of PI3K pathway in response to palcar and histamine 
The PI3K pathway is a significant pathway in PC3 cells, since it has been 
found that the expression of PTEN, which negatively regulates PI3K pathway, is 
non-functional in PC3 cells in contrast to PNT1A and BPH-1 cells [170], therefore 
resulting in PI3K signalling being more dominant in PC3 cells [118]. Activation of 
the PI3K pathway has been found to activate L-type Ca2+ channels. Therefore, the 
PI3K pathway may play an important role in Ca2+ influx in PC3 cells.  
To investigate the involvement of PI3K pathway, PC3 cells were treated 
with 50µM PI3K inhibitor (LY294002) for 1 hour. It has been shown that 1 hour 
treatment with 50µM PI3K inhibitor (LY294002) is able to completely inhibits the 
phosphorylation of AKT, which is also known as PKB, by PI3K enzyme in PC3 
and PNT1A cells [165]. Other studies also show that using PI3K inhibitor 
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(LY294002) at 50µM inhibit the increase in [Ca2+]i, [171, 172]. The results of the 
work performed in this chapter regarding the role of PI3K pathway in Ca2+ influx 
showed that PI3K inhibitor (LY294002) reduced the levels of Ca2+ influx in 
response to palcar injection suggesting that the PI3K pathway was partly 
responsible for palcar-induced Ca2+ influx in PC3 cells (figure 4.10). Similar 
results were also found in response to histamine (figure 4.10), which indicate that 
the PI3K pathway may be partly responsible for linking the activation of PTX-
sensitive GPCRs with the L-type Ca2+ channels.  
Figure 4.17 illustrates the proposed mechanism for the Ca2+ influx in PC3 
cells and the role of the PI3K pathway. The proposed mechanism includes the 
activation of GPCR by palmitoylation, which recruit G-proteins to bind the 
receptor. The receptor then activates the Gα subunit, regardless its subfamily, to 
exchange its GDP with GTP and dissociate from the Gβγ complex. The dissociated 
Gβγ complex can phosphorylate, and thus activate PI3K, which subsequently 
phosphorylates the β subunit of the L-type Ca2+ channel, activating the channel, 
and allowing the entrance of Ca2+. 
 
 
Figure 4.17: A schematic representation for the hypothesis of Ca2+ influx through 
GPCR, PI3K pathway and L-type Ca2+ channel in response to palcar. The presence 
of palcar induces the recruitment of G-proteins to bind to the GPCR. The Giα 
subunit exchanges its GDP with GTP and dissociates from both the receptor and 
Gβγ complex. The Gβγ complex activates the PI3K pathway, which subsequently 
phosphorylates the β-subunit of the L-type Ca2+ channel and opens the channel for 
Ca2+ influx. 
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4.5.4. Protein expression of GPCRs 
The stimulation of L-type Ca2+ channels in PC3 cells in response to palcar 
could be as a result of the activation of GPCR. PTX-sensitive GPCR was not 
involved in the mechanism; however other GPCRs may be involved. 
GPCRs are large group of receptors and there might be a number of GPCRs 
on which palcar could act. Recently, lipids and lipid derivatives have been found to 
be possible ligands for several orphan GPCRs. Palcar is a lipid derivative 
compound and therefore might be a possible ligand for these receptors. In order to 
find GPCR candidates, the constitutive expression of numerous genes obtained by 
microarray analysis, performed in PC3, DU145, PNT1A and RWPE1cells, were 
filtered for GPCRs gene expression. The fold difference of the gene expression of 
all the GPCRs detected in all cell lines were plotted (figure 4.11, 4.12, 4.13, 4.14 
and 4.15). The results show that GPCRs were differently expressed between PC3, 
DU145, PNT1A and RWPE1 cells.  
There were certain GPCRs genes that were highly expressed in PC3 
compared to PNT1A (figure 4.11), DU145 (figure 4.12) and RWPE1 cells (figure 
4.13). In DU145 cells, the profile of the GPCRs were similar to that in PNT1A 
(figure 4.14) and RWPE1 (figure 4.15) cells. These results suggest that although 
DU145 cells are a metastatic cancerous cell line, the similarities in its GPCRs gene 
expression with PNT1A and RWPE1 may explain why DU145 cells have a similar 
response to that of PNT1A cells to palcar in regards the Ca2+ influx. 
Based on the results of the profile of the GPCRs gene expression in PC3, 
DU145 and PNT1A cells, three candidate GPCRs were selected to measure the 
levels of their protein expression; these were GPR110, a GPCR that was highly 
expressed in PC3 as compared to PNT1A and DU145 cells, GPR87, a GPCR that 
was highly expressed in PNT1A compared to DU145 and PC3 cells, and finally 
GPRC6A, a GPCR that was equally expressed between all the cell lines.  GPRC6A 
was selected to confirm the validity of the microarray data since the levels of gene 
expression did not necessarily imply the same levels of protein expression. 
GPR107 and GPR126 were two genes that were highly expressed in PNT1A 
cells in comparison to PC3 cells. However, an association between the receptors 
encode by these two genes and Ca2+ influx has not been reported, therefore they 
were not selected for further protein quantification. 
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GPRC6A was one of the genes that were equally expressed between all the 
cell lines. Therefore, GPRC6A was selected for investigating the protein 
expression. 
GPR87 was linked to the increase in [Ca2+]i in response to LPA [173]. This 
receptor was expressed in mouse normal tissue of placenta, ovary, testis, prostate, 
brain, and skeletal muscle [173]. 
GPRC6A was also linked to the increase in [Ca2+]i in response to amino 
acids in intestinal GLUTag cells via the activation of Gq protein, which activates 
PLC and increases [Ca2+]i through IP3-mediated release from the ER [174].  
The immunoblotting with the appropriate antibodies in the work performed 
in this chapter revealed that GPR110 protein was most abundantly expressed in 
PC3 cells as compared to the other cell lines giving a band of approximately 
100kDa (figure 4.16A). Also, the results showed that the protein expression of 
GPR110 was not detected in DU145 cell line. Although the microarray analysis 
performed in this study showed that GPR110 was expressed in very low levels in 
DU145 cells (figure 4.14), previous RT-PCR gene expression work has shown that 
this gene is absent in DU145 cells [175]. 
The findings of this chapter showed that GPR87 protein expression was 
equally expressed by all cell lines with a band of approximately 41kDa (figure 
5.16B). The equal protein expression was also observed for GPRC6A that has a 
band of approximately 100kDa, except in DU145 cells, which has lower 
expression levels (figure 4.16C). 
In this work, β-integrin-1 was used as a loading control for the membrane 
proteins based on the findings of Lum et al [175]. β-integrin-1 is heterodimeric cell 
surface receptor that has an essential role in cell adhesion and migration, as well as 
in growth and survival [176, 177]. The results of the protein expression of β-
integrin-1 in this chapter showed that this protein was not the best choice for a 
loading control. BPH-1 cells showed a weak expression of β-integrin-1 across of 
three independent experiments. Another reason for β-integrin-1 being a poor 
choice of control is on western blot of DU145 cells three bands were detected for 
β-integrin-1, whereas only two bands were observed in PNT1A and PC3 cells, 
suggesting difference in the expression of β-integrin-1 between these cell types. 
However, the poor loading control did not affect the evaluation of the levels of the 
protein expression of GPR110, GPR87 and GPRC6A, because even though the 
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band for the β-integrin-1 in BPH-1 cells was weak, the protein expression of 
GPR87 and GPRC6A in this cell line still can be observed clearly and in levels that 
were very close to that in PNT1A and PC3 cells. 
It is important to note that another membrane protein loading control 
Na+/K+–ATPase was investigated, however the expression of this protein was 
weak and only observed in PC3 and DU145 cells and not in the other cell lines. 
There are other loading controls that could be investigated, such as β-actin, 
however this was not possible due to the time limitation for the completion of this 
thesis. 
Since palcar-induced Ca2+ influx was only observed in PC3 cells, this 
indicates the involvement of a GPCR that is present in PC3, but not in PNT1A and 
DU145 cells. The protein expression of both GPR87 and GPRC6A in PC3, PNT1A 
and DU145 cells, therefore implies that both GPR87 and GPRC6A receptors are 
unlikely to be involved in the mechanism of Ca2+ influx and thus suggest that 
GPR110 may be the gene that is linked to the Ca2+ influx in these cells.  
Further research is needed to investigate the link between Ca2+ influx and 
the activation of GPR110 in addition to determining whether the activation of this 
receptor is induced by the presence of palcar, thus provide more insights on the 
mechanism by which palcar act in prostate cancer. 
 
4.6. Conclusion  
In this study, palcar induced Ca2+ influx in PC3 cells via the activation of L-
type Ca2+ channels, but not PTX-sensitive GPCR. Since PTX treatment is specific 
for the Giα subunit, the PTX insensitivity of Ca2+ influx in response to palcar 
suggested that Giα subunit and its associated pathways were not involved in the 
mechanism of Ca2+ influx. However, different Gα subunits, other than Giα subunit, 
could bind to the receptor leading to the activation of L-type Ca2+ channel. The 
results of this study suggested that the mechanism also includes a partial 
involvement of the PI3K pathway. The PI3K pathway may provide a link between 
the activation of GPCR and L-type Ca2+ channel. 
In this study, the profile of the GPCRs gene expression investigated in PC3, 
DU145, PNT1A and RWPE1 cells showed that GPR110 was highly expressed in 
PC3 as compared to the other cell lines. GPR87 was highly expressed in PNT1A as 
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compared to PC3 and DU145 cells, and GPRC6A was equally expressed between 
all the cell lines. The protein expression of these receptors showed that GPR110 
was more expressed in PC3 cells as compared to PNT1A, BPH-1 and DU145 cells. 
In addition, GPR110 was the most abundantly expressed protein as compared to 
the other GPCRs in PC3 cells, which suggests that this receptor might have a role 
in the Ca2+ influx observed in PC3 cells. 
Collectively, although the concentration of palcar used in this study was 
above the reported human physiological levels in plasma and tissue, and that the 
effects of palcar may be related to a stress response, the results of this study 
highlight the potential importance of acylcarnitines, in particular palcar, under high 
concentrations as a signalling molecule in prostate cancer. However, the 
physiological role in signalling is unclear. 
In the cell-model that was used in this chapter, the induction of Ca2+ influx 
was a biological consequence of using a high concentration of palcar, therefore this 
may raise a question of whether palcar at lower concentrations may have any other 
biological consequences. The answer to this question is to be addressed in the next 
chapter. 
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5.1. Introduction  
Previously, it was shown that palcar is associated with the induction of IL-6 
gene expression in prostate non-cancerous PNT1A and cancerous PC3 cells. This 
was thought to be related to the effect of palcar on inducing Ca2+ influx. Ca2+ 
influx was also induced by DHT, which is a hormone associated with prostate 
cancer progression. The mechanism of Ca2+ influx in response to both palcar and 
DHT was investigated in Chapter 4, and it was found that palcar induced Ca2+ 
influx in a mechanism that was different to that of DHT. However, all of these 
changes occur with a high concentration of palcar that was higher than the levels 
detected in prostate cancerous tissue quantified in Chapter 2, as well as in plasma 
from individuals with metabolic disorders reported in the literature (table 2.1, 
Chapter 2). This raised a question of whether palcar at lower concentrations would 
have any effect on prostate cells. Therefore, in this Chapter, the effect of lower 
concentrations of palcar was investigated by quantifying the global gene 
expression using Affymetrix Human Exon 1.0 ST arrays in non-cancerous PNT1A 
prostate cells treated with increasing concentrations of palcar (0-5µM) and 10nM 
DHT. PNT1A cell line was selected to investigate the hypothesis that palcar may 
be associated with the induction of genes important for cell transformation and 
prostate cancer progression. In this study palcar was compared to DHT in order to 
investigate the hypothesis that palcar may have DHT-like activities and have a role 
in prostate cancer progression.  
Studying the induction of genes by microarrays provides a general look at 
the behaviour of the cells in response to a specific compound. In prostate cells, 
studying the effect of palcar by microarray helps identify the patterns of gene 
activity in response to this compound. It may detect induced genes involved in 
certain signalling pathways that may have a role in initiating cancer, or may 
indicate an induction of protein, fat or carbohydrate synthesis or oxidation. In 
cancer cells, the induction of such processes may indicate cell proliferation through 
the induction of catabolic processes to provide energy for the proliferated cells as 
well as the induction of anabolic processes to provide the building blocks for these 
newly formed cells.   
Since PC3 cells represent the most metastatic form of prostate cancer, palcar 
effect on inducing genes in both PNT1A and PC3 cells suggest that palcar may 
have a role in prostate cancer progression. Therefore, the genes that were shown to 
be induced in response to both palcar and DHT by microarray analysis in PNT1A 
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cells were further quantified in PC3 cells using real time RT-PCR and compared 
with that in PNT1A cells. 
5.2. Aims 
– To investigate the effect of low concentrations of palcar on global gene 
expression profiles of PNT1A cells.   
– To compare the effect of palcar on gene expression profiles with that of 
DHT. 
– To compare the effect of palcar and DHT-induced gene expression in both 
PNT1A and PC3 cells. 
5.3. Materials and methods 
5.3.1. Measuring gene expression using microarray (Affymetrix 
Human Exon 1.0 ST Array) 
5.3.1.1. Background 
The Affymetrix GeneChip® Human Exon 1.0ST array is a whole-transcript-
based array for the profiling of gene expression. This array queries the entire 
transcript and is not specific for the 3’ end in contrast to the old Affymetrix array. 
This array contains more than 5.5 million individual probes. Four individual 
perfectly matched probes form one probe set. Therefore, this array has 
approximately 1.4 million probe sets. Each probe set represents an exon. A group 
of probe sets or exons form a transcript cluster, which corresponds to a gene. 
Therefore, analysis at the gene level is performed by considering all the probes 
within a single transcript cluster. Genes may have a number of transcripts and 
alternative splicing may produce different transcripts. 
5.3.1.2. RNA extraction, quality and quantity 
PNT1A cells were seeded in 6 well plates and once the growth reached 70% 
confluence, cells were treated with DMSO, palcar (0.005, 0.05, 0.5 or 5µM) or 
10nM DHT for 8 hours at 37°C and 5% CO2. RNA was extracted using RNeasy 
Mini kit as described in Chapter 3 (section 3.3.4.2). RNA quality and quantity 
were checked using RNA 1000 Nanodrop (Life Technologies) as described in 
Chapter 3 (section 3.3.4.3). RNA samples were stored at -80°C for later use. 
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Quality was checked on Agilent Bioanalyser, where all samples had RNA 
integrity number > 8. 
5.3.1.3. Analysis of gene expression 
Profiling of gene expression was performed using Affymetrix GeneChip 
Human Exon 1.0ST Array (Affymetrix Sana Clara, CA) at Nottingham 
Arabidopsis Stock Centre (Nottingham, UK) following the Affymetrix protocols. 
Data were analysed using R/Bioconductor [178] and the aroma.affymetrix package 
[179]. The raw signal intensity data was provided in .CEL files. The data were 
robust multiple average (RMA) background-corrected and quantile normalised. To 
obtain the gene-level summaries, linear probe level models were applied to the 
data. For annotation, the current custom CDF file available at the aroma.affymetrix 
Web site containing the core probe sets (18708 transcript clusters; 284258 probe 
sets) was used. To identify differentially expressed genes, subsequent statistical 
data analysis using benjamini hochberg multiple testing correction was performed 
using limma. Genes were identified as differentially expressed at P≤0.05. To 
identify pathways that were the most over represented in the lists of the 
differentially expressed genes, functional analyses was performed using the 
Database for Annotation, Visualization and Integrated Discovery v6.7 (DAVID; 
http://david.abcc.ncifcrf.gov/) [180]. 
Overlapping genes between treatments were identified using the overLapped 
package in R. The number of the common genes that is expected to be induced by 
chance was calculated using the following equation: 
Nchance =
     ×    ()
(   )
   , where 
Nchance: number of genes that is expected to be induced by chance  
N genes: number of genes 
N genes list (n): number of genes induced by treatment (n) compared to 
control. 
5.3.2. Quantification of mRNAs using real-time reverse-transcription-
polymerase chain reaction (RT-PCR)  
PNT1A and PC3 cells were seeded in 6 well plates until growth reached 
70% confluence. To validate the microarray results, PNT1A cells were treated with 
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DMSO, palcar (0.005, 0.05, 0.5 and 5µM) and 10nM DHT for 8 hours at 37°C and 
5% CO2. To investigate and compare the long term exposure of palcar and DHT on 
gene expression between PNT1A and PC3, cells were treated with DMSO, 5µM 
palcar and 10nM DHT for 24 hours at 37°C and 5% CO2. RNA was extracted from 
cells using RNeasy Mini kit as described in Chapter 3 (section 3.3.4.2). The 
quantity and quality of RNA was determined using RNA 1000 Nanodrop (Life 
Technologies) as described in Chapter 3 (section 3.3.4.3). The RNA samples were 
stored at -80°C for later use. 
HK2, aldehyde dehydrogenase 1 family, member A3 (ALDH1A3) and 
endothelin 1 (EDN1) gene expression was measured by real time RT-PCR 
performed using  an Applied Biosystems OneStep Plus real time RT-PCR system 
carried out on a microamp optical 96-well plate in a total volume of 20µl pre well, 
containing TaqMan 1-step RT-PCR master mix reagent kit (Applied Biosystems), 
20ng total RNA, and primers and probes of HK2 [forward sequence 5’-
GCATCAAGGAGAACAAAGGC-3’, 500nM, reverse sequence 5’- 
TCTTATATGTAGACGCTTGGCAA-3’, 500nM and probe 5’-
FAM/ACCGTCGACCCCAATAGTAGAGCG-TAMRA/-3’], ALDH1A3 
[forward sequence 5’-CTCTGGAAGGCAACCTGTG-3’, 500nM, reverse 
sequence 5’-GGAGCAAATATGTGAAGTGGAAG-3’ and probe 5’-
/FAM/AGATAAGCCCGACGTGGACAAGG-TAMRA/-3’] and EDN1 [forward 
sequence 5’-GATGCCAATGTGCTAGCCA-3’, 500nM, reverse sequence 5’-
CTTATGATTATTCCAGTCTTTCTCCA-3’, 500nM and probe 5’-
FAM/TCTTCAGCCCTGAGTTCTTTTCCTGC-TAMRA/-3’]. All were 
purchased from Integrated DNA Technologies, USA.  Reverse transcription was 
performed as described in Chapter 3 (section 3.3.4.4). Reactions were carried out 
in triplicate and were normalized against an endogenous housekeeping gene, 18S 
ribosomal RNA, as described in Chapter 3 (section 3.3.4.4). 
Relative quantification of the gene expression in samples was based on the 
relative standard curve method, where a relative standard curve is prepared by 
serial dilutions made form a sample containing the highest RNA concentration. 
Standard curves were prepared for both the samples and the endogenous gene 
because quantitation is normalized to the endogenous gene. 
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5.3.3. Effect of androgen-free environment on changing the gene 
expression 
Since in the literature a modified medium has always been used to measure 
the activity of DHT in LNCaP cells, the effect of using modified media on the gene 
expression was investigated in PNT1A, PC3 and LNCaP cells. Cells were seeded 
in 6 well plates using, first, RPMI media (RPMI-1640, Cat. # R8758, sigma-
aldrich) supplemented with 10% FBS until growth reached 70%. Then they were 
switched to modified media of phenol-free RPMI media (RPMI-1640, Cat. # 
11835-063, Invitrogen) supplemented with 10% Charcoal‑stripped FBS (CS‑FBS, 
Cat # F6765-500ML, sigma-aldrich). The phenol-free media were used to create a 
steroid–free environment, whereas charcoal-treated FBS was used to eliminate the 
endogenous steroids. Cells were kept for 48 hours in this media and then treated 
with DMSO, 5µM palcar and 10nM DHT for 24 hours at 37°C and 5% CO2. RNA 
was extracted using RNeasy Mini kit as described in Chapter 3 (section 3.3.4.2). 
The quality and quantity of RNA were checked using UV absorbance determined 
by RNA 1000 Nanodrop (Life Technologies) as described in Chapter 3 (section 
3.3.4.3). RNA samples were then kept in -80°C for later use. 
The extracted RNA was used as a template for measuring the gene 
expression of HK2, ALDH1A3 and EDN1 and was performed using real time RT-
PCR technique as described above (section 5.3.2).  
5.3.4. Statistical analysis 
In the microarray, to determine whether the genes in common between 
palcar and DHT were changed by the effect of treatments and not by chance, the 
proportion of genes in common were compared to the proportion of the genes 
expected to be changed by chance. Proportion is defined by the number of genes 
expected to be changed by chance (or by both treatments) divided by the total 
number of genes that changed significantly by treatment. Statistical analysis of the 
proportion was performed by a proportion test using R version 3.0.1.  
Real time RT-PCR was performed in triplicate measuring of three biological 
replicates of one experiment. Data were normalised against an endogenous gene 
and the data plotted as means ± SD. Statistical analysis was performed by one way 
ANOVA followed by Tukey’s multiple comparison post-test using GraphPad 
Prism version 5.00 for Windows (GraphPad Software, San Diego California USA, 
www.graphpad.com). Differences were considered significant at P ≤0.05. 
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5.4. Results  
5.4.1. Affymetrix Human Exon 1.0 ST gene expression of PNT1A cells 
in response to palcar and DHT 
The gene expression profile of PNT1A cells treated with palcar (0.005, 0.05, 
0.5 or 5µM) or 10nM DHT in three biological replicates were investigated by 
hybridisation of RNA samples to Affymetrix Human Exon 1.0 ST arrays. A total 
of 18 mRNA samples collected were hybridised to the array chip.  A total of 18708 
genes were compared and the number of genes altered in response to palcar or 
DHT treatment in comparison to control is shown in table 5.1. Initial analysis by 
multiple testing correction revealed that there were no genes differentially 
expressed (P≤0.05, benjamini hochberg multiple testing correction). However, due 
to the large number of analysed genes, it is expected that the multiple testing 
corrections would be very stringent and not allow the detection of real biological 
changes. Therefore, the gene expression values with uncorrected P-values were 
further analysed (P≤0.05, moderated t-statistic) to determine whether they have 
any biological significance. 
In order to determine whether a gene was up- or down-regulated, log2 
expression ratio was extracted and the fold change was calculated as the ratio of 
the gene expression value in either palcar (0.005, 0.05, 0.5 or 5µM) or 10nM DHT 
compared to DMSO (control). Positive or negative values represent up- or down-
regulated genes, respectively, in comparison to control. Table 5.1 shows the 
number of genes altered in response to each treatment, where the green and red 
colours represent the up- and down-regulated genes, respectively.  
Table 5.1: Number of genes differentially expressed in PNT1A in response to 
palcar and DHT treatment compared to control. 
 
P-value Palcar DHT 
5nM 50nM 500nM 5µM 10nM 
P ≤0.051 334  
(213, 121)2 
73 
(42, 31) 
180 
(107, 73) 
346 
(198, 148) 
605 
(235, 370) 
 
P≤0.005 30 
(25, 5) 
3 
(2, 1) 
9 
(6, 3) 
23 
(19, 4) 
66 
(30, 36) 
1
 P-value is calculated using moderated t-statistic. 
2 Number of genes up regulated (green) and down regulated (red).  
The data in table 5.1 showed that more genes were altered in response to the 
highest palcar concentration (5µM) compared to the other concentrations (0.005, 
0.05, 0.5µM). There were a total number of 346 genes altered in response to 5µM 
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palcar at P≤0.05. These genes are shown in annex I ranked in a descending order 
according to fold change levels.  
Functional pathway analysis with DAVID was performed for the genes 
altered by the 5µM palcar treatment. There were four over represented pathways 
affected by palcar treatment at P≤0.05 (table 5.2); one of them was the glycolytic 
pathway, which has highest fold enrichment value along with the metabolism of 
xenobiotic pathway. Fold enrichment is a term that describes the degree of 
enrichment, for example if a pathway has a fold enrichment of 4, this means that 4 
times the number of genes expected by chance within the pathway were identified. 
It has been proposed that a value of ≥1.5 is considered as an interesting finding 
[180].  
Table 5.2: Functional pathway analysis after 5µM palcar treatment for 8 hours 
(P≤0.05) arranged according to the fold enrichment in descending order. 
Pathway # genes P-value1 Fold Enrichment  
Glycolysis / Gluconeogenesis 5 0.038 3.888 
Metabolism of xenobiotics by 
cytochrome P450 
5 
 
0.038 
 
3.888 
 
Olfactory transduction 16 0.013 1.969 
Cytokine-cytokine receptor interaction 11 0.050 1.959 
1P value = Fisher Exact P-Value. 
 
The total number of genes that belong to the glycolytic pathway and were 
altered in response to palcar treatment was 5 genes (table 5.3). The genes that were 
altered in the other pathways are presented in annexes II – IV with their fold 
change levels. 
Table 5.3: Genes involved in pathway of glycolysis/gluconeogenesis affected by 
5µM palcar treatment for 8 hours arranged according to the fold change in 
descending order. 
Accession Gene description Gene 
name 
Fold 
change 
P-
value 
NM_000693 
 
aldehyde dehydrogenase 1 family, 
member A3 
ALDH1A3 
 
1.161 
 
0.003 
 
NM_000189 hexokinase 2 HK2 1.156 0.040 
NM_002633 phosphoglucomutase 1 PGM1 -1.133 0.049 
NM_000691 
  
aldehyde dehydrogenase 3 family, 
member A1 
ALDH3A1 
 
-1.148 
 
0.025 
 
NM_006066 
 
aldo-keto reductase family 1, member 
A1 (aldehyde reductase) 
AKR1A1 
 
-1.163 
 
0.022 
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Pathway analysis was also performed for the genes altered by 10nM DHT 
treatment. There were a total of three pathways that were significantly affected 
(table 5.4). Both pathways of glycolysis/gluconeogenesis and sulphur metabolism 
were potentially altered by DHT. 
Table 5.4: Functional pathway analysis after 10nM DHT treatment for 8 hours 
(P≤0.05) arranged according to the fold enrichment in descending order. 
Pathway # genes P-value Fold Enrichment 
Sulfur metabolism 3 0.076 6.42 
Porphyrin and chlorophyll metabolism 5 0.037 3.891 
Tyrosine metabolism 6 0.026 3.502 
TGF-beta signalling pathway 9 0.019 2.657 
Glycolysis / Gluconeogenesis 6 0.081 2.568 
 
Glycolytic pathway was altered in response to palcar and potentially in 
response to DHT treatment. The DHT-altered genes involved in glycolytic 
pathway were identified in order to determine whether DHT affect the same genes 
that were altered by palcar. The DHT-altered genes are shown in table 5.5 and 
ranked according to the fold change value.  
Table 5.5: Genes involved in the glycolytic / gluconeogentic pathway 
affected by 10nM DHT treatment for 8 hours arranged according to the fold 
change in descending order. 
Accession Gene title Short 
name 
Fold 
change 
P-value 
NM_000693 
  
aldehyde dehydrogenase 1 family, 
member A3 
ALDH1A3 
 
1.257 
 
0.0001 
 
NM_000189 hexokinase 2 HK2 1.168 0.030 
NM_000691 
 
aldehyde dehydrogenase 3 family, 
member A1 
ALDH3A1 
 
-1.146 
 
0.027 
 
NM_002633 phosphoglucomutase 1 PGM1 -1.150 0.030 
NM_004563 
 
phosphoenolpyruvate 
carboxykinase 2 (mitochondrial) 
PCK2 
 
-1.166 
 
0.044 
 
NM_006066 
 
aldo-keto reductase family 1, 
member A1 (aldehyde reductase) 
AKR1A1 
 
-1.238 
 
0.002 
 
 
ALDH1A3 and HK2 genes were up regulated in response to both palcar and 
DHT treatment (table 5.3 and 5.5). ALDH1A3 and HK2 have an induction of 
approximately 1.2 fold increase in their expression level in comparison to their 
control.  
The genes altered in the other pathways in response to DHT are presented in 
annex V, VI, VII and VIII. 
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5.4.1.1. Genes in common between palcar and DHT 
Because it was observed that the glycolytic pathway was altered by DHT 
and palcar treatments, and there were two genes, which belong to this pathway and 
altered by both treatments, the genes in common affected by all palcar 
concentrations (0.005, 0.05, 0.5 and 5 µM) were determined first and then the 
genes in common between all palcar concentrations and DHT was investigated, 
this is in order to answer the question of whether palcar might have DHT-like 
biological activities in PNT1A cells. There were a total of six genes affected by all 
palcar concentrations (figure 5.1); these genes are listed in table 5.6.  
 
Figure 5.1: Venn diagram of the total genes in common detected across varying 
concentrations of palcar in PNT1A cells treated for 8 hours. A, B, C and D 
represent the genes changed by varying concentrations of palcar compared to 
control; where A: 0.005µM palcar, B: 0.05µM palcar, C: 0.5µM palcar and D: 
5µM palcar. 
 
Table 5.6: Genes in common between all palcar concentrations (0.005, 0.05, 0.5 
and 5µM) arranged according to the fold change in descending order. 
Accession Gene title Short name 
NM_000693  aldehyde dehydrogenase 1 family, member A3 ALDH1A3 
NM_004613  
transglutaminase 2 (C polypeptide, protein-
glutamine-gamma-glutamyltransferase) TGM2 
NM_005242 coagulation factor II (thrombin) receptor-like 1 F2RL1 
NM_001955 endothelin 1  EDN1 
NM_002068 
guanine nucleotide binding protein (G protein), 
alpha 15 (Gq class) GNA15 
NM_174976 zinc finger, DHHC-type containing 22 ZDHHC22 
 
When DHT was incorporated in the Venn diagram, the common number of 
genes across all treatments becomes five (figure 5.2). These genes are presented in 
table 5.7. 
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Figure 5.2: Venn diagram of the genes in common detected across varying 
concentrations of palcar and 10nM DHT treatment in PNT1A cells treated for 8 
hours. 
 
Table 5.7: Genes in common between palcar (0.005, 0.05, 0.5 and 5µM) and 
10nM DHT treatment arranged according to the fold change in descending order. 
Accession Gene title Short 
name 
Fold change  P-value 
NM_000693  
aldehyde dehydrogenase 1 
family, member A3 ALDH1A3 1.257 6.0E-05 
NM_004613  
transglutaminase 2 (C 
polypeptide, protein-
glutamine-gamma-
glutamyltransferase) TGM2 1.219 0.001 
NM_005242 
coagulation factor II 
(thrombin) receptor-like 1 F2RL1 1.207 0.007 
NM_002068 
guanine nucleotide binding 
protein (G protein), alpha 15 
(Gq class) GNA15 1.118 0.028 
NM_174976 
zinc finger, DHHC-type 
containing 22 ZDHHC22 -1.322 0.001 
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The genes that were induced by all palcar concentrations and DHT belong to 
different pathways and thus have different functions. TGM2 is a gene that encodes 
for the production of the protein transglutaminase 2. This protein has a role in the 
modification of other proteins by forming an inter- or intramolecular bond that is 
highly resistant to proteolysis. This reaction is Ca2+ dependent. Forming such a 
bond is important for cell adhesion, which is essential in cancer development. 
Moreover, TMG2 has a role in GTP-binding/hydrolysing process [181]. 
Since this gene was induced by both DHT and palcar, the functions of this 
gene may provide more insights into the role of DHT in prostate cells, which 
include its mediatory effect in the deamination of the glutamate to form α-
ketoglutarate, which is important for the TCA cycle. Also the induction of TGM2 
means the formation of a proteolysis-resistant bond between proteins, which is as 
mentioned earlier is a requirement for cell adhesion. This may indicate the 
mediatory role of both DHT and palcar in cancer development. In addition, the role 
of TGM2 in the GTP-binding/hydrolysing process might provide information 
about the role of DHT and palcar in the activation of GPCR. 
EDN1 is a gene that encodes for the production of preproendothelin-1, 
which can be proteolytically converted into endothelin 1 [182]. This protein is 
released by endothelial cells and behaves as a vasoconstrictor; therefore it was 
associated with hypertension. This gene has been found to be involved in many 
diseases, such as CVD, reproductive, and renal diseases in addition to cancer 
[183]. Moreover, this gene has been found to have a role in controlling the blood 
flow in the epididymis, which is necessary for the movement of the sperms [184]. 
Gene orthology revealed that this gene can be activated as a consequence of 
stimulating NFκB and HIF-1–dependant pathways.  
The other gene that was induced by all palcar concentrations and DHT is 
F2RL1. It is a gene that encodes the production of coagulation factor II (thrombin) 
receptor-like 1, also known as GPR11 and PAR2, thus it is a member of the GPCR 
family and the protease-activated receptor family. It is involved in the 
inflammatory pathways and has a role in the sensory system, in which it acts as a 
sensor for proteolytic enzymes generated during infection [185]. The induction of 
this gene, therefore, indicates that both palcar and DHT might be involved in 
inflammatory responses in the prostate cells.  
GNA15 was induced by all palcar concentrations. It is the gene that encodes 
for G protein, alpha 15 (Gq class). This GPCR is activated in response to 
Chapter 5 
139 
 
nuerotransmitters and hormones. The activation of this receptor stimulates the 
dissociation of Gαq subunit, which is able to activate PLC. The latter stimulates the 
release of Ca2+ from Ca2+ stores via IP3  and does not involve the activation of L-
type Ca2+ channels [186]. Because L-type Ca2+ channels are not involved in the 
mode of action of GNA15, the possibility of the contribution of GNA15 to the 
mechanism of action induced by palcar was not considered. However, it can be 
involved in the mechanism by which DHT induces Ca2+ influx since the levels of 
DHT-induced Ca2+ influx (shown in Chapter 3, figure 3.19 B and C) was higher 
than that induced by palcar, which indicate the involvement of the Ca2+ stores in 
DHT mechanism of action. 
The last gene that was induced by all palcar concentrations is the zinc finger 
DHHC-type containing 22 (ZDHHC22) gene. Gene ontology annotations related to 
this gene revealed that this gene has transferase activity and is involved in 
transferring acyl groups [187]. This role of the gene may indicate a possible role in 
transferring the acyl group from palcar to the GPCR and also has a role in 
transferring palcar into the mitochondrial matrix for β-oxidation.  
The genes overlapped between each individual palcar concentration and 
DHT was investigated and illustrated in figure 5.3. There were a total of 79, 21, 62 
and 196 genes common between DHT and 0.005, 0.05, 0.5 and 5µM palcar, 
respectively (figure 5.3A).  
The number of the common genes that are expected to be induced by chance 
is illustrated in the table in figure 5.3B. It is clear that the number of the genes 
induced by treatment was significantly higher than the number of genes that could 
be induced by chance, which indicate that this effect was due to the treatment in 
and not by chance. 
The largest number of common genes was between 5µM palcar and 10nM 
DHT, which were 169 genes. These genes are listed annex IX. 
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Figure 5.3: Genes in common across palcar and DHT treatment in PNT1A cells 
treated for 8 hours. A) Venn diagram of genes across each palcar (5, 50, 500 and 
5000nM) and 10nM DHT treatments. B) A comparison between the numbers of 
the genes expected to be induced by chance and treatment. P values are calculated 
using a proportion test [188]. 
 
Some of the 169 genes were up-regulated and some down-regulated. Figure 
5.4 represents the fold change of DHT compared to control against the fold change 
of palcar compared to control. This figure show that palcar have DHT-like 
activities in the prostate cell.  
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Figure 5.4: Fold change of DHT compared to control against fold change of palcar 
compared to control. The genes that are up-regulated by palcar are also up-
regulated by DHT and vice versa. FC: fold change, ctrl: control, vs: versus. 
 
5.4.2. Real time RT-PCR measurement of gene expression 
To confirm the validity of the gene expression obtained by microarray, two 
genes were selected for further analysis by real-time RT-PCR. These genes were 
ALDH1A3 and HK2. They were selected because they demonstrated the highest 
level of expression in response to palcar and DHT in comparison to their controls 
(P≤0.05, table 5.3 and 5.5). EDN1 gene was also selected, which is a gene that is 
common between all palcar treatments, but not induced by DHT treatment in this 
experiment; however, it has been reported to be induced by DHT treatment 
previously [184]. Therefore, a total of three genes were selected to be further 
analysed by real-time RT-PCR. In this study, DHT was considered as a positive 
control for the effect of palcar as it has been reported previously to induce both 
HK2 and ALDH1A3 [189, 190]. The real time RT-PCR results showed that 
ALDH1A3, HK2 and EDN1 gene expression were not induced in response to 
palcar (0.005, 0.05, 0.5 and 5µM) or DHT, except for ALDH1A3, which was 
down-regulated (figure 5.5) by DHT. These results therefore, confirm the 
microarray data that palcar and DHT were not associated with an induction of gene 
expression. 
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Figure 5.5: Real time RT-PCR analysis of HK2, ALDH1A3 and EDN1 mRNA 
expression in PNT1A cells. Cells were cultured in RPMI media supplemented with 
10% FBS at 37°C and 5% CO2. Cells were treated with DMSO, 5µM palcar or 
10nM DHT for 8 hours. Data represent means ± SD of three biological replicates. 
Statistical analysis was performed using one way ANOVA followed by Tukey’s 
post-test. Neither palcar (0.005, 0.05, 0.5 and 5µM) nor 10nM DHT induces an 
induction of HK2, ALDH1A3 or EDN1 genes expression. 
 
5.4.3. Effect of palcar and DHT on HK2, ALDH1A3 and EDN1 gene 
expression in PNT1A and PC3 cells in response to 24 hours 
To investigate whether longer incubation of palcar would result in inducing 
the expression of the above genes, the effect of the highest palcar concentration 
(5µM) for 24 hours was determined in PNT1A cells and were compared to that in 
PC3 cells. In PNT1A cells, DHT significanlty induced HK2 and EDN1 gene 
expression (P≤0.01), but not ALDH1A3, while palcar treatment had no effect 
(figure 5.6). However, in PC3 cells, DHT did not induce gene expression of 
ALDH1A3 and EDN1, but there was a trend to induce HK2 although it did not 
reach a statisticaly significant level (figure 5.6 A). In contrast, 5µM palcar 
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treatment significantly induced HK2 (P≤0.05), but not ALDH1A3 and EDN1 
genes in PC3 cells.  
 
 
Figure 5.6: Real time RT-PCR analysis of HK2, ALDH1A3 and EDN1 mRNA 
expression in PNT1A and PC3 cells. Cells were cultured in RPMI media 
supplemented with 10% FBS at 37°C and 5% CO2. Cells were treated with DMSO, 
5µM palcar or 10nM DHT for 24 hours. Data represent means ± SD of three 
biological replicates. Statistical analysis was performed using one way ANOVA 
followed by Tukey’s post-test performed in each PNT1A and PC3 cells separately. 
Palcar (5µM) treatment for 24 hours only induced the gene expression of HK2 in 
PC3 cells, but not in PNT1A, while 10nM DHT treatment induced the induction of 
EDN1 gene expression only in PNT1A cells. **P≤0.01. 
 
5.4.4. Effect of androgen-free environment on palcar and DHT-
induced gene expression  
The lack of change in  ALDH1A3 gene expression in response to DHT in 
both PNT1A and PC3 cells as well as the gene expression of HK2 in PC3 cells 
were thought to be due to the media that was used, which contains steroids. 
Steroids can be converted by cells into androgens that can bind with cellular 
receptors and induce changes to the gene expression, thus presence of androgen in 
the media used to culture these cells may prevent the observation of any effect of 
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DHT added from the treatment, which may affect the results of the gene expression 
and may explain why palcar did not have an effect. Therefore, the effect of a DHT 
free environment was investigated by using another type of media that is free of 
steroids; also a charcoal-stripped FBS was used to adsorb any endogenous lipid-
related compounds including androgens. This media was called modified media. 
Since DHT was reported to induce gene expression in the prostate cancerous 
LNCaP cells, DHT effect was also investigated in this cell line and compared to 
that in PNT1A and PC3 cells cultured in the modified media. The results showed 
that changing the type of media where the cells were cultured prior to the addition 
of DHT from the treatment has no effect on the gene expression of HK2, 
ALDH1A3 and EDN1 in PNT1A and PC3 cells (figure 5.7).  
 
Figure 5.7: Real time RT-PCR analysis of HK2, ALDH1A3 and EDN1 mRNA 
expression in PNT1A, PC3 and LNCaP cells. Cells were cultured in RPMI media 
until growth reached 70% confluence and then switched to phenol-free RPMI 
media supplemented with charcoal-stripped FBS for 48 hours at 37°C and 5% 
CO2. Cells were treated with DMSO, 5µM palcar or 10nM DHT for 24 hours. Data 
represent means ± SD of three biological replicates. Statistical analysis was 
performed using one way ANOVA followed by Tukey’s post-test performed in 
each cell line separately. Changing the media did not induce a detectable gene 
expression in PNT1A, PC3 and LNCaP cells in response to 5µM palcar, but it 
induced a significant gene expression of ALDH1A3 (B) and EDN1 (C) in LNCaP 
cells in response to DHT treatment. *** P≤0.001. 
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In fact, using this media abolished the effect of palcar in inducing HK2 gene 
expression observed in PC3 cells, in addition to the effect of DHT on HK2 and 
EDN1 gene expression in PNT1A cells. However, in LNCaP cells, the gene 
expression of ALDH1A3 and EDN1 were significantly different compared to 
control in response to DHT, but not palcar.  
5.5. Discussion  
Following from the previous findings in this thesis showing that palcar 
induced Ca2+ influx and IL-6 at supra-physiological levels (Chapter 3); this 
Chapter investigate the effect of lower concentrations of palcar, and it was 
hypothesized that palcar at physiological concentrations is associated with changes 
on the gene expression. The results indicate that palcar was not associated with any 
changes on the gene expression of PNT1A cells, after 8 hours, measured by 
microarray study. This was also confirmed by real time RT-PCR.  
The concentration range of palcar used in the microarray study performed in 
this Chapter was based on the levels of palcar previously quantified in Chapter 2 in 
both normal and cancerous prostate tissue (figure 2.7A, Chapter 2). Therefore, 
PNT1A cells were treated with DMSO, palcar (0.005, 0.05, 0.5 and 5µM) or 10nM 
DHT. The latter was investigated since it was found to induce Ca2+ influx in the 
same pattern as that of palcar (figure 3.19 B, Chapter 3), therefore a comparison of 
the effect of palcar with that of DHT would be interesting and might provide 
indication that palcar may have a DHT-like effect.  
In this study, the analysis of the Affymetrix Human Exon 1.0 ST gene 
expression revealed that in PNT1A cells, both palcar (at all concentrations) and 
DHT treatments induced the expression of a number of genes (table 5.1) only when 
uncorrected, which support that notion that the changes induced by palcar was real 
since they occur for all concentrations rather than for only one or two 
concentrations. The largest number of the altered genes was caused by the DHT 
treatment, whereas 5µM palcar was associated with the largest number of altered 
genes compared to the other palcar concentrations. At this concentration palcar 
induced 346 genes compared to the control (P≤0.05).  These genes are listed annex 
I. Functional pathway analysis performed on the list of genes altered by 5µM 
palcar showed that most of the genes belong to the glycolysis/gluconeogenesis and 
the metabolism of xenobiotics by cytochrome P450 pathways (table 5.2). The 
genes that were up regulated are HK2 and ALDH1A3. However, the fold change 
of these genes was only 1.161 (table 5.3), which is considered very small to 
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describe that certain compound induce an effect on the gene expression and make 
it difficult for any interpretation, therefore confirming that palcar did not induce 
any gene expression. When compared to palcar, DHT potentially altered the 
glycolysis/gluconeogenesis pathway (table 5.4), and the genes belong to this 
pathway and up regulated by DHT were the same as those altered by palcar with a 
fold change of 1.168 and 1.257 for HK2 and ALDH1A3, respectively (table 5.5), 
which also considered very low for an indication of an alteration in gene 
expression. Therefore, these results suggest that both palcar and DHT were not 
associated with alteration in the gene expression in PNT1A cells. 
Since both palcar and DHT were shown to have the same effect of inducing 
Ca2+ influx in PC3 cells and therefore palcar might have a DHT-like effect in these 
cells (Chapter 3), the DHT-like property of palcar was also investigated on the 
gene expression in PNT1A cells. This was determined using Venn diagram. There 
were a total of six gene s affected by all palcar concentrations (figure 5.1); these 
genes are listed in table 5.6. Then, when DHT was incorporated, a total of five 
genes were found in common between all palcar concentrations and DHT (figure 
5.2), these genes were given in table 5.7. These results indicate that all genes 
induced by all palcar concentrations were also induced by DHT treatment, except 
one gene, which is EDN1. However, EDN1 gene has been shown to be induced by 
androgen treatment [191], therefore this suggests that EDN1 may have missed the 
significance threshold, and thus was not detected. 
When studying the number of genes in common between each individual 
palcar concentration and DHT, different concentrations altered different numbers 
of genes in common with DHT. However, the largest number of common genes in 
common was found between DHT and 5µM palcar, which was 169 genes (figure 
5.3). The number of the overlapped genes was not due to chance (the P values are 
indicated in the table within figure 5.2), but rather due to the treatment. Therefore, 
these data may provide preliminary support to the notion that palcar might have a 
DHT-like effect. In order to support this notion further follow up research is 
needed, where some of the genes in common between palcar and DHT can be 
selected for further investigation gene and protein expression in response to palcar 
and DHT.  
5.5.1. Confirmation of the gene expression by real time RT-PCR  
Real time RT-PCR is a routine follow up experiment conducted following 
microarray study in order to confirm the validity of the microarray study. Three 
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genes were selected for this purpose; ALDH1A3, HK2 and EDN1. These genes 
were selected because they were up regulated by palcar and DHT, although their 
low fold change. ALDH1A3 and HK2 genes were induced in response to both 
palcar and DHT, while EDN1 gene was induced in response to all palcar 
concentrations, but not induced by DHT; however, it was selected because it has 
been found to be induced by DHT in the published literature [191]. 
The results indicate that 8 hours treatment with palcar (0.005, 0.05, 0.5 or 
5µM) or 10nM DHT did not induce the gene expression of HK2, ALDH1A3 and 
EDN1 in PNT1A cells (figure 5.5), which confirm the microarray data that both 
palcar and DHT were not associated with an alteration in gene expression.  
It has been shown that in prostate cancerous LNCaP cells, DHT induced the 
gene expression of HK2 and ALDH1A3 after 24 and 48 hours treatment, 
respectively [189, 190]. Thus, the lack of changes in the gene expression in 
PNT1A cells in response to both palcar and DHT was thought to be due to the 
incubation time. Therefore, the gene expression was measured in PNT1A cells in 
response to 24 hours treatment of palcar and DHT. In these cells, 24 hours 
treatment with 5µM palcar did not induce the gene expression of HK2, ALDH1A3 
and EDN1, while 10nM DHT induced the gene expression of HK and EDN1, but 
not ALDH1A3 (figure 5.6). These results again confirm the inability of palcar to 
induce the gene expression of HK2, ALDH1A3 and EDN1 in PNT1A cells even 
when higher incubation time was used, but in contrast show that DHT was able to 
induce HK2 and EDN1 gene expression in these cells. These results, therefore, 
support the null hypothesis that palcar at low concentrations do not have an effect 
on the gene expression.  
5.5.2. Palcar and DHT effect on the gene expression of PNT1A and 
PC3 cells detected by real time RT-PCR 
Since the effect of palcar was previously observed in the cancerous PC3 
cells, the gene expression of HK2, ALDH1A3 and EDN1 were performed in PC3 
cells in response to 5µM palcar and 10nM DHT for 24 hours and were compared 
to that in PNT1A cells. In PC3 cells, palcar treatment induced the gene expression 
of HK2, but not ALDH1A3 and EDN1. When compared to palcar, DHT was not 
associated with any effect on the expression of these genes. The lack of alteration 
in the gene expression in response to DHT in PC3 cells may be due to the 
unresponsiveness of these cells to DHT due to the absence of ARs.  In PNT1A 
cells, palcar has no effect on the three genes; in contrast DHT induced the gene 
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expression of HK2 and EDN1, but not ALDH1A3 (figure 5.6), suggesting that 
palcar effect in PC3 cells might be similar to the effect of DHT in PNT1A cells.  
5.5.3. Effect of androgen-free media on palcar- and DHT-induced 
gene expression  
Since the effect of DHT was not observed on ALDH1A3 gene expression in 
PNT1A cells, which has previously been shown to be induced by DHT in LNCaP 
cells [189, 190], the effect of using androgen-free environment on the levels of the 
gene expression was investigated in PNT1A, PC3 and LNCaP cells. LNCaP cells 
were used as a positive control to compare the effect of this environment on the 
gene expression in PNT1A and PC3 cells and determine the validity of the 
procedure followed. The results showed that culturing PNT1A cells in phenol-free 
media supplemented with charcoal-stripped serum did not affect the gene 
expression of ALDH1A3, HK2 and EDN1 in response to palcar and DHT (figure 
5.7). In PC3 cells, changing the environment did not affect the previous results of 
the gene expression of ALDH1A3, but affected the gene expression of HK2 in 
response to palcar. However, in LNCaP cells, this environment induced an increase 
in the gene expression of ALDH1A3and EDN1compared to the control (P≤0.001) 
in response to DHT, but not in response to palcar. DHT effect in these cells agrees 
with the previous published result [189]. These results suggest that culturing 
PNT1A and PC3 cells in androgen-free environment had no effect on enhancing 
the responsiveness of these cells to palcar or DHT treatment, but may be important 
if LNCaP cells are to be investigated. Moreover, the lack of the effect of this 
androgen-free media on the gene expression confirm the validity of the microarray 
experiment since the media used to treat the cells from which RNA were extracted 
to be used for microarray was not an androgen-free media.   
The results of both microarray and real time RT-PCR did not support the 
hypothesis that palcar at lower concentration is associated with alteration in the 
gene expression in PNT1A cells, and therefore may not be associated with the 
induction of gene expression important for transforming the cells into the 
cancerous stage. However, the results of the real time RT-PCR conducted in PC3 
and PNT1A cells indicate that in PC3 cells 24 hour treatment with palcar was 
associated with the induction of the gene expression of HK2, which is a gene that 
encodes for the production of HK enzyme. HK enzyme is a regulatory enzyme that 
is essential for the initiation of the glycolysis by phosphorylating glucose using one 
molecule of ATP into glucose-6-phosphate (figure 5.8).  
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Figure 5.8: Conversion of glucose into pyruvate during glycolysis. Glucose is 
converted into pyruvate by series of enzyme-catalysed reactions. The regulatory 
enzymes of glycolytic pathway include HK, PFK and PK. HK. (Based on Devlin 
and Devlin [13]). 
 
Once the latter has formed, it gets trapped inside the cells and used for 
energy production through glycolysis, glycogen synthesis, or a substrate for PPP. 
The latter is important for providing the reducing molecules of NADH and FADH2 
required for the anabolic processes as well as the production of pentose sugar that 
is a component of fundamental cellular compounds, such as ATP, CoA, NAD, 
FAD, RNA, and DNA [13]. In prostate cancerous cells, induction of glycolysis is 
important to provide the carbon skeleton required for the lipogenesis [5]. In this 
process, pyruvate resulted from glycolysis is converted into acetylCoA, which is 
shifted away from TCA cycle and excreted into the cytosol to be used as a 
substrate for lipid and cholesterol synthesis [5], in this process acetylCoA can be 
converted into acetylcarnitine, which can be transported into the cytosol and to 
reform acetylCoA. The resultant acetylCoA can be converted into malonylCoA, 
which is used along with other molecules of malonylCoA to produce fatty acids by 
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the aid of FASN. It is unlikely that the formation of malonylCoA is associated with 
the inhibition of CPTI enzyme since malonylCoA is not accumulated in case of 
prostate cancer, but rather being used to produce fatty acids, which are considered 
the building blocks for cell membrane formation and supporting the proliferated 
cells. In fact this does not goes against fatty acid-glucose cycle as it has been 
shown that exposure to long chain fatty acids is associated with a decrease in PDH 
activity in cultured rat islets in addition to an inhibition of PFK, leading to a 
decrease in glucose oxidation and an increase in the levels of glucose-6-phosphate 
[192]. In prostate cancer cells, PFKFB4 is up regulated and associated with a 
decrease in the levels of Fru-2,6-BP, which is a regulator of PFK1 [87]. Diverting 
glucose from entering TCA cycle highlights the importance of fatty acids as the 
main energy source in these cells. Therefore, as a consequence of the stimulated 
fatty acid oxidation in PC3 cells along with the metabolic disruption in these cells, 
the resultant intermediates of incomplete fatty acid oxidation such as palcar, may 
act as a signalling molecule to induce the expression of HK2, which induces 
glycolysis to produce the carbon skeleton required for providing the building 
blocks for the proliferating cells. Thus, palcar-induced HK2 gene expression in 
PC3 cells may suggest that palcar may have a potential role in the induction of 
cellular proliferation through the induction of glycolysis. However, the mechanism 
by which palcar induces HK2 gene expression and thus glycolysis need further 
investigation. 
 
5.6. Conclusion  
In this study, the effect of low concentrations of palcar on the gene 
expression was investigated and compared to that of DHT. In the microarray 
experiment performed in PNT1A cells, multiple testing revealed that there were no 
genes altered by either DHT or palcar at any concentrations. However, to 
investigate the biological importance of the data, analysis of the uncorrected P 
values was conducted and indicated that there were a number of altered genes in 
common between palcar and DHT treatments including HK2 and ALDH1A3. 
However, these results were not confirmed by real time RT-PCR in PNT1A cells. 
Nevertheless, real time RT-PCR indicated that in PC3 cells a low concentration of 
palcar was able to induce HK2 gene expression. HK2 is a gene that encodes for the 
production of a rate limiting enzyme that drive glycolysis, which suggest a 
potential role for palcar to induce glycolysis. Induction of glycolysis in these cells 
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is important for providing the carbon skeleton required for anabolic processes, 
such as lipogenesis and PPP. Therefore, suggesting a possible potential role of 
palcar in enhancing prostate cancer progression.  
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6.1. General discussion 
The rationale behind this thesis was influenced by previous work [66], 
which had primarily focussed on investigating the effect of a diet rich in high 
GSLs broccoli on reducing the risk of developing CVD. This diet had been found 
to reduce the accumulation of acylcarnitines [66]. Acylcarnitines are metabolites 
of fatty acid oxidation that accumulate as a result of a mitochondrial dysfunction. 
High levels of plasma acylcarnitines have been detected in chronic disorders, such 
as obesity and DM type 2 [7], in which a metabolic disturbance has been observed. 
Accumulation of acylcarnitines has also been observed in kidney cancer tissue [8]. 
However, there are no reports currently in regards to their levels in prostate cancer. 
Therefore, this thesis focuses on investigating the accumulation of palcar, a long 
chain acylcarnitine, in prostate cancer tissue and the effects of high levels of palcar 
on prostate non-cancer and cancer cell models.    
In this chapter I will discuss the main findings of the four results chapters 
and their contributions to my original thesis aims, also their context within the 
wider field of research and finally the future plans for this work. The original aims 
of my thesis as stated out in Chapter 1 were: 
- To test the hypothesis that palcar accumulates in the prostate cancer 
tissue as compared to the non-cancerous tissue, thus providing a 
biomarker for the metabolic dysfunction in prostate cancer (Chapter 2). 
- To test the hypothesis that the accumulation of palcar is associated with 
induction of IL-6 and Ca2+ influx in prostate epithelial cancer cells 
(Chapter 3). 
- To test the hypothesis that the mechanism by which palcar induces Ca2+ 
influx involves the activation of PTX-sensitive GPCR and L-type Ca2+ 
channels (Chapter 4). 
- To investigate the hypothesis that low concentrations of palcar are 
associated with changes in gene expression in prostate epithelial cells 
(Chapter 5). 
6.1.1. Levels of palcar in prostate cancer tissues 
The first aim of my thesis was to quantify the levels of palcar in prostate 
non-cancer and cancer tissue. Prostate cancer has been shown to be associated with 
metabolic disturbances [111]. With this in mind, I quantified the levels of palcar in 
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prostate non-cancerous and cancerous tissue to determine whether the metabolic 
disturbances were linked to accumulation of acylcarnitines. In cancer tissue the 
levels were higher than the non-cancer tissue (figure 2.7, Chapter 2). Therefore, 
suggesting that palcar could represent a potential biomarker for the metabolic 
dysfunction associated with prostate cancer. The exact reason for the accumulation 
of palcar in prostate cancer need further investigation and may include either a 
defect or less efficient TCA cycle, which affect the rate of β-oxidation, or a defect 
in CPTII enzyme. However, the small sample size of prostate tissue samples 
(n=20) considered a limitation since having more tissue samples would give a 
more robust assessment for the potential role of palcar as a diagnostic tool.  In this 
work, I was not able to measure total acylcarnitine due to the lack of the internal 
standards required for the quantification process by LC-MS/MS. Knowing that 
fatty acid oxidation represents the main energy source for the prostate cells; 
quantifying total acylcarnitines may have provided information on the type of fatty 
acids consumed for energy production. Short and medium chain fatty acids are 
oxidized via β-oxidation in the mitochondria, whereas long and branch chain are 
oxidized via β-oxidation in the peroxisome.  
6.1.2. Effect of high concentrations of palcar in vitro: effect on IL-6 and 
Ca2+ influx 
Accumulation of palcar in cancer tissue indicate that the plasma membrane 
of the cancer cells is exposed to increased levels of palcar, therefore, the question 
of whether the presence of palcar in prostate cancer only represents a potential 
biomarker for the metabolic disturbances or induces other effects was investigated. 
Therefore, the next aim of this thesis was to investigate the effects of palcar. This 
was performed using in vitro cell models of prostate non-cancer and cancer cells. 
The use of a cell model is more appropriate for studying the effect and the 
molecular mechanism of a compound than using human tissue as it eliminates the 
large inter-variability from different donors, therefore ensuring greater 
reproducibility of the results.  
In this study it was shown that palcar was able to induce its effect at high 
concentrations that were not reported in the human plasma or tissues, however, has 
been within the range reported in ischemic heart of animal model [103]. In PC3 
cells, 50µM palcar induced IL-6 secretion (figure 3.4, Chapter 3), which was 
associated with the induction of IL-6 gene expression (figure 3.5, Chapter 3). The 
induction of IL-6 gene expression indicates that palcar was not associated with 
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detergent effect. This was also supported from the data of the fluorescence signals; 
where there was no reduction in the fluorescence values from both 340 and 
380nm, which is an indication of a FURA leakage as a result of a damaged cell 
membrane.  In endothelial cells, a concentration higher than 10µM was associated 
with a detergent effect indicated from the leakage of FURA [44], which suggest 
that palcar effect is a  dependent on the cell type being investigated. The ability of 
palcar to induce IL-6 gene expression and protein secretion suggest that palcar 
may act as a potential pro-inflammatory mediator in prostate cells.  
The effect of acylcarnitine at high concentrations, notably palcar, has been 
previously investigated [6-8] and they have been shown to be associated with an 
alteration of membrane proteins that act as ion channel and pumps, such as Na+/K+ 
pump and Ca2+ pump [39, 41, 42]. Altering the functions of these channels leads to 
a change in membrane permeability, which changes the concentrations of ions that 
may be involved in signalling pathways. This could trigger signal transduction 
mechanisms that may eventually initiate immune responses. It has been shown that 
acylcarnitines at high concentrations are associated with the induction of pro-
inflammatory cytokines [46] as well as the induction of Ca2+ influx [136]. Indeed, 
in addition to its ability to induce IL-6 at high concentration, palcar was able to 
induce Ca2+ influx in PC3 cells, but not in DU145, PNT1A and BPH-1 cells 
(figure 3.11. and 3.16, Chapter 3). There are no reported studies in the literature 
regarding the biological activities of palcar in prostate cells. However, there is 
only one published study in prostate cancerous LNCaP cells, where they measure 
Ca2+ influx in response to DHT (10 – 1000nM) [45]. DHT is the potent form of the 
hormone testosterone and synthesized by 5α-reductase present in the prostate, 
testes, hair follicles and adrenal gland [14]. It is important for the growth and 
development of prostate gland [14] and associated with prostate cancer 
progression [190]. In my study, DHT did not have an effect on IL-6 secretion 
(figure 3.7, Chapter 3), but induced Ca2+ influx in PC3 cells in response to 1µM 
DHT (figure 3.18, Chapter 3), which is above the reported physiological levels. 
However, no effect was observed for DHT in DU145, PNT1A and BPH-1 cells. 
The Ca2+ influx induced by DHT followed the same pattern of that induced by 
palcar and histamine, which is known to induce Ca2+ influx [166, 167].  
Ca2+ is an important secondary ion that is involved in many signalling 
pathways, some of which are related to inflammatory responses [193]. It has been 
shown that inhibiting Ca2+ influx was associated with a decrease in IL-6 
production in response to endothelin-1 [193]. IL-6 has been shown to be 
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associated with prostate cancer progression through the activation of AR due to its 
DHT-like effect [135, 194]. The ability of palcar to induce both Ca2+ influx and 
IL-6 secretion at high concentrations suggest that palcar has no effect on cultured 
prostate cancer cells at physiological concentrations and therefore it is difficult to 
interpret that palcar would represent a potential biomarker for the development of 
prostate cancer. 
In this study, I measured Ca2+ influx using a plate reader and one of its 
limitations is the increase in the baseline levels of Ca2+ influx, which was observed 
in some samples of this study. The increase in the baseline levels is caused by the 
time delay between the samples. The procedure for measuring the fluorescence 
ratio required that the cell suspension is seeded in the wells first and then the 
fluorescence ratio is measured in each well subsequently for 5 minutes per well. 
Also, another limitation is the variability in the fluorescence values that could 
results from uneven number of the cells in each well. Although the cells were 
seeded in uniform cell density, the seeding process may lead to a slight difference 
in the number of the cells seeded in each well. Despite the technical difficulty in 
measuring Ca2+ influx, the technique was able to show that palcar induced Ca2+ 
influx in PC3 cells similar to the effect of DHT. 
Since Ca2+ influx was measured in PNT1A, BPH-1, DU145 and PC3 cells, it 
would be of great value if IL-6 secretion in BPH-1 and DU145 cells was also 
measured. This would give an interesting comparison of the effect of palcar at high 
concentrations on IL-6 secretion in different prostate cells and gives information of 
whether the effect of palcar on IL-6 would be the same as its effect on Ca2+ influx.  
The mechanism underlying palcar-induced IL-6 production via Ca2+ influx 
in PC3 cells has not been investigated yet. It is possible that the increase in [Ca2+]i 
is important for the activation of transcription factors, such as NFκB, which is 
known to regulate IL-6 secretion. Further studies are needed to investigate the 
downstream events of Ca2+ induced signalling on IL-6 secretion in PC3 cells. 
6.1.3. Mechanism of Ca2+ influx in PC3 cells in response to high levels of 
palcar 
It has been previously shown that in LNCaP cells DHT induces Ca2+ influx 
by activating PTX-sensitive GPCR and L-type Ca2+ channels [45]. Since both 
palcar and DHT showed a similar effect in inducing Ca2+ influx in PC3 cells, 
although at high concentrations, I hypothesized in Chapter 4 that palcar may act as 
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a signalling molecule and activate specific pathways that are induced by DHT. 
However the results indicate that DHT and palcar at high concentration activate 
different pathways. DHT induced the activation of L-type Ca2+ channels and PTX-
sensitive GPCR (figures 4.6 and 4.9, Chapter 4). Palcar also activated L-type Ca2+ 
channels, but not PTX-sensitive GPCRs (figure 4.5 and 4.7, Chapter 4), with a 
possible involvement of PI3K pathway (figure 4.10, Chapter 4), which provides a 
possible link to connects the activation of GPCR with the L-type Ca2+ channels. 
Figure 4.17, Chapter 4 illustrates the proposed mechanism.  
It is important to note that PC3 cells are an androgen-independent cell line, 
which implies that these cells do not have an active AR or low levels of AR [80, 
85, 195], therefore, the growth of these cells is induced by the activation of 
signalling pathways that bypass AR, such as PI3K.  
The PI3K pathway is negatively regulated by the PTEN pathway. In PC3 
cells, the PTEN pathway is functionally inactive in contrast to PNT1A and BPH-1 
cells [170], which result in PI3K /AKT signalling pathway being more dominant 
in PC3 cells [118]. Activation of the PI3K pathway has been associated with fatty 
acid and cholesterol synthesis [196]. The mechanism of lipogenesis induced by the 
PI3K pathway includes the loss of PTEN activity in PC3 cells with subsequent 
activation of the PI3K/AKT pathway, activating the transcription factors that 
regulate lipogenesis [196].  The results of my study showed that high 
concentrations of palcar induced Ca2+ influx through the activation of the 
PI3K/AKT pathway, suggesting that palcar induced the activation of the 
PI3K/AKT pathway, and therefore palcar may indirectly mediate lipogenesis that 
is essential for prostate cancer progression. However, palcar-induced lipogenesis 
in PC3 cells need further investigation. One approach would be to investigate 
palcar-induced gene and protein expression of a rate limiting enzyme involved in 
lipogenesis, such as fatty acid synthase. 
6.1.4. The profile of the gene expression of GPCRs 
Although palcar did not activate PTX-sensitive GPCR, it may activate PTX-
insensitive GPCRs, especially that L-type Ca2+ channel are known to be an 
effector protein for the GPCR. GPCRs is a large group of receptors, and therefore 
to investigate which receptor might be involved in Ca2+ influx, I analysed the gene 
expression obtained from a separate microarray study performed DMSO-treated 
PC3, DU145, PNT1A and RWPE1 cells. The array analysis revealed that the 
profile of GPCR gene expression in PC3 cells was different to that in DU145 cells 
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with DU145 gene expression profile similar to that observed in PNT1A and 
RWPE1 cells. Although DU145 cells are metastatic cancerous cell line, the 
similarities of the profile of GPCRs gene expression between DU145 and both 
PNT1A and RWPE1 cells may explain the similar reaction of DU145 and PNT1A 
cells in the lack of response to palcar. 
The profile of the gene expression also revealed that GPR110 was highly 
expressed in PC3 cells as compared to RWPE1, PNT1A and DU145 cells. GPR87 
was highly expressed in PNT1A in comparison to DU145 and PC3 cells. 
Additionally, GPRC6A was one of the genes that were equally expressed between 
all cell lines (figure 4.11, 4.12, 4.13, 4.14 and 4.15, Chapter 4). Therefore, based 
on these results I measured the protein expression of GPR110, GPR87 and 
GPRC6A by western blot in PNT1A, BPH-1, DU145 and PC3 cells. This revealed 
that the level of protein expression of GPR110 was higher in PC3 cells as 
compared to the other cell lines (figure 4.16, Chapter 4) as well as higher than the 
levels of GPR87 and GPRC6A (figure 4.16, Chapter 4), suggesting that GPR110 
may represent a potential receptor by which palcar could induce its effect.  
Nevertheless, one difficulty with the loading control was observed. In this 
study, I used integrin β-1 as a loading control for the membrane proteins. There 
were differences in the expression of this protein in DU145 cells and BPH-1 cells 
compared to PNT1A and PC3 cells, which results in differences in the number and 
the band size of the protein (figure 4.16, Chapter 4). However, the poor loading 
control did not affect the estimation of the levels of the protein expression of 
GPR110, GPR87 and GPRC6A. Yet, one possible loading control that could be 
further investigated and alternatively used is β-actin.  
The potential receptor involved in the mechanism of Ca2+ influx in response 
to palcar may not only limited to GPR110 as the profile of the GPCRs gene 
expression in PC3 cells revealed a number of GPCRs, other than GPR110, that 
were highly expressed in PC3 cells compared to DU145 and PNT1A. However, 
GPR110 was considered a potential biomarker for the development of both lung 
and prostate cancer since the gene and protein expression of GPR110 were 
detected in the tissue and cell lines of both cancer types [175]. This is considered 
important since lung cancer is the number one cause of deaths in the UK followed 
by prostate cancer [1]. This may suggest the importance of investigating the role of 
GPR110 in Ca2+ influx. Due to the time limit for the completion of the work 
involved in this thesis, I did not investigate palcar-induced activation of GPCR as 
Chapter 6 
159 
 
well as the link between the activation of GPCR and Ca2+ influx. Studying these 
would provide a clearer image of the mechanism of Ca2+ influx induced by palcar 
in PC3 cells.  
Although the supraphysiological concentration of palcar used to induce the 
Ca2+ influx would make the physiological relevance questionable, studying the 
mechanism by which palcar induces Ca2+ influx may uncover a signalling pathway 
that represents a target for future dietary intervention aiming to investigate the role 
of dietary components on reducing the effect palcar accumulation in prostate 
cancer. As mentioned earlier a diet rich in high GSL broccoli was able to reduce 
the levels of acylcarnitines. The active component that may induce this effect is 
SF. SF may increase the anti-oxidant capacity of the cells by increasing the 
concentration of the reduced form of glutathione, which in turn can reduce the 
levels of ROS that negatively affecting the efficiency of TCA cycle. Therefore, it 
is interesting to study to the effect of SF on the mechanism of Ca2+ influx, thus 
providing a more understanding of the mechanism by which SF induces its effect.  
6.1.5. The effect of low concentration of palcar on the profiles of gene 
expression in vitro 
The final aim of the thesis was to identify whether low concentrations of 
palcar were associated with changes in the gene expression of prostate epithelial 
cells. I investigated this by conducting a microarray study in PNT1A cells 
followed by real time RT-PCR in both PNT1A and PC3 cells, in which the effect 
of palcar was compared to that of DHT. The range of concentration selected for 
palcar was based on the levels of palcar obtained from the prostate non-cancer and 
cancer tissue (figure 2.7, Chapter 2). The highest concentration of palcar (5µM) 
was selected since it was the highest concentration of acylcarnitine, other than 
palcar, that was reported in the literature and it was reported in subjects with 
metabolic dysfunction [31]. Therefore, it was thought that the accumulation of 
palcar under metabolic dysfunction may reach to this level, thus the effect of this 
concentration was investigated. The concentration of DHT that was selected in this 
study represents a physiologically relevant dose. Since DHT is known to be 
associated with prostate cancer progression, the findings of my study might aid in 
understanding whether palcar have a DHT-like effects. The rationale behind the 
use of PNT1A cells was to investigate whether palcar may have a role in inducing 
malignant transformation of the cells by inducing genes involved in signalling 
pathways that are associated with cancer progression or induction of anabolic or 
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catabolic processes essential for the biology of cancer, such as glycolysis and 
lipogenesis.  
The results of the microarray revealed that low concentrations of palcar 
were associated with changes in the gene expression of a number of genes in 
PNT1A cells (table 5.1, Chapter 5) only when uncorrected P value was used, 
which make the effect of both DHT and palcar on the gene expression 
questionable. However, with the use of uncorrected P value, 5µM palcar was 
associated with the largest number of significantly altered genes. When pathway 
analysis was performed, 5µM palcar was associated with the induction of 
glycolysis/gluconeogenesis and metabolism of xenobiotic pathways (table 5.3, 
Chapter 5). Glycolysis/gluconeogenesis was also potentially induced by 10nM 
DHT (table 5.5, Chapter 5). Two genes involved in the glycolytic pathway 
(ALDH1A3 and HK2) were induced by both DHT and palcar (table 5.4 and 5.6, 
Chapter 5), however their fold change was only 1.161, which suggest that both 
palcar and DHT were not associated with the induction of these genes. The pattern 
of the gene expression between palcar and DHT was similar (figure 5.4).  
Real time RT-PCR confirmed that both palcar and DHT were not associated 
with any induction of the gene expression. The genes selected for this purpose 
were HK2, ALDH1A3 and EDN1 (figure 5.5, Chapter 5). However, due to the 
lack effect of palcar and DHT after 8 hours, the expression of these three genes 
was measured after 24 hours treatment in PNT1A and was compared to that in 
PC3 cells. In PNT1A cells, 24 hours treatment with 5µM palcar has no effect on 
the gene expression of ALDH1A3, HK2 and EDN1. DHT, in contrast, induced the 
gene expression of HK2 and EDN1. The results of the DHT-induced gene 
expression of HK2 in PNT1A cells agree with the previously reported results in 
LNCaP cells [190].  
In PC3 cells, palcar induced the gene expression of HK2, but not ALDH1A3 
and EDN1, whereas DHT has no effect (figure 5.6, Chapter 5). The 
unresponsiveness of PC3 cells to DHT may be explained by the un-functional or 
absence of AR in these cells. There are some studies reported that both PNT1A 
and PC3 cells do not express the AR [80, 85] and that PC3 cells might express AR, 
but it is functionally inactive [195]. However, the effect of DHT in PNT1A cells 
suggest that AR may present in these cells and DHT either induced its effect 
through this receptor or other receptors in which DHT could be a possible ligand. 
The variation in the effect of DHT on the gene expression of HK2, ALDH1A3 and 
Chapter 6 
161 
 
EDN1 in PNT1A and lack of its effect in PC3 cells was thought to be as a result of 
receptor saturation with the androgen already present in the media or synthesized 
by the cells themselves. Cells were therefore cultured in an androgen-free 
environment and the effect of DHT in these cells were compared to that in LNCaP 
cells, in which DHT has been reported to induce the gene expression of HK2, 
EDN1 and ALDH1A3. Using such environment did not affect the gene expression 
in PNT1A and PC3 cells. In LNCaP cells, however an androgen-free environment 
induced the expression of ALDH1A3 in response to DHT after 24 hours, which  
disagrees with the previously reported results, in which it has been shown that 24 
hour was not sufficient to induce the gene expression of ALDH1A3, and thus it 
was observed after 48 hours [189]. 
6.2. Future plans 
The work described in this thesis investigates the role of high concentrations 
of palcar in prostate cancer. There are some aspects that are considered important 
for the completion of this work, which were not investigated due to the time 
limitation for the completion of this thesis. These include first, the profile of total 
acylcarnitines in prostate tissue. Second, the role of Ca2+ influx in IL-6 secretion in 
prostate cancer cells, and finally the role of GPR110 in Ca2+ influx and whether 
the activation of this receptor is induced by the presence of palcar. Research to 
investigate the above issues will provide evidence whether palcar at high 
concentrations has a mediatory effect on the development and progression of 
prostate cancer. The concentration of palcar used to induce these effects was 
within the concentration range reported in ischemic heart of animal model, 
however, because it was higher than those reported in the human plasma, it would 
make the physiological relevance of these studies questionable. 
The profile of total acylcarnitines in prostate cancer has not been 
investigated. Studying total acylcarnitines would provide information as to the 
type of fatty acids consumed for energy production. Accumulation of palcar in 
prostate tissue might be related to a defect in CPT II enzyme, part of a large family 
of transferases that transfer fatty acid from C12 – C18 acylcarnitines. Therefore, 
measuring total acylcarnitines may provide an insight into the metabolic 
disturbance in these tissue samples. 
The second aspect is the link between Ca2+ and IL-6. Since palcar induced 
both Ca2+ influx and IL-6 secretion, studying the association between Ca2+ influx 
and IL-6 may aid in understanding the role of palcar in prostate cancer cells. There 
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are some studies that addressed the role of changing [Ca2+]i in IL-6 secretion, 
however, there are no published studies regarding this issue in prostate cells. One 
approach, which can be used to investigate this includes treating the cells with 
nifedipine to block Ca2+ influx and then measure the secretion of IL-6 using 
commercially available ELISA kits. However, because Ca2+ is a dynamic ion that 
is important for many cellular functions, blocking Ca2+ influx may lead to less 
viable cells, therefore affecting the levels of IL-6 secreted, thus a method 
optimisation to determine the concentration and time of nifedipine incubation is 
needed prior to investigating the role of Ca2+ influx on palcar-induced IL-6 
secretion.  
The third important aspect of this research is the role of palcar in activating 
GPR110 and whether it is linked to the Ca2+ influx. This can be investigated by 
using a specific antibody for that receptor, however, because there are no 
published studies regarding the role of GPR110 in Ca2+ influx in prostate cancer, it 
is important first to determine the concentration and the incubation time of the 
antibody required to completely block the receptor prior to measuring palcar-
induced Ca2+ influx. 
Since the effects of palcar were shown in PC3 cells, a microarray study 
using PC3 cells treated with 5µM palcar for 24 hours would provide much 
information about what and how genes changed in response to palcar. This will 
give a broader image of the effect of palcar on the different pathways affected in 
these cells. 
The effects of palcar in this research were measured using in vitro cell 
models of prostate non-cancerous and cancerous cells. However, it would be 
interesting to investigate whether palcar would induce the same effects in ex. vivo 
human prostate tissue, which could provide evidence as to the effect of palcar in 
vivo. 
In conclusion, the findings of the work presented in this thesis suggest that 
accumulation of palcar, the most abundant acylcarnitine, in prostate cancer tissue 
may represent a potential biomarker for the metabolic disturbance associated with 
prostate cancer. However, more tissue samples are needed to confirm the potential 
role of palcar to be a diagnostic tool. Palcar was not associated with any effects in 
the non-cancerous cell models used in this study including an effect on the gene 
expression profile.  Nevertheless, in the most aggressive form of the prostate 
cancerous cells, palcar at high concentrations induced physiological changes 
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including gene expression that could be related to prostate cancer progression. 
Some of these effects were in common with DHT, suggesting a possible DHT-like 
property of palcar in these cells. However, since these effects were not observed at 
physiological levels, this study conclude that palcar has no effect on the cultured 
prostate cancer cells at physiological concentrations, and therefore it is difficult to 
conclude any physiological relevance of the effect of palcar in these cells.
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A list of genes altered in PNT1A cells after 5µM palcar treatment for 8 hours (P≤0.05) 
arranged according to the fold change in descending order. 
Accession Gene description Gene name Fold 
change 
NM_018728 myosin VC MYO5C 0.91 
NM_182643 deleted in liver cancer 1 DLC1 0.91 
NM_015589 sterile alpha motif domain containing 4A SAMD4A 0.91 
NM_198531 ATPase, class II, type 9B ATP9B 0.91 
NM_001964 early growth response 1 EGR1 0.90 
NM_004196 cyclin-dependent kinase-like 1 (CDC2-related 
kinase) CDKL1 0.90 
NM_000393 collagen, type V, alpha 2 COL5A2 0.90 
NM_014391 ankyrin repeat domain 1 (cardiac muscle) ANKRD1 0.90 
NM_014011 suppressor of cytokine signaling 5 SOCS5  0.90 
NM_001554 cysteine-rich, angiogenic inducer, 61 CYR61 0.90 
NM_199441 zinc finger protein 334 ZNF334 0.90 
NM_173354 salt-inducible kinase 1 SIK1 0.89 
NM_002784 pregnancy specific beta-1-glycoprotein 9 PSG9 0.89 
NM_005737 ADP-ribosylation factor-like 4C ARL4C 0.89 
NM_031938 beta-carotene oxygenase 2 BCO2 0.89 
NM_003268 toll-like receptor 5 TLR5 0.89 
ENST00000342887 chromosome 12 open reading frame 63 C12orf63 0.89 
NM_020348 cyclin M1 CNNM1 0.89 
NM_058237 protein phosphatase 4, regulatory subunit 4 PPP4R4 0.88 
NM_152597 fibrous sheath interacting protein 1 FSIP1 0.88 
NM_173039 aquaporin 11 AQP11 0.88 
NM_002068 guanine nucleotide binding protein (G protein), 
alpha 15 (Gq class) GNA15  0.88 
NM_022842 CUB domain containing protein 1 CDCP1 0.88 
NM_145016 glycine-N-acyltransferase-like 2 GLYATL2 0.88 
NM_007069 phospholipase A2, group XVI PLA2G16 0.88 
NR_027786 serine hydrolase-like hydrolase-like 2 SERHL 0.88 
NM_001083602 patched 1 PTCH1 0.88 
NM_002356 myristoylated alanine-rich protein kinase C 
substrate MARCKS  0.88 
NM_002298 lymphocyte cytosolic protein 1 (L-plastin) LCP1 0.88 
NM_199254 transmembrane phosphoinositide 3-phosphatase 
and tensin homolog 2 TPTE2  0.88 
NM_032387 WNK lysine deficient protein kinase 4 WNK4  0.88 
NM_024764 cation channel, sperm-associated, beta CATSPERB 0.87 
AK127870 FLJ45974 protein FLJ45974 0.87 
BC026884 chromosome 9 open reading frame 43 C9orf43 0.87 
NM_176880 nuclear receptor 2C2-associated protein NR2C2AP 0.87 
NM_058187 chromosome 21 open reading frame 63 C21orf63  0.87 
NM_174891 chromosome 14 open reading frame 79 C14orf79  0.87 
NM_004190 lipase, gastric LIPF 0.87 
NM_139171 StAR-related lipid transfer (START) domain 
containing 6 STARD6 0.87 
NM_005542 insulin induced gene 1 INSIG1 0.87 
NM_022475 hedgehog interacting protein HHIP  0.87 
NM_002019 fms-related tyrosine kinase 1 (vascular endothelial 
growth factor/vascular permeability factor 
receptor) FLT1 0.87 
NM_080817 G protein-coupled receptor 82 GPR82 0.87 
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NM_003247 thrombospondin 2 THBS2  0.87 
NM_001097579 G protein-coupled receptor 34 GPR34 0.87 
NM_031955 spermatogenesis associated 16 SPATA16 0.87 
NM_153267 MAM domain containing 2 MAMDC2 0.87 
NM_199136 chromosome 7 open reading frame 46  C7orf46  0.87 
NM_000189 hexokinase 2 HK2 0.87 
NM_024688 chromosome 10 open reading frame 68 C10orf68  0.86 
NM_023016 ankyrin repeat domain 57 ANKRD57 0.86 
NM_025015 heat shock 70kDa protein 12A HSPA12A 0.86 
NM_138812 DPY30 domain containing 1 DYDC1 0.86 
NM_0005271 low density lipoprotein receptor LDLR  0.86 
NM_004613 transglutaminase 2 (C polypeptide, protein-
glutamine-gamma-glutamyltransferase) TGM2  0.86 
NM_003897 immediate early response 3 IER3  0.86 
NM_0006931 aldehyde dehydrogenase 1 family, member A3 ALDH1A3  0.86 
NM_213599 anoctamin 5 ANO5  0.86 
NM_000212 integrin, beta 3 (platelet glycoprotein IIIa, antigen 
CD61) ITGB3  0.86 
NM_003567 breast cancer anti-estrogen resistance 3 BCAR3  0.86 
NM_152779 GLI pathogenesis-related 1 like 1 GLIPR1L1 0.86 
NR_026838 Down syndrome critical region gene 8 DSCR8  0.86 
NR_027713 keratin 8 pseudogene FLJ46111 0.86 
NM_002982 chemokine (C-C motif) ligand 2 CCL2  0.86 
NM_001005205 olfactory receptor, family 8, subfamily J, member 
1 OR8J1 0.86 
NM_021992 thymosin beta 15a TMSB15A 0.86 
NM_002658 plasminogen activator, urokinase PLAU  0.86 
NM_000767 cytochrome P450, family 2, subfamily B, 
polypeptide 6 CYP2B6 0.86 
NM_058229 F-box protein 32 FBXO32 0.85 
NM_001993 coagulation factor III (thromboplastin, tissue 
factor) F3  0.85 
NM_024514 cytochrome P450, family 2, subfamily R, 
polypeptide 1 CYP2R1 0.85 
NM_002228 jun proto-oncogene JUN  0.85 
NM_030763 high-mobility group nucleosome binding domain 5 HMGN5 0.85 
NM_170723 chromodomain protein, Y-linked, 1 CDY1 0.85 
NM_199289 NIMA (never in mitosis gene a)-related kinase 5 NEK5 0.85 
NM_021624 histamine receptor H4 HRH4 0.85 
NM_003714 stanniocalcin 2 STC2   0.85 
NM_006446 solute carrier organic anion transporter family, 
member 1B1 SLCO1B1 0.85 
NM_001955 endothelin 1 EDN1 0.85 
NM_000880 interleukin 7 IL7  0.85 
NM_001163560 chromosome 16 open reading frame 73 C16orf73 0.85 
NM_001764 CD1b molecule CD1B 0.85 
NM_001340 cylicin, basic protein of sperm head cytoskeleton 2 CYLC2 0.85 
NM_001924 growth arrest and DNA-damage-inducible, alpha GADD45A  0.85 
NM_014344 four jointed box 1 (Drosophila) FJX1 0.84 
NM_001136505 coiled-coil domain containing 79 CCDC79 0.84 
NM_005842 sprouty homolog 2 (Drosophila) SPRY2 0.84 
NM_152251 defensin, beta 106A DEFB106A 0.84 
NM_144594 gametocyte specific factor 1 GTSF1 0.84 
NR_024060 family with sequence similarity 27, member A FAM27A 0.84 
NM_175878 XK, Kell blood group complex subunit-related 
family, member 3 XKR3 0.84 
NM_003813 ADAM metallopeptidase domain 21 ADAM21 0.84 
NR_027263 chromosome 14 open reading frame 128 C14orf128 0.84 
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NM_139167 sarcoglycan, zeta SGCZ 0.84 
NM_006566 CD226 molecule CD226 0.84 
ENST00000400419 hypothetical protein MGC5590 MGC5590 0.84 
NM_003140 sex determining region Y SRY 0.83 
NM_001165 baculoviral IAP repeat-containing 3 BIRC3 0.83 
NM_001143668 adhesion molecule with Ig-like domain 2 AMIGO2 0.83 
NM_018327 serine palmitoyltransferase, long chain base 
subunit 3 SPTLC3 0.83 
NR_026825 ribosomal protein SA pseudogene 52 RPSAP52  0.83 
NM_012472   leucine rich repeat containing 6 LRRC6 0.83 
NM_152505 Leber congenital amaurosis 5-like LCA5L  0.83 
NM_181610 keratin associated protein 19-4 KRTAP19-4 0.83 
NM_015714 G0/G1switch 2 G0S2  0.83 
NM_003469 secretogranin II SCG2  0.83 
NM_001008391 coiled-coil domain containing 73 CCDC73 0.83 
NM_001508 G protein-coupled receptor 39 GPR39  0.83 
NM_001004730 olfactory receptor, family 5, subfamily AR, 
member 1 OR5AR1 0.83 
NR_026693 zinc finger protein 487, pseudogene ZNF487P  0.83 
AL831934 zinc finger protein 663 ZNF663  0.83 
NM_004780 transcription elongation factor A (SII)-like 1 TCEAL1  0.83 
NM_001143 amelogenin, Y-linked AMELY 0.83 
NM_152323 Spi-C transcription factor (Spi-1/PU.1 related) SPIC  0.83 
NM_003007 semenogelin I SEMG1 0.82 
NM_000074 CD40 ligand CD40LG  0.82 
NM_001143811 brain-derived neurotrophic factor BDNF  0.82 
NM_001004461 olfactory receptor, family 10, subfamily A, 
member 6 OR10A6 0.82 
NM_0025461 tumor necrosis factor receptor superfamily, 
member 11b TNFRSF11B  0.82 
NM_001443 fatty acid binding protein 1, liver FABP1 0.82 
NM_0035401 histone cluster 1, H4f HIST1H4F 0.82 
NM_152647 chromosome 15 open reading frame 33 C15orf33  0.82 
NM_005810 killer cell lectin-like receptor subfamily G, member 
1 KLRG1  0.82 
NM_001195234 tripartite motif-containing 49-like 2 TRIM49L2 0.82 
NM_213658 killer cell lectin-like receptor subfamily C, member 
1 KLRC1  0.82 
NM_001001961 olfactory receptor, family 13, subfamily C, 
member 3 OR13C3 0.81 
NM_0052421 coagulation factor II (thrombin) receptor-like 1 F2RL1  0.81 
NM_021966   T-cell leukemia/lymphoma 1A TCL1A 0.81 
NM_153444 olfactory receptor, family 5, subfamily P, member 
2 OR5P2 0.81 
NM_000133 coagulation factor IX F9  0.81 
NM_001004726 olfactory receptor, family 4, subfamily X, member 
1 OR4X1 0.81 
NM_005118 tumor necrosis factor (ligand) superfamily, 
member 15 TNFSF15 0.81 
NM_206998 secretoglobin, family 1D, member 4 SCGB1D4 0.81 
NM_001098272 3-hydroxy-3-methylglutaryl-CoA synthase 1 
(soluble) HMGCS1 0.81 
NM_005635 synovial sarcoma, X breakpoint 1 SSX1 0.81 
NR_0027761 MCM3AP antisense RNA (non-protein coding) MCM3AP-AS  0.81 
NM_001005204 olfactory receptor, family 8, subfamily U, member 
1 OR8U1  0.81 
NM_024775 gem (nuclear organelle) associated protein 6 GEMIN6  0.81 
NM_002240 potassium inwardly-rectifying channel, subfamily KCNJ6 0.81 
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J, member 6 
NM_005059 relaxin 2 RLN2  0.81 
NM_032330 calpain, small subunit 2 CAPNS2 0.81 
NM_001005197 olfactory receptor, family 8, subfamily D, member 
4 OR8D4 0.81 
NM_001192 tumor necrosis factor receptor superfamily, 
member 17 TNFRSF17  0.80 
NM_0008911 potassium inwardly-rectifying channel, subfamily 
J, member 2 KCNJ2  0.80 
NM_002175 interferon, alpha 21 IFNA21 0.80 
NM_001145465 NANOG neighbor homeobox NANOGNB  0.80 
NM_017680 asporin ASPN  0.80 
NM_002424 matrix metallopeptidase 8 (neutrophil collagenase) MMP8  0.80 
NM_031457 membrane-spanning 4-domains, subfamily A, 
member 8B MS4A8B 0.80 
NM_000686 angiotensin II receptor, type 2 AGTR2 0.79 
NM_013243 secretogranin III SCG3  0.79 
NM_005292 G protein-coupled receptor 18 GPR18 0.79 
NR_024004 DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 
11 like 2 DDX11L2 0.79 
NM_176891 interferon, epsilon IFNE 0.79 
NM_173857 vomeronasal 1 receptor 4 VN1R4  0.79 
NM_001001960 olfactory receptor, family 5, subfamily W, member 
2 OR5W2 0.79 
NM_001039916 zinc finger protein 384 ZNF384  0.79 
NM_172312 sperm associated antigen 8 SPAG8  0.78 
NR_0269831 basic transcription factor 3 pseudogene 11 BTF3P11  0.78 
NM_000371 transthyretin TTR  0.78 
NM_032461 SPANX family, member B1 SPANXB1 0.77 
NM_021225 proline rich, lacrimal 1 PROL1 0.77 
NM_0330571 olfactory receptor, family 2, subfamily B, member 
2 OR2B2  0.77 
NM_001004756 olfactory receptor, family 51, subfamily M, 
member 1 OR51M1  0.77 
NM_020903 ubiquitin specific peptidase 29 USP29 0.77 
NM_207339 P antigen family, member 2 (prostate associated) PAGE2 0.77 
NR_026935 hypothetical LOC158696 LOC158696 0.77 
ENST00000325812 chromosome 14 open reading frame 177 C14orf177 0.77 
AF210651 NAG18 mRNA NAG18  0.77 
NM_0005751 interleukin 1, alpha IL1A  0.77 
NM_001005329 olfactory receptor, family 51, subfamily A, 
member 2 OR51A4  0.76 
NM_0021731 interferon, alpha 16 IFNA16  0.76 
NM_006205 phosphodiesterase 6H, cGMP-specific, cone, 
gamma PDE6H 0.76 
NM_001004735 olfactory receptor, family 5, subfamily D, member 
14 OR5D14 0.75 
NM_033048 CPX chromosome region, candidate 1 CPXCR1 0.75 
NM_0010051671 olfactory receptor, family 52, subfamily E, member 
6 OR52E6 0.75 
NM_001005182 olfactory receptor, family 6, subfamily C, member 
1 OR6C1 0.74 
NM_178455 serine peptidase inhibitor, Kunitz type 4 SPINT4  0.74 
NM_1456621 SPANX family, member A2 SPANXA2  0.74 
BC021580 nuclear apoptosis inducing factor 1 NAIF1  0.72 
NM_020646 achaete-scute complex homolog 3 (Drosophila) ASCL3  0.72 
NM_0133181 HLA-B associated transcript 2-like 1 BAT2L1  0.70 
AF165185 LSM14B, SCD6 homolog B (S. cerevisiae) LSM14B 0.70 
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NM_0010019221 olfactory receptor, family 52, subfamily N, 
member 5 OR52N5 0.70 
NM_1383311 ribonuclease, RNase A family, 8 RNASE8  0.70 
NM_001134657 proline rich 23C PRR23C 0.66 
NM_130388 ankyrin repeat and SOCS box-containing 12 ASB12  0.66 
NR_0268131 chromosome 15 open reading frame 5 C15orf5  0.64 
NR_0023081 ubiquinol-cytochrome c reductase binding protein 
pseudogene LOC442454  0.61 
NM_0334391 interleukin 33 IL33 0.56 
NM_033198 phosphatidylinositol glycan anchor biosynthesis, 
class S PIGS -1.09 
NM_015060 AVL9 homolog (S. cerevisiase) AVL9 -1.10 
NM_006076 ArfGAP with FG repeats 2 AGFG2 -1.10 
NM_025155 proteasomal ATPase-associated factor 1 PAAF1 -1.10 
NM_006809 translocase of outer mitochondrial membrane 34 TOMM34 -1.10 
NM_005469 acyl-CoA thioesterase 8 ACOT8 -1.10 
NM_014773 KIAA0141 KIAA0141 -1.10 
NM_017849 transmembrane protein 127 TMEM127 -1.11 
NM_001109903 ring finger protein, transmembrane 2 RNFT2 -1.11 
NM_170607 MAX-like protein X MLX -1.11 
NR_026728 ER degradation enhancer, mannosidase alpha-like 
2 EDEM2 -1.11 
NM_017873 ankyrin repeat and SOCS box-containing 6 ASB6 -1.11 
NM_001610 acid phosphatase 2, lysosomal ACP2 -1.11 
NM_053064 guanine nucleotide binding protein (G protein), 
gamma 2 GNG2 -1.11 
NM_201540 NDRG family member 2 NDRG2 -1.11 
NM_145799 septin 6 Sep-06 -1.11 
NM_016099 golgin A7 GOLGA7 -1.11 
NM_001033549 chromosome 19 open reading frame 62 C19orf62 -1.11 
NM_032635 transmembrane protein 147 TMEM147 -1.11 
NM_015476 chromosome 18 open reading frame 10 C18orf10  -1.11 
NM_057161 kelch domain containing 3 KLHDC3 -1.11 
NM_006896 homeobox A7 HOXA7 -1.12 
NM_018283 nudix (nucleoside diphosphate linked moiety X)-
type motif 15 NUDT15 -1.12 
NM_003079 SWI/SNF related, matrix associated, actin 
dependent regulator of chromatin, subfamily e, 
member 1 SMARCE1 -1.12 
NM_016243 cytochrome b5 reductase 1 CYB5R1  -1.12 
NM_014306 chromosome 22 open reading frame 28 C22orf28 -1.12 
NM_015651 PHD finger protein 19 PHF19 -1.12 
NM_001039673 Yip1 interacting factor homolog B (S. cerevisiae) YIF1B -1.12 
NM_153713 Lix1 homolog (mouse)-like LIX1L -1.12 
NM_178148 solute carrier family 35, member B2 SLC35B2 -1.12 
NM_014604 Tax1 (human T-cell leukemia virus type I) binding 
protein 3 TAX1BP3 -1.12 
NM_213601 transmembrane emp24 protein transport domain 
containing 8 TMED8 -1.12 
NM_153273 inositol hexakisphosphate kinase 1 IP6K1 -1.12 
NR_002786 cell death-inducing DFFA-like effector c 
pseudogene CIDECP -1.12 
NM_024592 steroid 5 alpha-reductase 3 SRD5A3 -1.12 
NM_005698 secretory carrier membrane protein 3 SCAMP3 -1.12 
NM_198563 transmembrane protein 110 TMEM110 -1.12 
NM_004231 ATPase, H+ transporting, lysosomal 14kDa, V1 
subunit F ATP6V1F  -1.12 
NM_001135021 ELMO/CED-12 domain containing 3 ELMOD3 -1.12 
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NM_176783 proteasome (prosome, macropain) activator subunit 
1 (PA28 alpha) PSME1 -1.13 
NM_203413 chromosome 17 open reading frame 81 C17orf81  -1.13 
NM_007067 MYST histone acetyltransferase 2 MYST2 -1.13 
NM_001105203 RUN and SH3 domain containing 1 RUSC1 -1.13 
NM_005015 oxidase (cytochrome c) assembly 1-like OXA1L -1.13 
NM_153002 G protein-coupled receptor 156 GPR156 -1.13 
NM_001184768 armadillo repeat containing, X-linked 6 ARMCX6 -1.13 
NM_025202 EF-hand domain family, member D1 EFHD1 -1.13 
NM_003309 TSPY-like 1 TSPYL1 -1.13 
NM_022823 fibronectin type III domain containing 4 FNDC4 -1.13 
NM_014971 EFR3 homolog B (S. cerevisiae) EFR3B -1.13 
NM_006841 solute carrier family 38, member 3 SLC38A3 -1.13 
NR_026582 inhibitor of DNA binding 2B, dominant negative 
helix-loop-helix protein (pseudogene) ID2B  -1.13 
NM_173659 RNA pseudouridylate synthase domain containing 
3 RPUSD3  -1.13 
NM_199249 chromosome 19 open reading frame 48 C19orf48 -1.13 
NM_002633 phosphoglucomutase 1 PGM1 -1.13 
NM_001005333 melanoma antigen family D, 1 MAGED1  -1.13 
NM_012279 zinc finger protein 346 ZNF346 -1.13 
NM_001167820 bladder cancer associated protein BLCAP  -1.13 
NM_000543 sphingomyelin phosphodiesterase 1, acid 
lysosomal SMPD1 -1.14 
NM_024584 coiled-coil domain containing 121 CCDC121 -1.14 
NM_004577 phosphoserine phosphatase PSPH -1.14 
NM_000304 peripheral myelin protein 22 PMP22  -1.14 
NM_006623 phosphoglycerate dehydrogenase PHGDH -1.14 
NM_024095 ankyrin repeat and SOCS box-containing 8 ASB8  -1.14 
NM_032015 ring finger protein 26 RNF26 -1.14 
NM_007039 protein tyrosine phosphatase, non-receptor type 21 PTPN21 -1.14 
NM_004095 eukaryotic translation initiation factor 4E binding 
protein 1 EIF4EBP1 -1.14 
NM_016506 kelch repeat and BTB (POZ) domain containing 4 KBTBD4 -1.14 
NR_028450 branched chain amino-acid transaminase 2, 
mitochondrial BCAT2 -1.14 
NM_002923 regulator of G-protein signaling 2, 24kDa RGS2 -1.14 
NM_001080473 major facilitator superfamily domain containing 2B MFSD2B -1.15 
NM_032385 chromosome 5 open reading frame 4 C5orf4 -1.15 
NM_032336 GINS complex subunit 4 (Sld5 homolog) GINS4 -1.15 
NM_030821 phospholipase A2, group XIIA PLA2G12A -1.15 
NM_024887 dehydrodolichyl diphosphate synthase DHDDS -1.15 
NM_005736 ARP1 actin-related protein 1 homolog A, 
centractin alpha (yeast) ACTR1A  -1.15 
NM_0528751 vacuolar protein sorting 26 homolog B (S. pombe) VPS26B  -1.15 
NM_004548 NADH dehydrogenase (ubiquinone) 1 beta 
subcomplex, 10, 22kDa NDUFB10 -1.15 
NM_003525 histone cluster 1, H2bi HIST1H2BI -1.15 
NM_000691 aldehyde dehydrogenase 3 family, member A1 ALDH3A1  -1.15 
AY568085 chromosome 6 open reading frame 125 C6orf125 -1.15 
NM_032342 chromosome 9 open reading frame 125 C9orf125  -1.15 
NM_004776 UDP-Gal:betaGlcNAc beta 1,4- 
galactosyltransferase, polypeptide 5 B4GALT5 -1.15 
NM_004528 microsomal glutathione S-transferase 3 MGST3 -1.15 
NM_177528 sulfotransferase family, cytosolic, 1A, phenol-
preferring, member 2 SULT1A2  -1.15 
NM_018379 family with sequence similarity 63, member A FAM63A -1.15 
NM_0001371 fumarylacetoacetate hydrolase FAH  -1.15 
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(fumarylacetoacetase) 
NM_006221 peptidylprolyl cis/trans isomerase, NIMA-
interacting 1 PIN1 -1.15 
NM_016952 Cdon homolog (mouse) CDON  -1.15 
NM_022453 ring finger protein 25 RNF25 -1.15 
NM_033204 zinc finger protein 101 ZNF101  -1.16 
NM_018208 ethanolamine kinase 2 ETNK2 -1.16 
NM_017777 Meckel syndrome, type 1 MKS1  -1.16 
NM_001312 cysteine-rich protein 2 CRIP2 -1.16 
NM_194296 spermatogenesis associated 24 SPATA24 -1.16 
NM_020438 dolichyl pyrophosphate phosphatase 1 DOLPP1  -1.16 
NM_006503 proteasome (prosome, macropain) 26S subunit, 
ATPase, 4 PSMC4  -1.16 
NM_005227 ephrin-A4 EFNA4 -1.16 
NM_006066 aldo-keto reductase family 1, member A1 
(aldehyde reductase) AKR1A1  -1.16 
NM_006118 HCLS1 associated protein X-1 HAX1 -1.16 
NM_025263 proline rich 3 PRR3  -1.17 
NM_006245 protein phosphatase 2, regulatory subunit B', delta PPP2R5D  -1.17 
NM_032377 elongation factor 1 homolog (S. cerevisiae) ELOF1 -1.17 
NM_182491 zinc finger, AN1-type domain 2A ZFAND2A  -1.17 
NM_016060 mediator complex subunit 31 MED31 -1.17 
NM_020154 chromosome 15 open reading frame 24 C15orf24 -1.17 
NM_138573 neuregulin 4 NRG4 -1.17 
NM_000784 cytochrome P450, family 27, subfamily A, 
polypeptide 1 CYP27A1 -1.18 
NM_032822 family with sequence similarity 136, member A FAM136A  -1.18 
NM_053045 transmembrane protein 203 TMEM203  -1.18 
NM_198849 seven in absentia homolog 3 (Drosophila) SIAH3 -1.18 
NM_016440 vaccinia related kinase 3 VRK3  -1.18 
NM_001338 coxsackie virus and adenovirus receptor CXADR -1.18 
NM_012412 H2A histone family, member V H2AFV -1.18 
NM_001077351 RNA binding motif protein 23 RBM23 -1.18 
NM_032940 polymerase (RNA) II (DNA directed) polypeptide 
C, 33kDa POLR2C  -1.18 
NM_001353 aldo-keto reductase family 1, member C1 
(dihydrodiol dehydrogenase 1; 20-alpha (3-alpha)-
hydroxysteroid dehydrogenase) AKR1C1  -1.19 
NM_174976 zinc finger, DHHC-type containing 22  ZDHHC22 -1.19 
NM_004234 zinc finger protein 235 ZNF235  -1.19 
NM_032505 kelch repeat and BTB (POZ) domain containing 8 KBTBD8 -1.20 
NM_012446 single-stranded DNA binding protein 2 SSBP2 -1.20 
NM_001170423 protease, serine, 35 PRSS35 -1.20 
NM_006945 small proline-rich protein 2D SPRR2D -1.20 
NM_017414 ubiquitin specific peptidase 18 USP18  -1.20 
NM_014365 heat shock 22kDa protein 8 HSPB8  -1.20 
NR_036639 Yip1 domain family, member 1 YIPF1 -1.21 
NM_014206 chromosome 11 open reading frame 10 C11orf10   -1.21 
NM_003754 eukaryotic translation initiation factor 3, subunit F EIF3F  -1.21 
NM_198179 pyroglutamylated RFamide peptide receptor QRFPR  -1.22 
NM_002167 inhibitor of DNA binding 3, dominant negative 
helix-loop-helix protein ID3  -1.22 
NR_002722 zinc finger protein 204, pseudogene ZNF204P  -1.22 
NM_001001317 trypsin X3 TRYX3 -1.22 
NM_004405 distal-less homeobox 2 DLX2  -1.22 
NM_0057401 dynein, axonemal, light chain 4 DNAL4  -1.23 
NM_002124 major histocompatibility complex, class II, DR 
beta 1 HLA-DRB1  -1.25 
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NM_006156 neural precursor cell expressed, developmentally 
down-regulated 8 NEDD8  -1.25 
NM_017700 Rho guanine nucleotide exchange factor (GEF) 38 ARHGEF38 -1.26 
NM_001001918 olfactory receptor, family 14, subfamily C, 
member 36 OR14C36 -1.27 
NM_007227 G protein-coupled receptor 45 GPR45 -1.28 
NR_024277 non-protein coding RNA 241 NCRNA00241 -1.29 
NM_175886 phosphoribosyl pyrophosphate synthetase 1-like 1 PRPS1L1  -1.29 
NM_181619 keratin associated protein 21-1 KRTAP21-1  -1.34 
NM_0191201 protocadherin beta 8 PCDHB8  -1.35 
NM_001496 GDNF family receptor alpha 3 GFRA3 -1.36 
NM_019599 taste receptor, type 2, member 1 TAS2R1 -1.37 
NM_005285 neuropeptides B/W receptor 1 NPBWR1  -1.47 
NM_002500 neurogenic differentiation 1 NEUROD1  -1.73 
1 Genes those were significant at P≤0.005 in table 5.1 in Chapter 5. There were 9 genes removed from 
this list as they were not annotated in the latest national centre for biotechnology information (NCBI) 
build 2009-01-31. However, they were all up-regulated, with approximately 0.8 fold increase in gene 
expression compared to control except one, which had a 1.24 fold reduction in gene expression 
compared to control.  
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Genes altered in the “Metabolism of xenobiotics by cytochrome P450 pathway” in response 
to 5µM palcar treatment for 8 hours: 
 
Accession Gene title Short name Fold change P-value 
NM_000693 aldehyde dehydrogenase 1 family, 
member A3 
ALDH1A3 
 1.161 0.00276 
NM_000691 aldehyde dehydrogenase 3 family, 
member A1 
ALDH3A1 
 -1.148 0.024582 
NM_001353  aldo-keto reductase family 1, 
member C1 (dihydrodiol 
dehydrogenase 1; 20-alpha (3-
alpha)-hydroxysteroid 
dehydrogenase) 
AKR1C1 
 
 -1.191 0.008281 
NM_004528  microsomal glutathione S-
transferase 3 
MGST3 
 -1.151 0.028535 
NM_000767 cytochrome P450, family 2, 
subfamily B, polypeptide 6 
CYP2B6 
 1.169 0.045439 
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Genes that were affected in olfactory transduction pathway in response to 5µM palcar 
treatment for 8 hours: 
 
Accession Gene title Short 
name 
Fold 
change 
P-value 
NM_001004461 olfactory receptor, family 10, subfamily A, 
member 6 
OR10A6 
 
1.218 
 
0.041 
 
NM_001005167  olfactory receptor, family 52, subfamily E, 
member 6 
OR52E6 
 
1.341 
 
0.003 
 
NM_001004726 olfactory receptor, family 4, subfamily X, 
member 1 
OR4X1 
 
1.231 
 
0.032 
 
NM_001005204 olfactory receptor, family 8, subfamily U, 
member 1 
OR8U1 
 
1.236 
 
0.014 
 
NM_001001961 olfactory receptor, family 13, subfamily C, 
member 3 
OR13C3 
 
1.228 
 
0.038 
 
NM_001004756  olfactory receptor, family 51, subfamily M, 
member 1 
OR51M1 
 
1.294 
 
0.007 
 
NM_001004735 olfactory receptor, family 5, subfamily D, 
member 14 
OR5D14 
 
1.325 
 
0.025 
 
NM_001005205 olfactory receptor, family 8, subfamily J, 
member 1 
OR8J1 
 
1.168 
 
0.041 
 
NM_001001922 olfactory receptor, family 52, subfamily N, 
member 5 
OR52N5 
 
1.427 
 
0.001 
 
NM_001004730 olfactory receptor, family 5, subfamily AR, 
member 1 
OR5AR1 
 
1.206 
 
0.044 
 
NM_033057  olfactory receptor, family 2, subfamily B, 
member 2 
OR2B2 
 
1.293 
 
0.004 
 
NM_153444 olfactory receptor, family 5, subfamily P, 
member 2 
OR5P2 
 
1.230 
 
0.035 
 
NM_001005197 olfactory receptor, family 8, subfamily D, 
member 4 
OR8D4 
 
1.241 
 
0.044 
 
NM_001001918 olfactory receptor, family 14, subfamily C, 
member 36 
OR14C36 
 
-1.273 
 
0.040 
 
NM_001005182 olfactory receptor, family 6, subfamily C, 
member 1 
OR6C1 
 
1.345 
 
0.046 
 
NM_001005329 olfactory receptor, family 51, subfamily A, 
member 4 
OR51A4 
 
1.315 
 
0.006 
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Genes that were affected in cytokine-cytokine receptor interaction pathway in response to 
5µM palcar treatment for 8 hours: 
 
Accession Gene title Short name Fold change P-value 
NM_001192  tumor necrosis factor receptor 
superfamily, member 17 
TNFRSF17 
 
1.243 
 
0.023 
 
NM_000880 interleukin 7 IL7 1.180 0.006 
NM_000074 CD40 ligand CD40LG 1.216 0.025 
NM_002173  interferon, alpha 16 IFNA16 1.317 0.001 
NM_002546 tumor necrosis factor receptor 
superfamily, member 11b 
TNFRSF11B 
 
1.219 
 
0.004 
 
NM_002175  interferon, alpha 21 IFNA21 1.247 0.038 
NM_000575 interleukin 1, alpha IL1A 1.306 0.003 
NM_005118  tumor necrosis factor (ligand) 
superfamily, member 15 
TNFSF15 
 
1.231 
 
0.026 
 
NM_002982  chemokine (C-C motif) ligand 2 CCL2 1.167 0.017 
NM_002019 fms-related tyrosine kinase 1 
(vascular endothelial growth 
factor/vascular permeability 
factor receptor) 
FLT1 
 
 
1.151 
 
 
0.048 
 
 
NM_176891 interferon, epsilon IFNE 1.267 0.029 
 
 
Annex V 
175 
 
Annex V 
 
Genes altered in the Sulfur metabolic pathway in response to 10nM DHT treatment for 8 
hours: 
 
Accession Gene title Short name Fold 
change 
P-value 
NM_177528  sulfotransferase family, cytosolic, 
1A, phenol-preferring, member 2 
SULT1A2 
 
-1.161 
 
0.008041 
 
NM_003166 sulfotransferase family, cytosolic, 
1A, phenol-preferring, member 3 
SULT1A3 
 
-1.124 
 
0.048171 
 
NM_000456 sulfite oxidase SUOX -1.290 0.000384 
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Genes that were affected in the porphyrin and chlorophyll metabolic pathway in response to 
10nM DHT treatment for 8 hours: 
 
Accession Gene title Short name Fold 
change 
P-value 
NR_036510  uroporphyrinogen decarboxylase UROD -1.120 0.026 
NM_000713 biliverdin reductase B (flavin 
reductase (NADPH)) BLVRB -1.159 0.046 
NM_000031 aminolevulinate dehydratase ALAD -1.167 0.004 
NM_001303 COX10 homolog, cytochrome c 
oxidase assembly protein, heme A: 
farnesyltransferase (yeast) COX10 -1.132 0.043 
NM_001012515 ferrochelatase FECH -1.181 0.010 
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Genes that were affected in the tyrosine metabolic pathway in response to 10nM DHT 
treatment for 8 hours: 
 
Accession Gene title Short name Fold 
change 
P-value 
NM_000693 aldehyde dehydrogenase 1 family, 
member A3 
ALDH1A3 1.257 
 
0.0001 
 
NM_002415 macrophage migration inhibitory 
factor (glycosylation-inhibiting 
factor) 
 
MIF 1.157 
 
0.025 
 
NM_000137 fumarylacetoacetate hydrolase 
(fumarylacetoacetase) 
FAH -1.143 
 
0.005 
 
NM_000691  aldehyde dehydrogenase 3 family, 
member A1 
ALDH3A1 -1.146 
 
0.027 
 
NM_000754 catechol-O-methyltransferase COMT -1.165 0.026 
NM_016173 HemK methyltransferase family 
member 1 
HEMK1 -1.185 
 
0.008 
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Genes that were affected in the TGF-beta signalling pathway in response to 10nM DHT 
treatment for 8 hours: 
 
Accession Gene title Short name Fold 
change 
P-value 
NM_002467 v-myc myelocytomatosis viral 
oncogene homolog (avian) 
MYC 
 
1.159 
 
0.019 
 
NM_003246 thrombospondin 1 THBS1 1.136 0.035 
NM_002167 inhibitor of DNA binding 3, 
dominant negative helix-loop-helix 
protein 
ID3 
 
-1.240 
 
0.009 
 
NM_001719 bone morphogenetic protein 7 BMP7 -1.144 0.015 
NM_003247 thrombospondin 2 THBS2 1.162 0.006 
NM_001720  bone morphogenetic protein 8b BMP8B -1.197 0.046 
NM_153426  paired-like homeodomain 2 PITX2 -1.157 0.025 
NM_001135599 transforming growth factor, beta 2 TGFB2 1.251 0.009 
NM_001127217 SMAD family member 9 SMAD9 -1.136 0.033 
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The list of the 169 genes in common between 10nM DHT and 5µM palcar in 
PNT1A cells after treatment for 8 hours (P≤0.05) arranged according to the fold 
change in descending order. 
Accession Gene description Gene 
name 
Fold change 
of palcar vs 
ctrl  
Fold change 
of DHT vs 
ctrl 
NR_026813 chromosome 15 open reading 
frame 5  C15orf5 1.569 1.613 
NM_138331 ribonuclease, RNase A family, 8 RNASE8 1.434 1.240 
NM_001001922 
 
olfactory receptor, family 52, 
subfamily N, member 5  OR52N5 1.427 1.382 
AF165185 
 
LSM14B, SCD6 homolog B (S. 
cerevisiae)  LSM14B 1.426 1.372 
NM_013318 
 HLA-B associated transcript 2-like 
1 BAT2L1 1.420 1.308 
NM_020646 
 
achaete-scute complex homolog 3 
(Drosophila) ASCL3 1.395 1.346 
NM_178455 
serine peptidase inhibitor, Kunitz 
type 4  SPINT4 1.352 1.412 
NM_001004735 
 
 olfactory receptor, family 5, 
subfamily D, member 14 OR5D14 1.325 1.486 
NM_000575 interleukin 1, alpha  IL1A 1.306 1.284 
AF210651  NAG18 mRNA NAG18 1.305 1.239 
NM_020903  ubiquitin specific peptidase 29 USP29 1.295 1.380 
NM_001004756 
olfactory receptor, family 51, 
subfamily M, member 1 OR51M1 1.294 1.256 
NM_033057 
 
olfactory receptor, family 2, 
subfamily B, member 2 OR2B2 1.293 1.223 
NM_176891 interferon, epsilon  IFNE 1.267 1.336 
NM_017680 asporin ASPN 1.249 1.186 
NM_024775 
 
gem (nuclear organelle) associated 
protein 6  GEMIN6 1.238 1.253 
NR_002776 
 
MCM3AP antisense RNA (non-
protein coding) 
MCM3A
P-AS 1.233 1.100 
NM_005118 
 
tumor necrosis factor (ligand) 
superfamily, member 15  
TNFSF1
5 1.231 1.267 
NM_005242 
 
coagulation factor II (thrombin) 
receptor-like 1 F2RL1 1.229 1.207 
NM_213658 
 
 killer cell lectin-like receptor 
subfamily C, member 1 KLRC1 1.223 1.170 
NM_152647 
chromosome 15 open reading 
frame 33  C15orf33 1.221 1.142 
NM_003540 histone cluster 1, H4f  
HIST1H
4F 1.221 1.195 
NM_002546 
 
tumor necrosis factor receptor 
superfamily, member 11b 
TNFRSF
11B 1.219 1.132 
NM_001004461 
 
olfactory receptor, family 10, 
subfamily A, member 6  OR10A6 1.218 1.256 
NM_001143811  brain-derived neurotrophic factor  BDNF 1.217 1.261 
NM_000074 CD40 ligand CD40LG 1.216 1.236 
NM_003007 semenogelin I  SEMG1 1.214 1.244 
NM_004780 
 
transcription elongation factor A 
(SII)-like 1 TCEAL1 1.210 1.149 
AL831934  zinc finger protein 663  ZNF663 1.209 1.195 
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NM_001008391 coiled-coil domain containing 73  CCDC73 1.206 1.179 
NM_015714 G0/G1switch 2 G0S2 1.205 1.288 
NR_026825 
 ribosomal protein SA pseudogene 
52 
RPSAP5
2 1.201 1.174 
NM_001143668 
adhesion molecule with Ig-like 
domain 2 
AMIGO
2 1.200 1.337 
NM_001165 
baculoviral IAP repeat-containing 
3 BIRC3 1.199 1.334 
NM_144594 gametocyte specific factor 1 GTSF1 1.188 1.207 
NM_005842 sprouty homolog 2 (Drosophila)  SPRY2 1.187 1.333 
NM_014344  four jointed box 1 (Drosophila) FJX1 1.184 1.264 
NM_001924 
 
 growth arrest and DNA-damage-
inducible, alpha 
GADD4
5A 1.183 1.253 
NM_001163560 
chromosome 16 open reading 
frame 73  C16orf73 1.182 1.247 
NM_000880 interleukin 7  IL7 1.180 1.250 
NM_003714 stanniocalcin 2  STC2 1.179 1.182 
NM_002228  jun proto-oncogene  JUN 1.172 1.314 
NM_001993 
 
coagulation factor III 
(thromboplastin, tissue factor) F3 1.170 1.290 
NM_002658 plasminogen activator, urokinase PLAU 1.168 1.322 
NM_001005205 
 
olfactory receptor, family 8, 
subfamily J, member 1 OR8J1 1.168 1.253 
NM_002982  chemokine (C-C motif) ligand 2  CCL2 1.167 1.329 
NR_026838 
 Down syndrome critical region 
gene 8  DSCR8 1.165 1.196 
NM_000212 
 
 integrin, beta 3 (platelet 
glycoprotein IIIa, antigen CD61) ITGB3 1.162 1.169 
NM_213599 anoctamin 5  ANO5 1.162 1.149 
NM_000693 
 
aldehyde dehydrogenase 1 family, 
member A3 
ALDH1
A3 1.161 1.257 
NM_003897 immediate early response 3 IER3 1.161 1.176 
NM_004613 
 
transglutaminase 2 (C polypeptide, 
protein-glutamine-gamma-
glutamyltransferase) TGM2 1.160 1.219 
NM_024688 
chromosome 10 open reading 
frame 68  C10orf68 1.157 1.109 
NM_000189 hexokinase 2 HK2 1.156 1.168 
NM_001097579 G protein-coupled receptor 34 GPR34 1.154 1.158 
NM_003247 thrombospondin 2 THBS2 1.154 1.162 
NM_080817  G protein-coupled receptor 82 GPR82 1.152 1.177 
NM_022475 hedgehog interacting protein HHIP 1.150 1.199 
NM_004190 lipase, gastric LIPF 1.148 1.163 
NM_058187 
chromosome 21 open reading 
frame 63 C21orf63  1.147 1.124 
NM_024764 
 cation channel, sperm-associated, 
beta 
CATSPE
RB 1.144 1.139 
NM_199254 
 
transmembrane phosphoinositide 3-
phosphatase and tensin homolog 2 TPTE2 1.140 1.103 
NM_002356 
 
 myristoylated alanine-rich protein 
kinase C substrate 
MARCK
S 1.138 1.194 
NR_027786  serine hydrolase-like SERHL 1.136 1.140 
NM_022842  CUB domain containing protein 1 CDCP1 1.135 1.200 
NM_002068 
 
 guanine nucleotide binding protein 
(G protein), alpha 15 (Gq class)  GNA15 1.134 1.118 
NM_020348 cyclin M1 CNNM1 1.129 1.110 
NM_031938 beta-carotene oxygenase 2 BCO2 1.124 1.154 
NM_001554 
cysteine-rich, angiogenic inducer, 
61 CYR61 1.114 1.121 
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NM_014011 suppressor of cytokine signaling 5 SOCS5 1.114 1.148 
NM_014391 
ankyrin repeat domain 1 (cardiac 
muscle) 
ANKRD
1 1.114 1.207 
NM_004196 
 
cyclin-dependent kinase-like 1 
(CDC2-related kinase) CDKL1 1.110 1.112 
NM_001964 early growth response 1 EGR1 1.106 1.126 
NM_182643 deleted in liver cancer 1  DLC1 1.097 1.114 
NM_033198 
 
phosphatidylinositol glycan anchor 
biosynthesis, class S PIGS -1.094 -1.108 
NM_015060 AVL9 homolog (S. cerevisiase)  AVL9 -1.097 -1.125 
NM_006076 ArfGAP with FG repeats 2 AGFG2 -1.101 -1.153 
NM_005469  acyl-CoA thioesterase 8 ACOT8 -1.104 -1.175 
NM_014773 KIAA0141 
KIAA01
41 -1.105 -1.163 
NM_017849 transmembrane protein 127 
TMEM1
27 -1.107 -1.124 
NM_001109903 
ring finger protein, transmembrane 
2 RNFT2 -1.108 -1.127 
NM_170607 MAX-like protein X  MLX -1.108 -1.119 
NM_017873 
ankyrin repeat and SOCS box-
containing 6  ASB6 -1.109 -1.127 
NM_001610  acid phosphatase 2, lysosomal  ACP2 -1.111 -1.166 
NM_201540 NDRG family member 2  NDRG2 -1.112 -1.137 
NM_145799 septin 6 SEPT6 -1.114 -1.149 
NM_032635   transmembrane protein 147 
TMEM1
47  -1.114 -1.107 
NM_003079 
 
 
 SWI/SNF related, matrix 
associated, actin dependent 
regulator of chromatin, subfamily 
e, member 1  
SMARC
E1  -1.117 -1.108 
NM_014306 
 chromosome 22 open reading 
frame 28  C22orf28  -1.117 -1.119 
NM_015651 PHD finger protein 19 PHF19 -1.119 -1.177 
NM_001039673 
 
 Yip1 interacting factor homolog B 
(S. cerevisiae) YIF1B  -1.119 -1.201 
NM_153713  Lix1 homolog (mouse)-like  LIX1L -1.120 -1.155 
NM_014604 
 
Tax1 (human T-cell leukemia virus 
type I) binding protein 3 
TAX1BP
3  -1.120 -1.134 
NM_178148 
solute carrier family 35, member 
B2 
SLC35B
2 -1.120 -1.125 
NM_153273 inositol hexakisphosphate kinase 1 IP6K1 -1.120 -1.141 
NR_002786 
 
cell death-inducing DFFA-like 
effector c pseudogene CIDECP -1.121 -1.181 
NM_005698 
 secretory carrier membrane protein 
3  
SCAMP
3 -1.123 -1.124 
NM_198563 transmembrane protein 110 
TMEM1
10 -1.123 -1.206 
NM_001135021 
ELMO/CED-12 domain containing 
3  
ELMOD
3 -1.125 -1.220 
NM_176783 
 
 proteasome (prosome, macropain) 
activator subunit 1 (PA28 alpha)  PSME1 -1.126 -1.116 
NM_203413 
 chromosome 17 open reading 
frame 81 C17orf81 -1.126 -1.157 
NM_007067  MYST histone acetyltransferase 2  MYST2 -1.128 -1.134 
NM_001105203 RUN and SH3 domain containing 1 RUSC1 -1.128 -1.195 
NM_153002 G protein-coupled receptor 156 GPR156 -1.129 -1.128 
NM_025202 
EF-hand domain family, member 
D1  EFHD1 -1.130 -1.132 
NM_003309 TSPY-like 1 TSPYL1 -1.130 -1.136 
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NM_022823 
 fibronectin type III domain 
containing 4  FNDC4 -1.131 -1.144 
NM_014971 EFR3 homolog B (S. cerevisiae) EFR3B -1.131 -1.141 
NM_006841 solute carrier family 38, member 3 
SLC38A
3 -1.132 -1.132 
NM_173659 
 
 RNA pseudouridylate synthase 
domain containing 3  RPUSD3 -1.133 -1.222 
NM_002633 phosphoglucomutase 1 PGM1 -1.133 -1.150 
NM_199249 
chromosome 19 open reading 
frame 48  C19orf48 -1.133 -1.223 
NM_001167820  bladder cancer associated protein  BLCAP -1.135 -1.107 
NM_004577 phosphoserine phosphatase PSPH -1.137 -1.138 
NM_000304 peripheral myelin protein 22 PMP22 -1.137 -1.112 
NM_006623 phosphoglycerate dehydrogenase  PHGDH -1.140 -1.216 
NM_024095 
ankyrin repeat and SOCS box-
containing 8  ASB8 -1.141 -1.176 
NM_032015 ring finger protein 26 RNF26 -1.141 -1.165 
NM_004095 
 
eukaryotic translation initiation 
factor 4E binding protein 1 
EIF4EBP
1 -1.142 -1.202 
NM_016506 
 
kelch repeat and BTB (POZ) 
domain containing 4 
KBTBD
4 -1.142 -1.164 
NR_028450 
 
branched chain amino-acid 
transaminase 2, mitochondrial  BCAT2 -1.142 -1.186 
NM_001080473 
 
 major facilitator superfamily 
domain containing 2B  
MFSD2
B -1.145 -1.181 
NM_032385 
chromosome 5 open reading frame 
4  C5orf4 -1.146 -1.211 
NM_024887 
dehydrodolichyl diphosphate 
synthase DHDDS -1.147 -1.189 
NM_005736 
 
ARP1 actin-related protein 1 
homolog A, centractin alpha 
(yeast) 
ACTR1
A -1.147 -1.106 
NM_052875 
 
vacuolar protein sorting 26 
homolog B (S. pombe) VPS26B -1.148 -1.112 
NM_004548 
 
 NADH dehydrogenase 
(ubiquinone) 1 beta subcomplex, 
10, 22kDa  
NDUFB
10 -1.148 -1.147 
NM_000691 
 
aldehyde dehydrogenase 3 family, 
member A1 
ALDH3
A1  -1.148 -1.146 
NM_032342 
chromosome 9 open reading frame 
125  C9orf125 -1.149 -1.118 
NM_177528 
 
sulfotransferase family, cytosolic, 
1A, phenol-preferring, member 2 
SULT1A
2 -1.151 -1.161 
NM_018379 
 
family with sequence similarity 63, 
member A 
FAM63
A -1.152 -1.181 
NM_000137 
 
fumarylacetoacetate hydrolase 
(fumarylacetoacetase)  FAH -1.152 -1.143 
NM_033204  zinc finger protein 101 ZNF101 -1.156 -1.155 
NM_017777 Meckel syndrome, type 1 MKS1 -1.157 -1.130 
NM_001312  cysteine-rich protein 2  CRIP2 -1.157 -1.200 
NM_194296 spermatogenesis associated 24 
SPATA2
4 -1.159 -1.217 
NM_020438 
dolichyl pyrophosphate 
phosphatase 1 DOLPP1 -1.160 -1.140 
NM_006503 
 
proteasome (prosome, macropain) 
26S subunit, ATPase, 4 PSMC4 -1.160 -1.155 
NM_005227 ephrin-A4  EFNA4 -1.161 -1.236 
NM_006066 
 
 aldo-keto reductase family 1, 
member A1 (aldehyde reductase) AKR1A1 -1.163 -1.238 
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NM_006118  HCLS1 associated protein X-1 HAX1 -1.164 -1.169 
NM_025263 proline rich 3  PRR3 -1.165 -1.138 
NM_006245 
 
 protein phosphatase 2, regulatory 
subunit B', delta  
PPP2R5
D -1.166 -1.225 
NM_032377 
 elongation factor 1 homolog (S. 
cerevisiae) ELOF1 -1.168 -1.221 
NM_138573  neuregulin 4 NRG4 -1.174 -1.359 
NM_000784 
 
cytochrome P450, family 27, 
subfamily A, polypeptide 1 
CYP27A
1 -1.175 -1.221 
NM_032822 
 
family with sequence similarity 
136, member A 
FAM136
A -1.175 -1.169 
NM_053045  transmembrane protein 203 
TMEM2
03  -1.179 -1.202 
NM_198849 
seven in absentia homolog 3 
(Drosophila) SIAH3 -1.181 -1.163 
NM_016440  vaccinia related kinase 3 VRK3  -1.182 -1.213 
NM_001077351  RNA binding motif protein 23  RBM23 -1.183 -1.177 
NM_032940 
 
polymerase (RNA) II (DNA 
directed) polypeptide C, 33kD POLR2C -1.184 -1.127 
NM_174976 
 zinc finger, DHHC-type 
containing 22 
ZDHHC
22 -1.192 -1.322 
NM_032505 
 
kelch repeat and BTB (POZ) 
domain containing 8 
KBTBD
8 -1.196 -1.182 
NM_017414 ubiquitin specific peptidase 18  USP18 -1.204 -1.198 
NM_014365 heat shock 22kDa protein 8  HSPB8 -1.204 -1.179 
NR_036639 Yip1 domain family, member 1  YIPF1 -1.205 -1.239 
NM_014206 
chromosome 11 open reading 
frame 10 C11orf10 -1.209 -1.193 
NM_003754 
 
eukaryotic translation initiation 
factor 3, subunit F EIF3F -1.214 -1.304 
NM_002167 
 
inhibitor of DNA binding 3, 
dominant negative helix-loop-helix 
protein  ID3 -1.216 -1.240 
NR_002722 
zinc finger protein 204, 
pseudogene 
ZNF204
P -1.217 -1.216 
NM_004405 distal-less homeobox 2  DLX2 -1.222 -1.245 
NM_005740  dynein, axonemal, light chain 4 DNAL4 -1.231 -1.156 
NM_175886 
 
phosphoribosyl pyrophosphate 
synthetase 1-like 1 
PRPS1L
1 -1.294 -1.280 
NM_019120 protocadherin beta 8 PCDHB8 -1.347 -1.433 
NM_005285  neuropeptides B/W receptor 1 
NPBWR
1 -1.472 -1.430 
Three genes were not annotated in the latest NCBI build 2009-01-31, therefore they were 
removed from this list. However, they were all up-regulated, with approximately 1.3 fold 
increase in gene expression compared to control. 
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